CARDIOMYOPATHY UK

England & Wales · Charity number 1164263

Details

Status	Registered
Legal form	CIO
Registered	2015-11-05
Register	View on the Charity Commission register

Contact

Address	75A Woodside Road Amersham Buckinghamshire HP6 6AA
Phone	01494791224
Email	info@cardiomyopathy.org
Website	www.cardiomyopathy.org

Activities

Objects: TO RELIEVE PEOPLE SUFFERING FROM THE CONDITION OF CARDIOMYOPATHY AND RELATED CONDITIONS IN PARTICULAR (BUT WITHOUT PREJUDICE TO THE GENERALITY THEREOF) BY:A) DEVELOPING AND MAINTAINING A NETWORK OF SUPPORT FOR PEOPLE SUFFERING FROM THE CONDITION AND THEIR FAMILIESB) PROMOTING EDUCATION AMONG SUFFERERS OF THE CONDITION, THEIR FAMILIES AND THOSE HAVING THE PROFESSIONAL CARE OF SUFFERERS ABOUT THE SYMPTOMS AND THE TREATMENT OF THE CONDITION; ANDC) PROMOTING OR ASSISTING IN THE PROMOTION OF RESEARCH INTO THE CONDITION AND ITS TREATMENT AND THE PUBLICATION OF THE RESULTS OF THAT RESEARCH.

Activities: Cardiomyopathy UK saves lives and reduces the misery caused by the heart muscle disease cardiomyopathy. We want people affected by the disorder to live long and fulfilling lives and work to achieve this by raising awareness of the condition, improving access to quality treatment, promoting clinical research and supporting anyone affected by cardiomyopathy every step of the way.

Classification

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** People With Disabilities

Downloaded from opencharities.uk/ew/1164263

Geography

- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£1,054,678	£1,149,954	£742,685	20
2023-12-31	£1,053,351	£921,272	£837,961	19
2022-12-31	£1,031,133	£892,213	£705,882	18
2021-12-31	£945,478	£901,250	£566,962	18
2020-12-31	£771,829	£793,361	£522,734	18

Trustees

Name	Role	Appointed
Alyson Smith		2026-01-28
Betsy Thomas		2025-09-06
Mark Anthony Rees		2023-03-18
Martin Bloom		2023-03-18
Peter Thomas		2016-01-23
Stephen Kirkham MC		2017-06-24
TINA AMISS		2015-11-14
Teofila Bueser		2020-01-25

Downloaded from opencharities.uk/ew/1164263

CARDIOMYOPATHY UK

England & Wales - Charity number 1164263

Accounts








Cardiomyopathy UK
the heart muscle charity

20 Annual 24 Report

The difference we made in 2024














We're Cardiomyopathy UK

We save and improve the lives of people affected by cardiomyopathy. Our vision is a world where everyone affected by cardiomyopathy should live a long and fulfilling life.

In pursuit of this vision:

We raise awareness of the condition so that more people know the signs and symptoms and can be diagnosed early.

We campaign to improve access to quality treatment that meets the needs of people with cardiomyopathy.

We promote clinical research to advance the development of new treatments and provide hope for the future.

We support people affected by cardiomyopathy every step of the way, so that nobody has to face cardiomyopathy alone.

1 in 250 people have cardiomyopathy. That's approximately 266,000 people in the UK currently living with the condition.



Cardiomyopathy UK
the heart muscle charity

Contents

Reference & administrative details	1
Trustees' report	3-19
Independent auditors' report	20-24
Statement of financial activities	25-26
Balance sheet	27
Statement of cash flows	28
Notes to the financial statements	29-44



Administrative details

Trustees

R Sutton
(Chair)

E Jarman

S Cornish MBE

S Kirkham MC

M Bloom

P Thomas

T Bueser

A Smith

M Rees
(Treasurer)

G Favier

T Amiss

E B K Roy

Senior management / leadership team

A Tomlinson
Chief Executive Officer

Registered office

75a Woodside Road
Amersham
Buckinghamshire
HP6 6AA

Auditors

Hodson & Co
Wiston House,
1 Wiston Avenue
Worthing,
West Sussex
BN14 7QL

Charity number

Cardiomyopathy UK is registered as a charity in England and Wales (no. 1164263) and in Scotland (no. SC053398)

Bankers

Lloyds
82 High Street
Rickmansworth
Hertfordshire
WD3 1AG

Charity Aid Foundation Ltd
Kings Hill
West Malling
Kent
ME19 4TA

A message from our chair

The charity has continued to develop and grow throughout the year, embracing all new developments in the cardiac field.

The knowledge, skills and experience of the Board of Trustees continues to serve the charity well. In September one of our long-standing trustees, Dr Ian McPherson stepped down from the board. Ian's contribution over the past nine years has been invaluable. At the same time, we welcomed Erin Roy. Erin brings to the board a wealth of knowledge and experience in marketing and communications. Our number of trustees remains at twelve, with two trustees, Peter Thomas having served nine years, and Tina Amis having served more than nine years. Our team of trustees continue to work together for the good of the charity, participating in many aspects of the charity's work outside of their trustee duties e.g. acting as Support Group Leaders.

We will always be truly grateful for the dedication, enthusiasm, and passion our volunteers and supporters who give their time freely to the charity. With our army of volunteer support, Cardiomyopathy UK will continue to be there and provide services for anyone and everyone whose life is affected by cardiomyopathy.

My thanks go to my fellow trustees, our presidents, staff and other professionals for their time, expertise and all the work they have undertaken for us on behalf of the charity this past year. Together they have enabled us to continue to support our community and make a difference in people's lives.

The charity continues to be in good shape financially. Our grateful thanks go to our grant givers, donors, community and event fundraisers and all who support the work of the charity through their generous donations.

As we look forward to the year ahead, it is with sadness that I report that Joel Rose, Chief Executive Officer has resigned. Joel has moved on to take up a new challenge within the voluntary sector. Joel's leadership has taken the charity to another level during his ten years in post. Joel leaves the charity having developed a clear plan for growth, transformation and progress, for which trustees and our cardiac community are truly grateful. We wish him well.

As we move forward with the delivery of year two of the charity's five-year strategic plan, I am pleased to welcome and introduce Anna Tomlinson, our new Chief Executive Officer. Anna brings to the charity a wealth of knowledge and experience and is passionate about driving meaningful change. Anna is eager to build on the charity's strong foundations to further our mission of hope for the future. On appointment Anna said: "I am very much looking forward to driving the charity's ambitious strategy forward over the coming years. By working with the community and the broader ecosystem to further raise awareness of the condition, and to deliver more support, more research, and ultimately better treatments and therapies, I firmly believe that we can deliver significant long-term impact to all of those affected by cardiomyopathy".

I look forward to embracing the new and exciting opportunities that lie ahead. There is still a great deal of work to be done to bring about positive change in the lives of our members. Together we can, and do continue to make a difference.



Rita

Rita Sutton
Chair, Cardiomyopathy UK

Cardiomyopathy UK
the heart muscle charity

Trustees' report



Objectives & activities

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements and auditors' report of the charitable company for the year ended 31 December 2024.

Public benefit

Cardiomyopathy UK confirms that in setting its programme of activity, it has had due regard to the Charity Commission's general guidance on public benefit. The programme of activity also conforms to the charity's charitable objectives and aims. No persons are excluded from the work of the charity on grounds of gender, race or religion.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.



Achievements & performance

Providing support and information

Our support and information services aim to help people affected by cardiomyopathy feel more informed, less scared, and better able to cope day to day. Together, our services tackle the physical, emotional and practical impact that cardiomyopathy has on a person and on their loved ones.


We were really pleased that our pilot project to provide additional high level emotional support to people affected by cardiomyopathy showed to be extremely valuable. We were able to demonstrate how important this service is and subsequently received three years funding to enable us to make this service available for more people. In 2024, our support groups continued to flourish and provide a mixture of online and face-to-face support, providing opportunities for individuals affected by cardiomyopathy to meet others in a supportive environment. These groups, led by our team of exceptional volunteers, held 258 meetings during the year. Attendees told us,

"Before the group meeting I felt very alone in my condition. It was so helpful to interact with others that understand."

"Very useful and positive to realise other people are going through similar experiences, it successfully alleviated feelings of isolation"

As well as our online and face to face support groups, our peer support "Heart to Heart" volunteers spoke to 157 people during the year and our Facebook volunteers helped to ensure that this unique source of support remained a safe, informative and supportive forum for over 2,819 active members. One recent caller of our Heart to Heart service said;









'It was good to find out that I'm not going crazy and that my volunteer has gone through all the things I have gone through. It's been amazing having you guys available; without it I don't know what I would have done next"

Achievements & performance

Our Cardiomyopathy UK Specialist Nurses continued to be busy on the Helpline supporting people over the phone and online. Feedback from service users continues to be overwhelmingly positive.

National Conference is always a real highlight for the year. In 2024 our programme focused on supporting the whole person and our packed programme included a wide range of subjects aimed at helping attendees feel better able to manage the physical, practical and emotional impact of cardiomyopathy.

Feedback from the event was overwhelmingly positive. We were especially pleased that so many attendees told us they felt more confident about living with their condition after attending the meeting.

Attendees told us that after the event...

"I feel empowered."

"I can do more to assist myself."

"I am more hopeful and aware of new developments and knowledge."

"Thank you for all your work and for today. Cardiomyopathy UK have been a key part of navigating my diagnosis and coming out the other side. Thank you all!"

Raising awareness

During the year we once again joined with cardiomyopathy charities from around the world as part of an international awareness campaign. This campaign was focused on the genetics of cardiomyopathy and the importance of knowing the history of heart disease in your family. Work as part of this international campaign enabled us to reach more people and in particular, individuals who we do not normally reach.

As well as joining in with international campaigns, we continued to create and share personal stories of people living with cardiomyopathy on our website, in our MyLife Magazine and across our social media channels. This approach proved to be popular with more people engaging with and sharing our important awareness messages.

We measure how well we are doing on social media platforms by tracking our impressions (the number of times our posts are seen) and our engagement (the percentage of people who interact with our posts once they are seen). In 2024 our impressions increased over previous years and our engagement was well over average for the platforms that we use.

Facebook Impressions for 2024 was 162,996

Instagram Impressions for 2024 was 127,670

8% Facebook Engagement	7% Instagram Engagement	4% Twitter Engagement
platform average 0.03%	platform average 0.05%	platform average 0.05%

Achievements & performance

Promoting research

Our research work really took off in 2024. One highlight was the launch of our MyInsight survey which sought to get an accurate snapshot of the state of cardiomyopathy care and treatment across the country. We worked with an expert survey company to help us strengthen the survey methodology. We were really pleased with the response to this survey and the depth of understanding it gives on the experiences of our community. We will be publishing the data in Summer 2025.


Another highlight was the conclusion of our priority setting partnership project. In 2024 we were able to share the results of this work to our community as well as at national research and healthcare professional education events. Our ability to identify and articulate the top research priorities in cardiomyopathy has enabled us to energise the research community and ensure that research projects are designed to truly meet the needs of people affected by cardiomyopathy.

myInsight

1323 responses

We established a research network to better enable those in our community who are interested in understanding research better and/or being involved in research to hear about the latest news and opportunities. The email network already has over 700 subscribers. Successes included connecting two volunteers to an opportunity to fly to Rotterdam to speak about their experiences.

In 2024 we continued our involvement in several research partnership projects, including the BHF funded CureHeart project. This is a hugely exciting, ground-breaking project which aims to develop genetic cures for cardiomyopathy. We also started working with SMASH-HCM, a digital twins research project studying the differences in HCM and how patients should be managed accordingly, and concluded our work on the CRUCIAL project into the impact of the loss of the smallest blood vessels in cognitive impairment and heart failure. Our role in these research partnerships included providing ongoing insight and advice, and ensuring that the cardiomyopathy community are kept up to date with promising research findings.



Laura & Alison presenting PSP at BCS event from MyLife

Achievements & performance

Advocating for people affected by cardiomyopathy

Our team of Change Makers volunteers continued to work hard during the year to help improve care and treatment for people affected by cardiomyopathy. We are incredibly thankful for their hard work in ensuring that the needs of people with cardiomyopathy are recognised by those who manage and deliver care for our community. We reviewed the Change Makers project towards establishing next steps.

Our national advocacy and policy work also increased in 2024. We were pleased to be able to take on board a specialist consultant to enhance our visibility in Scotland and prepare the groundwork for a more formal presence in that nation. We also worked to improve our presence and visibility in Northern Ireland. We were also pleased to be involved in a number of national initiatives including working with NHS England on the establishment of a network of clinical centres for people with amyloidosis cardiomyopathy. We used the general election and ensuing 100 day period to engage with our community about lobbying parliamentarians, towards building relationships with new and long-standing MPs to start conversations on cardiomyopathy care and treatment. We also made sure that the voice of people with cardiomyopathy was head in national consultations on the future of Personal Independence Payments, and the NHS ten year plan.

In 2023 we played an important role in the process of choosing which medications are available to people through the NHS providing evidence to the committees reviewing mavacamten, for hypertrophic cardiomyopathy with obstruction and tafamidis for amyloidosis cardiomyopathy. Last year, we worked hard to help ensure that these newly approved medications were accessible to the community. We also worked to ensure that NICE – which assesses new medicines - engages well with patient communities. Our work on medications also included efforts to improve access to disopyramide – a drug which has been beset by repeated shortages.

Our approach has always been to work in collaboration with a wide range of stakeholders on projects and initiatives that we believe help us to advance the goals set out in our Change Agenda. In 2024 we continued this way of working and played an important part in initiatives such as the Alliance for Heart Failure, The Health and Social Care Alliance Scotland and the Heart and Circulatory Diseases Network. We also joined our voices to collective efforts within the sector on a wide range of issues.

Achievements & performance

Working with healthcare professionals

During the year we continued to provide learning opportunities for health care professionals to ensure that they are better able to diagnose and treat cardiomyopathy. We were able to update our online learning platform and enable more healthcare professionals to access materials on YouTube and on our own website. We were also pleased to be able to provide an in-person education and training day in partnership with the team at Liverpool Heart and Chest Hospital. This event, our first since the COVID-19 pandemic, demonstrated the important role that we can play in bringing healthcare professionals together to improve their understanding of cardiomyopathy and best practice in care and treatment. These events also play an important role in helping healthcare professionals to create the networks and partnerships that better serve their patients.

"A very well organised event and excellent venue. All the speakers were v engaging with really informative sessions." Event attendee

545
Clinicians are making use of our MedEd platform





98
Med Ed Attendees

94%
of event attendees rated the event as excellent





97%
of event attendees said that the event provided valuable insights or tools that could be applied in their healthcare practice

Planning for the future


2024 was the first year of our current five-year strategic plan. This is perhaps the most ambitious strategic plan that we have produced and one which reflects our growing confidence and increasing ability to respond to the changing environment and, in doing so, do more for our community. You can read the plan at **cardiomyopathy.org/our-five-year-strategy**.

During the year, trustees worked with the senior leadership team to ensure that our activities were in-line with our plans and that objectives were met. Trustees also worked with the wider team, our Presidents and other stakeholders to ensure that we were fully up to date with the latest developments in "cardiomyopathy world" and the wider environment to make sure that our plans for 2025 remain relevant and that we are responsive to emerging challenges and opportunities.

Funding our work

Income & expenditure


Income



Community & challenge events
45%
Donations
16%
Legacies
12%
Trusts & foundations
8%
Companies
14%
Other
5%

Expenditure

Providing support
31%
Raising funds
28%
Research & campaigns
16%
Public & professional education
16%
Governance & administration
9%



Funding our work

We are delighted to report that 2024 was another successful year for fundraising. Despite the continued challenges across the fundraising landscape, income for the year grew to £1,054,678 thanks to the generosity of our supporters and commitment of our volunteer fundraisers.

Challenge Events continue to grow, some of our biggest highlights were the London Marathon with a team of 70 runners raising a staggering £222,173 and our cycling events which raised over £38,000. This included a team taking on London to Brighton and London to Paris, and the Great North Run continued raised £25,000. We have continued to develop our events portfolio and are pleased to have introduced new events this year including the Jurassic Coast Walk and a range of shorter distance runs of 5 and 10k.

2024 was the year of exceptional and diverse fundraising amongst our fundraising community. From charity walks, golf days and bake sales to head shaves, MMA fights, and galas, our supporters embraced a wide range of events and activities. A total of 60 different community fundraising events took place throughout the year, with a mix of families, individuals and groups hosting these events. We also had incredible support from clubs and groups, including schools, golf clubs and the Lions who chose Cardiomyopathy UK as their charity of the year, dedicating a full 12 months to support us, and raising up to £10,000 per club.

Many businesses chose to support us, not only raising important donations but also helping to raise awareness of Cardiomyopathy UK among staff and customers. From a football match held at a Championship stadium to a 3 Peak Challenge, our corporate supporters helped make a big impact. Many supporters also reached out to honour the memory of loved ones, organising funeral collections and in memory-events. Our team worked hard to support these families through this journey.



Funding our work



Fundraising responsibly

We are committed to raising funds in a responsible and sustainable way. Our fundraising is conducted either directly by our fundraising staff team or by volunteer fundraisers under their support and guidance. We do not use the services of third-party professional fundraisers or fundraising companies. We work to ensure that our fundraising activity meets the best practice standards laid out by the Charity Commission and the Fundraising Regulator and in 2024 we received no complaints regarding our fundraising activity. Our work is also conducted in line with all GDPR regulations, and we are signed up to the Fundraising Preference Service. The Fundraising Preference Service's purpose is to guard against unreasonable intrusion on privacy, unreasonable persistent approaches for donations or placing undue pressure on a person to give money or other property.

Thank you

We want to say a huge "thank you" to every single fundraiser, donor and volunteer who has raised funds that enable us to continue saving and changing the lives of people affected by cardiomyopathy, now and in the future. We would also like to give our heartfelt thanks for every donation made in memory of a loved one, including funeral collections, in-memory events, donations and gifts given in Wills. These donations create a lasting legacy by moving us a step closer towards our vision of a world where everyone affected by cardiomyopathy can live a long and full life. In 2024 we were also grateful for new and continued financial support from The National Lottery Community Fund, The Masonic Charitable Foundation and Browns Solicitors, as well as for pro bono support from Mayer Brown LLP.



Trustees & officers

The trustees and officers serving during the year and since the year end were as follows:

Trustees

I McPherson OBE
(resigned 30 September 2024)

R Sutton, (Chair)

E Jarman

S Cornish MBE

S Kirkham MC

M Bloom

P Thomas

T Bueser

A Smith

M Rees
(Treasurer)

G Favier

T Amiss

E B K Roy
(appointed 11 January 2025)

Senior management / leadership team

J Rose, Chief Executive Officer
(resigned 28 February 2025)

A Tomlinson, Chief Executive Officer
(appointed 1 March 2025)

Structure, governance & management

Nature of governing document

The charity is controlled by its governing document and constitutes a charitable incorporated organisation. The charity is governed by its constitution adopted on 5 November 2015.

Recruitment & appointment of trustees

The charity continues to review and, where necessary, improve its trustee induction and training resources to ensure that new trustees are equipped to support the work of the charity to their maximum ability. Appropriate policies and procedures have been put in place to ensure good governance including financial management, data protection and employment practice. Trustees maintain a risk register and work with the Chief Executive to ensure that strategies are in place to mitigate against identified risks.

Financial review

Trustees are pleased to report that the charity was able to sustain a strong level of income during the financial year due to the continued efforts of the charity's volunteer fundraisers and the generosity of its supporters.

During the year, the charity made significant investments in its research, policy and marketing activity in line with the charity's five year strategic plan.

The charity recognises that the biggest financial challenge in 2025 will be to secure additional income to fund the charity's research grant-making ambitions.



Structure, governance & management

Partnerships

The charity works closely with expert clinicians from a number of NHS Trusts to help ensure that its work is clinically appropriate and that it can reach as many people with cardiomyopathy as possible. During the year the charity continued to work with its President, Prof. Perry Elliott to develop the International Cardiomyopathy Network (ICoN), a registered UK charity. Cardiomyopathy UK's Chief Executive supported ICoN in their efforts to raise funding from corporate partners and provided strategic advice and patient insight as part of a shared commitment to improving the level of cardiomyopathy knowledge among clinicians, developing best practice and fostering research that will make a real difference to the lives of people with the condition. During the year ICoN made a payment of £15,000 to the charity to cover the costs incurred in providing this support.

The charity continued to have a positive relationship with The British Heart Foundation, The Pumping Marvellous Foundation, Gene People, Heart UK and a number of other charities and healthcare professional organisations that provide support and information relating to heart diseases. Where possible, the charity works in collaboration with these charities.

During 2024 the charity received funding from six pharmaceutical and medical devices companies (AstraZeneca, Pfizer, Tenaya, Cytokinetics. Medtronic and Bristol Myers Squibb) who have developed or who are developing treatments or devices used by people with cardiomyopathy.

The total income from these companies was £151,956 which is 14% of the charity's total income. Income from these sources covered the costs associated with the charity's medical education project, advocacy project, research and awareness raising, national survey and service delivery work. All funding was provided in accordance with the Association of British Pharmaceutical Industry code of practice and the charity's own policy on working with the pharmaceutical industry which is available at: **cardiomyopathy.org/about-us/our-approach**. This policy is designed to ensure the charity's independence.

Policy on reserves

The charity aims to maintain unrestricted reserves at a level that equates to around six to nine months of normal unrestricted expenditure. Trustees believe this to be a prudent amount given that the charity operates in a competitive environment and, as the leading specialist provider of support services for people affected by cardiomyopathy, there is a duty to ensure that it can maintain core services for individuals in need. Reserves at the end of 2024 were equal to just under eight months of normal unrestricted expenditure.

Plans for future periods

Aims and key objectives for future periods

Supporting people with cardiomyopathy and their loved ones

We believe the best way to help people affected by cardiomyopathy is to empower them with the information, skills and support they need to feel in control of their lives. Our goal is to be the most comprehensive and trusted provider of support and information for people living with cardiomyopathy and empower all our community so that everyone has the tools they need to live with the condition.

To achieve this, in 2025 we will continue to provide accurate, accessible and up to date information, resources and learning opportunities for all ages and will further extend our network of peer support opportunities both face to face and online.

We have always recognised that cardiomyopathy has a significant practical and emotional impact. Last year, we were able to secure additional funding from the National Lottery Community Fund to increase the support that we are able to provide to help people manage the emotional and practical impact of cardiomyopathy. This has enabled us to extend the provision of mental health support that we piloted in 2024 so that more people can access this support. We will also continue to provide professional advice for people who are having difficulties in accessing benefits.

Working with health & social care professionals

We want to be the most respected and accessible source of information for health and social care professionals regarding the diagnosis and treatment of cardiomyopathy.

In 2025, we will continue our work to foster a knowledgeable and engaged health and social care community that is better able to serve people affected by cardiomyopathy. In particular, we plan to provide additional learning modules to our professional education platform and, following a successful meeting in 2024, we aim to provide two further face to face educational meetings for health care professionals.



Plans for future periods

Promoting & shaping the most impactful research

Towards the end of 2024 we made an exciting announcement that we are on a journey towards being able to fund research for the first time. 2025 will see the charity making its first grants in line with the future research priorities identified by the priority setting partnership work. The team are working hard to get processes in place towards funding a doctoral fellowship and catalyst grants – to kick-start promising cardiomyopathy research. We will be working with our newly appointed research grants committee and with the National Institute of Health and Care Research to identify the best projects and researchers to support.

As well as this, we will continue to work as part of the BHF Funded CureHeart project which is now in its third year. Our role is to provide insights from people with lived experience of cardiomyopathy and to help ensure that the wider cardiomyopathy community are engaged with the project as it develops. As part of our CureHeart work, we will also be commissioning a research project that aims to improve our understanding of attitudes towards genetic testing and the barriers that may exist to accessing it.

We are pleased that 2024 saw more clinical researchers coming to the charity to ask us to play a part in helping them shape and manage their research project. In 2025, we plan to improve and increase our engagement with researchers and hope this will enable us to play an active and meaningful role in a larger number of research projects.

Raising awareness

Raising public awareness is the key to ensuring that people who may have cardiomyopathy or who are at risk of developing the condition seek medical help. When people are aware of the signs and symptoms of cardiomyopathy and the history of heart disease in their family, they are more likely to seek help, get diagnosed and treated sooner, lowering the risk of a sudden cardiac event.

In 2025 we will once again join with the international network of cardiomyopathy charities to run an international awareness raising campaign which will highlight the signs and symptoms of cardiomyopathy, the importance of knowing your family's "heart history" and encourage people to seek help.



Plans for future periods

Shaping local and national policy throughout the UK

We want to make it simpler and quicker to access appropriate support and treatment and in 2025 we will continue to work with the people who play a role in commissioning and managing the services that people with cardiomyopathy use and who set the policies that have an impact on their lives.

Last year, the Policy and Advocacy team did great work in ensuring that the voices of people with cardiomyopathy were heard. In 2025 we will be working with the National Council of Voluntary Organisations to update our advocacy and policy "calls for action" and put in place appropriate measures to help us understand and articulate the difference that this work makes to the lives of people affected by cardiomyopathy. We will also continue to strengthen our network of advocacy volunteers throughout the UK, and especially in the UK regions where, in the past, we have been under-represented.

Our part in the International Community

In 2025 we will continue to engage with the international cardiomyopathy community by playing a significant role as members of Global Heart Hub's Cardiomyopathy Council, the international network of cardiomyopathy charities.

We will also work to support the International Cardiomyopathy Network (ICoN), a network of Cardiomyopathy healthcare professionals and scientists, as they progress with their new project focusing on improving access to genetic testing across Europe.



Plans for future periods

Statement of trustees' responsibilities

The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable to charities in England and Wales, the Charities Act 2011, Charity , (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Disclosure of information to auditor

Each trustee has taken steps that they ought to have taken as a trustee in order to make themselves aware of any relevant audit information and to establish that the charity's auditor is aware of that information. The trustees confirm that there is no relevant information that they know of and of which they know the auditor is unaware.

The annual report was approved by the trustees of the charity on: **07/06/2025**

Signed on its behalf by:



Rita Sutton
Chair of Trustees

Cardiomyopathy UK
the heart muscle charity

Auditor's report



Auditor's Report

Opinion

We have audited the financial statements of Cardiomyopathy UK (the 'charity') for the year ended 31 December 2024, which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is United Kingdom Accounting Standards, comprising Charities SORP - FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and applicable law (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2024 and of its incoming resources and application of resources for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report.

We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Auditor's Report

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report Trustees' Report.

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Trustees' report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of trustees' responsibilities (set out on page 19), the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's Report

Auditor responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 144 Charities Act 2011 and report in accordance with the Act and relevant regulations made of having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- Obtaining an understanding of the legal and regulatory frameworks that the charity operates in, focusing on those laws and regulations that had a direct effect on the financial statements;
- Enquiry of management to identify any instances of known or suspected instances of fraud;
- Enquiry of management and those charged with governance around actual and potential litigation and claims;
- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates were indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business;
- Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. In addition, as with any audit, there remained a higher risk of non-detection of fraud, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.

Our audit procedures are designed to detect material misstatement. We are not responsible for preventing non-compliance or fraud and cannot be expected to detect noncompliance with all laws and regulations. If a breach of operational regulations is not disclosed to us or evident from relevant correspondence, an audit will not detect that breach.

A further description of our responsibilities is available on the Financial Reporting Council's website at: **www.frc.org.uk/auditorsresponsibilities**. This description forms part of our auditor's report.

Auditor's Report

Use of our report

This report is made solely to the charity's Trustees, as a body, in accordance with the Charities Act 2011. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Matthew Hodson FCA
For and on behalf of Hodson and Co
Statutory Auditor
Wiston House
1 Wiston Avenue
Worthing
West Sussex
BN14 7QL

Date: 14/06/2025



Statement of financial activities
for the year ended 31 December 2024

	Note	Unrestricted funds	Restricted funds	Total 2024	Total 2023
Income and Endowments from					
Donations and legacies	3	£704,375	£264,594	£968,969	£1,014,883
Charitable activities	4	-	£42,700	£42,700	£32,700
Other trading activities	5	£32,433	-	£32,433	-
Investment income	6	£10,576	-	£10,576	£5,768
Total income		**£747,384**	**£307,294**	**£1,054,678**	**£1,053,351**
Expenditure on					
Raising funds	7	(£316,695)	(£10,173)	(£326,868)	(£303,664)
Charitable activities	8	(£436,466)	(£278,111)	(£714,577)	(£558,891)
Other expenditure	9	(£108,509)	-	(£108,509)	(£58,717)
Total expenditure		**(£861,670)**	**(£288,284)**	**(£1,149,954)**	**(£921,272)**
Net income (expenditure)		**(£114,286)**	**£19,010**	**(£95,276)**	**£132,079**
Net movements in funds		**(£114,286)**	**£19,010**	**(£95,276)**	**£132,079**
Reconciliation of funds					
Total funds brought forward		**£678,875**	**£159,086**	**£837,961**	**£705,882**
Total funds carried forward	19	**£564,589**	**£178,096**	**£742,685**	**£837,961**

The notes on pages 29 to 44 form an integral part of these financial statements

Statement of financial activities
for the year ended 31 December 2024

	Note	Unrestricted funds	Restricted funds	Total 2023
Income and Endowments from				
Donations and legacies	3	£839,256	£175,627	£1,014,883
Charitable activities	4	-	£32,700	£32,700
Investment income	6	£5,768	-	£5,768
Total income		**£845,024**	**£208,327**	**£1,053,351**
Expenditure on				
Raising funds	7	(£300,418)	(£3,246)	(£303,664)
Charitable activities	8	(£323,988)	(£234,903)	(£558,891)
Other expenditure	9	(£58,717)	-	(£58,717)
Total expenditure		**(£683,123)**	**(£238,149)**	**(£921,272)**
Net income (expenditure)		**£161,901**	**(£29,822)**	**£132,079**
Net movements in funds		**£161,901**	**(£29,822)**	**£132,079**
Reconciliation of funds				
Total funds brought forward		**£516,974**	**£188,908**	**£705,882**
Total funds carried forward	19	**£678,875**	**£159,086**	**£837,961**

The notes on pages 29 to 44 form an integral part of these financial statements.

All of the charity's activities derive from continuing operations during the above two periods. The funds breakdown for 2023 is shown in note 19.

Balance Sheet
as at 31 December 2024

	Note	Total 2024	Total 2023
Fixed assets			
Tangible assets	14	£16,185	£17,320
Current assets			
Debtors	15	£218,764	£322,098
Cash at bank and in hand	16	£604,354	£575,185
		£823,118	**£897,283**
Creditors			
Amounts falling due within one year	17	**(£96,618)**	**(£76,642)**
Net current assets		**£726,500**	**£820,641**
Net assets		**£742,685**	**£837,961**
Funds of the charity:			
Restricted income funds			
Restricted funds	18	**£178,096**	**£159,086**
Unrestricted income funds			
Unrestricted funds		**£564,589**	**£678,875**
Total funds	19	**£742,685**	**£837,961**

The financial statements on pages 25 to 44 were approved by the trustees, and authorised for issue on 14/06/2025 and signed on their behalf by:



R Sutton
Trustee

Statement of cash flows
for the year

	Note	Total 2024	Total 2023
Cash flows from operating activities			
Net cash (expenditure)/income		(£95,276)	£132,079
Adjustments to cash flows from non-cash items			
Depreciation		£7,793	£3,852
Investment income		(£10,576)	(£5,767)
		(£98,059)	**£130,164**
Working capital adjustments			
Decrease/(increase) in debtors	15	£103,334	(£52,664)
Increase in creditors	17	£19,976	£18,692
Net cash flows from operating activities		**£25,251**	**£96,192**
Cash flows from investing activities			
Interest received		£10,576	£5,767
Acquisitions of tangible assets		(£6,658)	(£16,290)
Net cash flows from investing activities		£3,918	(£10,523)
Net increase in cash and cash equivalents		£29,169	£85,669
Cash and cash equivalents at 1 January		£575,185	£489,516
Cash and cash equivalents at 31 December		£604,354	£575,185

All of the cash flows are derived from continuing operations during the above two periods.

The notes on pages 29 to 44 form an integral part of these financial statements.

Notes to the financial statements
for the year ended 31 December 2024

1. Charity status

Cardiomyopathy UK is a charity limited by guarantee and incorporated in England and Wales.

The address of its registered office is:
75A Woodside Road
Amersham
Buckinghamshire
HP6 6AA

2. Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) `Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Basis of preparation

Cardiomyopathy UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

The presentation currency of these financial statements is Sterling (£), being the currency of the primary economic market in which the entity operates. All amounts in these financial statements have been rounded to the nearest pound unless stated otherwise.

Going concern

The finance statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the levels of reserves for the charity to be able to continue as a going concern.

Key sources of estimation uncertainty

Critical accounting judgements and key sources of estimation uncertainty

The charity makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing material adjustment to the carrying amounts of the assets and liabilities within the next financial year are addressed below.

Useful economic lives of tangible assets:

The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are reassessed annually. They are amended when necessary to reflect the current estimates, based on technological advancement, future investments, economic utilisation and physical condition of the assets. The carrying amount is £16,185 (2023 -£17,320).

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Legacy gifts are recognised on a case by case basis following the grant of probate when the administrator/executor for the estate has communicated in writing both the amount and settlement date. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title to the asset having been transferred to the charity.

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Gift aid

Incoming resources from tax reclaims are included in the Statement of Financial Activities at the same time as the gift to which they relate.

Notes to the financial statements
for the year ended 31 December 2024

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Taxation

The charity is exempt from tax on its charitable activities. The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable entity for UK Tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets costing £500 or more are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class

Computer equipment

Depreciation method and rate

Variable rates on reducing balance

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pensions and other post retirement obligations

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Financial instruments

Classification

The charity has applied the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instrument Issues" of FRS 102 to its financial statements.

Recognition and measurement

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

3. Income from donations and legacies

	Unrestricted funds general	Restricted funds	Total 2024
Donations and legacies			
Legacies	£120,224	-	£120,224
Grants, including capital grants			
Grants	-	£264,594	£264,594
Fundraising	£584,151	-	£584,151
	£704,375	**£264,594**	**£968,969**

3. Income from donations and legacies

	Unrestricted funds general	Restricted funds	Total 2023
Donations and legacies			
Donations	£35,157	-	£35,157
Legacies	£195,068	-	£195,068
Grants, including capital grants			
Grants	£60,800	£175,627	£236,427
Fundraising	£548,231	-	£548,231
	£839,256	**£175,627**	**£1,014,883**

	Unrestricted	Restricted	Total 2024	Total 2023
Browns Solicitors - Helpline	-	-	-	£30,000
Browns Solicitors - Advovacy	-	£30,000	£30,000	-
National Lottery	-	£89,081	£89,081	-
Masonic Charitable Fund	-	-	-	£20,000
Burdett Trust	-	£57	£57	-
National Survey project	-	£35,000	£35,000	£35,000
Pfizer advocacy	-	-	-	£26,700
AstraZeneca (Med Ed)	-	£15,000	£15,000	£10,000
Tenaya	-	£40,200	£40,200	£40,800
BLF	-	-	-	£53,927
The Norton Rose Fulbright Charitable Foundation	-	-	-	£20,000
Cytokinetics	-	£15,256	£15,256	-
Alnlam	-	£10,000	£10,000	-
Devolved Nations	-	£30,000	£30,000	-
	-	**£264,594**	**£264,594**	**£236,427**

4. Income from charitable activities

	Restricted funds	Total 2024
Research	£42,700	£42,700

	Restricted funds	Total 2023
Research	£32,700	£32,700

5. Income from other trading activities

	Unrestricted funds general	Total funds
Trading income		
Other trading income	£32,433	£32,433
Total for 2024	**£32,433**	**£32,433**

6. Investment income

	Unrestricted funds general	Total funds
Interest receivable and similar income		
Interest receivable on bank deposits	£10,576	£10,576
Total for 2024	**£10,576**	**£10,576**
Total for 2023	**£5,768**	**£5,768**

7. Expenditure on raising funds

a) Costs of generating donations and legacie

	Direct costs	Total 2024	Total 2023
Costs of generating donations and legacies	£326,868	£326,868	£303,664
Breakdown of costs		**Total 2024**	**Total 2023**
Staff costs		£202,735	£196,410
Rates and water		£713	£598
Insurance		£486	£433
Postage and stationery		£349	£2,173
Sundries		£3,670	£1,391
Event costs		£58,551	£47,108
Marketing		£29,460	£11,364
Travel and subsistence		£412	£887
Computer		£634	£3,952
Recruitment		£628	£1,027
Staff training		£1,140	£757
Rent		£5,280	£10,526
Professional fees		£6,297	£1,198
Donation charges		£14,752	£19,445
Bank charges		£203	£315
Subscriptions		-	£4,941
Depreciation		£1,558	£1,139
		£326,868	**£303,664**

8. Expenditure on charitable activities

	Unrestricted funds general	Restricted funds	Total funds
Providing Support	£210,072	£137,352	£347,424
Public and medical education	£140,074	£38,436	£178,510
Campaigning	£40,501	£41,313	£81,814
Research	£45,819	£61,010	£106,829
Total for 2024	**£436,466**	**£278,111**	**£714,577**
Total for 2023	**£323,988**	**£234,903**	**£558,891**

	Activity undertaken directly	Total expenditure
Providing Support	£347,424	£347,424
Public and medical education	£178,510	£178,510
Campaigning	£81,814	£81,814
Research	£106,829	£106,829
Total for 2024	**£714,577**	**£714,577**
Total for 2023	**£558,891**	**£558,891**

Notes to the financial statements
for the year ended 31 December 2024

9. Other expenditure

	Unrestricted funds general	Total funds
Staff costs		
Wages and salaries	£50,649	£50,649
Audit fees		
Audit of the financial statements	£6,000	£6,000
Rent	£4,224	£4,224
Office expenses	£46,246	£46,246
Bank charges	£143	£143
Depreciation of office equipment	£1,247	£1,247
Total for 2024	**£108,509**	**£108,509**
Total for 2023	**£58,717**	**£58,717**

10. Net incoming/outgoing resources

	2024	2023
Net (outgoing)/incoming resources for the year include:		
Audit fees	£6,000	£6,800
Other non-audit services	£1,084	£1,032
Depreciation of fixed assets	£7,793	£3,852

11. Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

During the year trustees were reimbursed expenses of £Nil (2023: £2,231) for equipment purchased for the charity and travel and subsistence expenses of £4,302 (2023: £2,411).

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any other benefits from the charity during the year.

12. Staff costs

	2024	2023
Staff costs during the year was:		
Wages and salaries	£491,207	£549,153
Social Security costs	£161,939	£48,162
Other pension costs	£47,539	£12,365
	£700,685	**£609,680**

The monthly average number of persons (including senior management/leadership team) employed by the charity during the year expressed as full time equivalents was as follows:

	2024	2023
Employees	21	19

Contributions to the employee pension schemes for the year totalled £18,410 (2023 - £12,365).

The charity operates a defined contribution pension scheme. The pension cost charge for the year repesents contributions payable by the charity.

The number of employees whose emoluments fell within the following bands was:

	2024	2023
£60,001 - £70,000	1	-
£70,001 - £80,000	-	1
£80,001 - £90,000	1	-

The total employee benefits of the key management personnel of the charity were £85,604 (2023 - £72,200).

13. Taxation

The charity is a registered charity and is therefore exempt from taxation.

14. Tangible fixed assets

	Furniture and equipment	Total
Cost		
At 1 January 2024	£51,409	£51,409
Additions	£6,658	£6,658
At 31 December 2024	**£58,067**	**£58,067**
Depreciation		
At 1 January 2024	£34,089	£34,089
Charge for the year	£7,793	£7,793
At 31 December 2024	**£41,882**	**£41,882**
Net book value		
At 31 December 2024	**£16,185**	**£16,185**
At 31 December 2023	**£17,320**	**£17,320**

15. Debtors

	2024	2023
Trade debtors	£36,180	£34,524
Prepayments and accrued income	£182,584	£287,574
	£218,764	**£322,098**

16. Cash and cash equivalents

	2024	2023
Cash on hand	£61	£65
Cash at bank	£47,898	£108,034
Short-term deposits	£556,395	£467,086
	£604,354	**£575,185**

17. Creditors: amounts falling due within one year

	2024	2023
Trade creditors	£4,387	£11,969
Other taxation and social security	£14,907	£13,160
Other creditors	£15,060	£3,321
Accruals	£62,264	£48,192
	£96,618	**£76,642**

18. Obligations under leases and hire purchase contracts

Operating lease commitments

Total future minimum lease payments under non-cancellable operating leases are as follows:

	2024	2023
Land and buildings		
Within one year	£26,400	£26,400
Between one and five years	£79,200	£79,200
After five years	£50,600	£77,000
	£156,200	**£182,600**

19. Funds

	Balance at 1 Jan 2024	Incoming resources	Resources expanded	Balance 31 Dec 2024
Unrestricted funds				
General				
General fund	£678,875	£747,384	(£861,670)	£564,589
Restricted funds				
Lottery Thriving	-	£61,243	(£22,773)	£38,470
Youth services	£1	-	-	£1
Advocacy	£22,141	£30,000	(£29,473)	£22,668
Community Peer Support (National Lottery Community Fund)	£10,918	£27,839	(£38,762)	(£5)
Online Medical Education	£18	£45,100	(£36,435)	£8,683
Advocacy	£34,725	-	(£12,083)	£22,642
Researching Further	-	£15,036	(£12,174)	£2,862
CAF Support Fund	£309	-	(£309)	-
BMS Grant	£20,362	-	(£20.362)	-
BMS Voice	£17,781	-	(£17,781)	-
Masonic Charitable Fund	£17,008	-	(£17,008)	-
National Survey	£30,553	£35,000	(£24,471)	£41,082
Cure Heart	£5,270	£42,700	(£34,608)	£13,362
Delivering for our community	-	£20,100	(£20,100)	-
Devolved Nations	-	£30,000	-	£30,000
Research appeal	-	£276	-	£276
Crucial	-	-	(£1,945)	(£1,945)
Total restricted funds	**£159,086**	**£307,294**	**(£288,284)**	**£178,096**
Total funds	**£837,961**	**£1,054,678**	**(£1,149,954)**	**£742,685**

Notes to the financial statements
for the year ended 31 December 2024

	Balance at 1 Jan 2023	Incoming resources	Resources expanded	Balance 31 Dec 2023
Unrestricted funds				
General				
General fund	£516,974	£845,024	(£683,123)	£678,875
Restricted funds				
Youth services	£1	-	-	£1
Helpline	£263	£30,000	(£30,263)	-
BBC Children In Need	£1,830	-	(£1,830)	-
Advocacy	-	£45,000	(£22,859)	£22,141
Max's Foundation	£431	-	(£431)	-
Community Peer Support (National Lottery Community Fund)	£547	£53,927	(£43,556)	£10,918
Online Medical Education	-	£10,000	(£9,982)	£18
Advocacy	£62,209	(£18,300)	(£9,184)	£34,725
CAF Resilience Fund	£11,778	-	(£11,778)	-
CAF Support Fund	£4,291	-	(£3,982)	£309
BMS Grant	£31,295	-	(£10,933)	£20,362
BMS Voice	£57,332	-	(£39,551)	£17,781
Masonic Charitable Fund	18,931	£20,000	(£21,923)	£17,008
National Survey	-	£35,000	(£4,447)	£30,553
Cure Heart	-	£32,700	(£27,430)	£5,270
Total restricted funds	**£188,908**	**£208,327**	**(£238,149)**	**£159,086**
Total funds	**£705,882**	**£1,053,351**	**(£921,272)**	**£837,961**

The specific purposes for which the funds are to be applied are as follows:

Advocacy
To cover the costs associated with the charity's regional advocacy volunteers and national advocacy work to improve access to treatment for people with cardiomyopathy.

Community Peer Support (National Lottery Community Fund)
A five year project partly funded by the National Lottery Community Fund to develop an innovative face to face and phone peer support service for people with life limiting heart muscle disease throughout England.

Online Medical Education
To fund the charity's online medical information and learning resource for healthcare professionals.

National Survey
To fund the charity's national state of cardiomyopathy survey ensuring that the charity is able to provide robust evidence to underpin its advocacy work and provide insights as to how to best target its services.

Cure Heart
Income received from the British Heart Foundation funded CureHeart research project looking for genetic cures for cardiomyopathy. Funds go towards the charity's expenditure relating to providing service user insights as part of the research team.

CAF Support Fund
Funding to ensure that the charity can continue to deliver its core services and improve its ability to reach more communities and individuals affected by cardiomyopathy. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

BMS Grant
Funding from the pharmaceutical company, Bristol Myers Squibb to cover the costs of the charity's national conference, website, outreach and awareness work.

BMS Patient Voice
Funding from the pharmaceutical company, Bristol Myers Squibb to support a program which will use patient experiences to help shape and improve the support and treatment of cardiomyopathy.

Masonic Charitable Fund
2-year grant to fund the development of the Youth Support Program.

Thriving together (Lottery)
A 3-year project partly funded by the national lottery community fund to develop an innovative face to face and phone peer support service for people with life limiting heart muscle disease throughout England. This includes enhancements in our service delivery that is centred around mental health, wellbeing and welfare.

Reaching Further
A grant to enable the charity to create impactful awareness raising and support content that can reach more people who have cardiomyopathy or who are at risk of having the condition.

Devolved Nations
Covers the cost of our advocacy work and enhancing our policy and advocacy activity -working to improve access to care and treatment for people affected by cardiomyopathy - across all UK devolved nations.

Crucial
An international research partnership aiming to understand the heart-brain axis, particularly the role of the microvasculature in impacting cognitive decline. The funds received are to cover our patient insight and dissemination activities in relation to the project.

Delivering for our community
To fund part of the deliverance of the annual Cardiomyopathy UK conference.

20. Analysis of net assets between funds

	Unrestricted funds general	Restricted funds	Total funds 31 Dec 2024
Tangible fixed assets	£16,185	-	£16,185
Current assets	£645,022	£178,096	£823,118
Current liabilities	(£96,618)	-	(£96,618)
Total net assets	**£564,589**	**£178,096**	**£742,685**

	Unrestricted funds general	Restricted funds	Total funds 31 Dec 2023
Tangible fixed assets	£17,320	-	£17,320
Current assets	£738,197	£159,086	£897,283
Current liabilities	(£76,642)	-	(£76,642)
Total net assets	**£678,875**	**£159,086**	**£837,961**

21. Related party transactions

There were no related party transactions in the year.

Cardiomyopathy UK
the heart muscle charity

Contact us:

75a Woodside Road, Amersham, Buckinghamshire, HP6 6AA

01494 791 224

Helpline: 0800 018 1024

contact@cardiomyopathy.org

www.cardiomyopathy.org

Keep in touch:

facebook.com/cardiomyopathyuk

@cardiomyopathyuk

@cardiomyopathy

youtube.com/cardiomyopathyuk

Cardiomyopathy UK is registered as a charity in England and Wales (no. 1164263) and in Scotland (no. SC053398)

CARDIOMYOPATHY UK

England & Wales - Charity number 1164263

Accounts








Cardiomyopathy UK
the heart muscle charity

20 Annual 23 Report

The difference we made in 2023












We're Cardiomyopathy UK

We save and improve the lives of people affected by cardiomyopathy. Our vision is a world where everyone affected by cardiomyopathy should live a long and fulfilling life.

In pursuit of this vision:

We raise awareness of the condition so that more people know the signs and symptoms and can be diagnosed early.

We campaign to improve access to quality treatment that meets the needs of people with cardiomyopathy.

We promote clinical research to advance the development of new treatments and provide hope for the future.

We support people affected by cardiomyopathy, every step of the way, so that nobody has to face cardiomyopathy alone.

1 in 250 people have cardiomyopathy. That's approximately 266,000 people in the UK currently living with the condition.



Cardiomyopathy UK
the heart muscle charity

Contents

Reference and administrative details 4

A message from our chair 5-6

Trustees' report 8-21

- Achievements in 2023 9-12
- Funding our work 13-15
- Trustee's and officers 16
- Structure governance and management 17
- Financial review 18
- Partnerships 19
- Plans for future periods 20-21

Independent auditors' report 23-27

- Statement of financial activities 28-29
- Statement of cash flows 31
- Notes to the financial statements 32-48



Administrative details

Trustees:

R Sutton, (Chair)
E Jarman
I McPherson OBE
S Cornish MBE
S Kirkham MC
M Bloom
P Thomas
T Bueser
A Smith
M Rees, (Treasurer)
G Favier
T Amiss

Senior Management / Leadership Team

Mr J. Rose, Chief Executive Officer

Charity Reg Number:

1164263

Registered Office:

75a Woodside Road
Amersham
Buckinghamshire
HP6 6AA

Auditor:

Hodson & Co
Wiston House, 1 Wiston Avenue
Worthing
West Sussex
BN14 7QL

Bankers:

Charity Aid Foundation Limited
Kings Hill
West Malling
Kent, ME19 4TA

Lloyds
82 High Street Rickmansworth
Hertfordshire, WD3 1AG

A Message From Our Chair



At the beginning of the year, we participated in International Women's Day by celebrating our founder, Carolyn Biro. Through Carolyn's dedication, drive and determination to help others, Cardiomyopathy UK was established. Carolyn's vision of expert support so that everyone affected by cardiomyopathy can lead long and fulfilling lives, remains at the core of the charity's work today.

The world of cardiomyopathy is changing, with recent new and exciting developments in research and drug development leading to greater understanding of cardiomyopathy and its impact. Now is the time for the charity to be more ambitious in what we aim to achieve. Throughout the year we have been busy working on a new and ambitious five-year strategic plan. The plan will come into effect in January 2024 and will run through to December 2028.

Having provided evidence from our national survey, focus groups, helpline and presentations, in June, we welcomed the long-awaited good news that NICE (National Institute for Health & Care Excellence) had approved Mavacamten, the first treatment specifically for hypertrophic cardiomyopathy with obstruction, and that people would be able to access the drug on the NHS.

In August we welcomed the publication of the new European Society of Cardiology Guidelines for Clinical Practice on the Management of Cardiomyopathies. The guidelines are aimed at helping healthcare professionals to diagnose and manage patients with cardiomyopathies of all ages, and to provide a practical diagnostic and treatment framework for patients and their relatives. The challenge will be to make sure GPs read the guidelines and work with them.

Many people do manage and live well with cardiomyopathy, however we also recognise that there are those who may be newly diagnosed or are facing the scary world of heart failure and heart transplant assessment. Our conference in November "Engaging Minds, Empowering Action" was attended by circa three hundred people, from newly diagnosed to those who have been living with the condition for many years. Delegates were able to learn from a wide range of sessions and engage with an extensive team of expert speakers. The charity has continued to be a lifeline for those affected by cardiomyopathy for more than thirty years. That said, we know because our members tell us, there is much more to be done.

We continue to play an active part in the international cardiomyopathy community, enabling us to ensure people affected by cardiomyopathy have a stronger voice. We are one of twenty four member charities that span across fourteen different countries that form the Cardiomyopathy Patient Council, which is part of Global Heart Hub that brings together over one hundred patient-led heart disease charities from across the globe. As part of this group, we played a leading role in delivering an international awareness campaign and produced international standards in involving people with cardiomyopathy in research activity.

A Message From Our Chair

We continue to support and work with ICoN, a newly formed charity chaired by our President, Perry Elliott. ICoN is made up of a network of healthcare professionals. We assisted with the development of their strategic plan, securing funding and creation of their policy manifesto.

Our team of trustees bring with them a wide range of knowledge, experiences and skills. During the year we welcomed three new trustees, bringing our numbers to twelve and strengthening the board with their skills in finance and marketing. Our trustees work hard to achieve best practice in charity governance, and take the lead in monitoring our progress against plans to ensure that we deliver on time and on budget. As well as attending board meetings, trustees participate in support groups and sub-groups and work directly with a member of the senior management team.

We will always be truly grateful for the dedication, enthusiasm and passion our volunteers, supporters, staff, professionals, and many others give to the charity. With our army of support, we will continue be there for anyone whose life is affected by cardiomyopathy. Through the direction of our Chief Executive, the charity continues to be in good shape financially. Grateful thanks go to our grant givers, community and event fundraisers and all who support the work of the charity through their generous donations.

I would like to take this opportunity to thank and commend my fellow trustees, presidents, staff, volunteers, and professionals for their time and the work they have undertaken this past year. Together they enable us to continue to support our community and make a difference in people's lives.

As we begin the process of delivering year one of the charity's ambitious five-year strategic plan, I remain optimistic for the future and look forward to the new and exciting opportunities that lie ahead. There is still a great deal of work to be done to bring about positive change in the lives of our cardiomyopathy community.



Rita Sutton,
Chair of the Board of Trustees

Cardiomyopathy UK
the heart muscle charity

Trustees' report



Objectives & Activities

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements and auditors' report of the charitable company for the year ended 31 December 2023.

Public Benefit

Cardiomyopathy UK confirms that in setting its programme of activity, it has had due regard to the Charity Commission's general guidance on public benefit. The programme of activity also conforms to the charity's charitable objectives and aims. No persons are excluded from the work of the charity on grounds of gender, race or religion.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Achievements in 2023

Providing support and information

Our support and information services aim to help people affected by cardiomyopathy feel more informed, less scared, and better able to cope day to day. Together, our services tackle the physical, emotional and practical impact that cardiomyopathy has on a person and on their loved ones.

In 2023, we were able to continue to provide a mixture of online and face-to-face support groups providing opportunities for individuals affected by cardiomyopathy to meet others in a supportive environment. These groups, led by our team of volunteers, held over 220 meetings during the year. One attendee told us,

"It felt like a great safe space which allowed people to release their emotions and allowed us all to support each other and give hope and reassurance."

As well as our online and face to face support groups, our peer support volunteers spoke to 265 people during the year and our Facebook volunteers helped to ensure that this unique source of support remained a safe, informative and supportive forum for over 2,000 active members.

Our Cardiomyopathy UK Specialist Nurses continued to be busy on the Helpline supporting people over the phone and online. Feedback from service users continues to be overwhelmingly positive.









As ever, one of the highlights of the year was our National Conference. We had a packed programme with sessions covering all aspects of cardiomyopathy and providing participants with the knowledge, support and motivation needed to feel empowered and better able to cope with their cardiomyopathy. Feedback from the event was overwhelmingly positive. We were especially pleased that so many attendees told us they felt more confident about living with their condition after attending the meeting.

"I felt a lot of support at the conference today and this helps me navigate the twists and turns of life with cardiomyopathy"

"I am more positive for the future and for my family members and the younger generation"

Achievements in 2023

Raising awareness

During the year we once again joined with cardiomyopathy charities from around the world as part of an international awareness campaign. This campaign was focused on the role of genetics in cardiomyopathy and the importance of knowing the history of heart disease in your family. Work as part of this international campaign enabled us to reach more people than ever before.

As well as joining in with international campaigns, we continued to create and share personal stories of people living with cardiomyopathy on our website, in our MyLife Magazine and across our social media channels. This approach proved to be popular with more people engaging with and sharing our important awareness messages.



The international cardiomyopathy awareness campaign 2023:

12 countries participated in the campaign, creating...

8.3 million opportunities for people to see, and...

Over 6.6 million impressions on social media

69% increase in engagement on Instagram

76% increase in engagement on X

Achievements in 2023

Promoting research

2023 saw the charity build on its work to promote research that aims to make a real and lasting difference to the lives of people affected by cardiomyopathy. One way in which we do this is through ensuring that the experiences of people with cardiomyopathy help to shape clinical research projects. The largest of these projects is the British Heart Foundation funded CureHeart project where we continued to play an active role as part of the research team. In addition to CureHeart, and a range of other smaller research projects, we continued to promote the HeartHive platform, encouraging more people to sign up and be connected to research opportunities.

As we take our first steps to become a funder of research, we want to make sure that the work that we support addresses the needs of our community. In 2023 we worked with the James Lind Alliance on a priority setting partnership, bringing together our community, researchers and other stakeholders to identify and agree the top ten research priorities. The results of this work will be published in 2024 and will be used to set our future research strategy.

Advocating for people affected by cardiomyopathy

Our team of Change Makers volunteers continued to work hard during the year to help improve care and treatment for people affected by cardiomyopathy. We are incredibly thankful for their hard work in ensuring that the needs of people with cardiomyopathy are recognised by those who manage and deliver care for our community.

"I volunteered for the Change Maker programme so I could speak up on behalf of those whose journey through the diagnosis and care pathway wasn't as good as mine. I've met some amazing people working to deliver better outcomes for people living with cardiomyopathy. It's great to be involved with an organisation that really values the patient voice and to see how policy work can improve lives." – Andy, Change Maker volunteer

During the year we also played an important role in the process of choosing which medications are available to people through the NHS. We provided evidence to the committees reviewing Mavacamten, for hypertrophic cardiomyopathy with obstruction and Tafamidis for amyloidosis cardiomyopathy. We are pleased to say that both these drugs have now been approved and for the first time ever, medication specifically for people with certain types of cardiomyopathy is now available.

Our approach has always been to work in collaboration with a wide range of stakeholders on projects and initiatives that we believe help us to advance the goals set out in our Change Agenda. In 2023 we continued this way of working and played an important part in initiatives such as The Alliance for Heart Failure, The Health and Social Care Alliance Scotland and work to address the palliative care needs of people with heart failure.

Achievements in 2023

Working with healthcare professionals

During the year we continued to provide learning opportunities for health care professionals to ensure that they are better able to diagnose and treat cardiomyopathy. We were able to expand our online learning platform and develop new content focusing on genetics and arrhythmogenic cardiomyopathy which will be launched in 2024.



clinicians are making use of our MedEd platform

Planning for the future


During the year Trustees led the process of developing our new five-year strategic plan. As part of this process, we consulted widely with our volunteers and service users as well as with healthcare professionals. This is perhaps the most ambitious strategic plan that we have produced and one which reflects our growing confidence and increasing ability to respond to the changing environment and, in doing so, do more for our community. You can read the plan at:

www.cardiomyopathy.org/our-five-year-strategy



Funding our work
Income & expenditure

Income



Community & challenge events 39%
Donations 16%
Legacies 19%
Trusts & foundations 13%
Companies 11%
Other 2%

Expenditure

Providing support 39%
Raising funds 33%
Research & campaigns 7%
Public & professional education 15%
Governance & administration 6%



Funding our work

We are delighted to report that 2023 was another successful year for fundraising. Despite the continued challenges of the fundraising environment, income for the year grew to £1,053,351 thanks to the generosity of our supporters and commitment of our volunteer fundraisers. Unrestricted income for the year grew considerably, mainly due to the receipt of a large legacy towards the end of the year.

2023 saw a rapid growth in our challenge events portfolio, with our biggest London Marathon team to date, where sixty-two runners ventured across the capital raising £164,000. The Great North Run had eleven taking part raising £10,000 and October was our biggest month for challenge events with eighteen participating across a range of events including the Royal Parks, Manchester Half and Yorkshire 3 Peaks. We had several longstanding family supporters rise to the challenge, including one family who completed the London Classics raising just under £5,000.

The cost-of-living crisis continued to impact community fundraising, where we saw fewer community events being organised, but we did see a rise in the amount of income they raised - for example, a gala raising over £7,000, a football match raising over £4,000 and a coffee morning raising £4,500.

We are so grateful for our regular fundraising families who really help make a difference and this year we had four of our longstanding community fundraisers hit huge milestones - one family reached £100,000 since they began supporting us over ten years ago. Two reached £30,000 and one reached £50,000.

As digital fundraising grew, we were pleased to be able to create and launch our first digital fundraising pack, with downloadable fundraising resources and ideas to help our fundraisers. We also created our Much Loved 'Always in our Hearts' page which is a digital platform where people can pay tribute to their loved ones.



Funding our work

Fundraising responsibly

We are committed to raising funds in a responsible and sustainable way. Our fundraising is conducted either directly by our fundraising staff team or by volunteer fundraisers under their support and guidance. We do not use the services of third-party professional fundraisers or fundraising companies. We work to ensure that our fundraising activity meets the best practice standards laid out by the Charity Commission and the Fundraising Regulator and in 2023 we received no complaints regarding our fundraising activity. Our work is also conducted in line with all GDPR regulations and we are signed up to the Fundraising Preference Service. The Fundraising Preference Service's purpose is to guard against unreasonable intrusion on privacy, unreasonable persistent approaches for donations or placing undue pressure on a person to give money or other property.

Thank you

We want to say a huge "thank you" to every single fundraiser, donor and volunteer who has raised funds that enable us to continue saving and changing the lives of people affected by cardiomyopathy, now and in the future. We would also like to give our heartfelt thanks for every donation made in memory of a loved one, including funeral collections, in memory events, donations and gifts given in Wills. These donations create a lasting legacy by moving us a step closer towards our vision of a world where everyone affected by cardiomyopathy can live a long and full life. In 2023 we were also grateful for new and continued financial support from The National Lottery Community Fund, The Masonic Charitable Foundation, Browns Solicitors and Norton Rose Fulbright as well as for pro bono support from Mayer Brown.

COMMUNITY FUND

Masonic Charitable Foundation

MAYER | BROWN

NORTON ROSE FULBRIGHT



Trustees & Officers

The trustees and officers serving during the year and since the year end were as follows:

Trustees:

I McPherson OBE
R Sutton, (Chair)
E Jarman
S Cornish MBE (appointed 1 July 2023)
S Kirkham MC
M Bloom (appointed 18 March 2023)
P Thomas
T Bueser
A Smith
M Rees, (Treasurer) (appointed 18 March 2023)
G Favier
T Amiss

Senior Management / Leadership Team

Mr J. Rose, Chief Executive Officer



Structure, governance & management

Nature of governing document

The charity is controlled by its governing document and constitutes a charitable incorporated organisation. The charity is governed by its constitution adopted on 5 November 2015.

Recruitment and appointment of trustees

The charity continues to review and, where necessary, improve its trustee induction and training resources to ensure that new trustees are equipped to support the work of the charity to their maximum ability. Appropriate policies and procedures have been put in place to ensure good governance including financial management, data protection and employment practice. Trustees maintain a risk register and work with the Chief Executive to ensure that strategies are in place to mitigate against identified risks.

Financial Review

Trustees are pleased to report that the charity was able to sustain a strong level of income during the financial year due to the continued efforts of the charity's volunteer fundraisers and the continued generosity of its supporters.

During the year, the charity was also able to build its un-restricted reserves in anticipation of making significant investments in its research, policy and marketing activity in 2024 in line with the charity's five year strategic plan.

The charity recognises that the biggest financial challenge in 2024 will be to secure ongoing project funding for a number of core support services where current funding is due to come to an end. The fundraising team will be focused on this along with meeting the challenge of raising additional income to fund the charity's research grant making ambitions.

Partnerships

The charity works closely with expert clinicians from a number of NHS Trusts to help ensure that its work is clinically appropriate and that it can reach as many people with cardiomyopathy as possible.

During the year the charity continued to work with its President, Prof. Perry Elliott to develop the International Cardiomyopathy Network (ICoN), a registered UK charity. Cardiomyopathy UK's Chief Executive supported ICoN in their efforts to raise funding from corporate partners and provided strategic advice and patient insight as part of a shared commitment to improving the level of cardiomyopathy knowledge among clinicians, developing best practice and fostering research that will make a real difference to the lives of people with the condition. During the year ICoN made a payment of £15,000 to the charity to cover the costs incurred in providing this support.

The charity continued to have a positive relationship with The British Heart Foundation, The Pumping Marvellous Foundation, Gene People, Heart UK and a number of other charities that provide support and information relating to heart diseases. Where possible, the charity works in collaboration with these charities.

During 2023 the charity received funding from five pharmaceutical companies (AstraZeneca, Pfizer, Tenaya, Cytokinetics and Bristol Myers Squibb) who have developed or who are developing treatments used by people with cardiomyopathy. The total income from these companies was £161,700; under 15% of the charity's total income. Income from these sources covered the costs associated with the charity's medical education project, advocacy project, research and awareness raising, national survey and service delivery work. All funding was provided in accordance with the Association of British Pharmaceutical Industry code of practice and the charity's own policy on working with the pharmaceutical industry which is available at:

www.cardiomyopathy.org/about-us/our-approach

This policy is designed to ensure the charity's independence.

Policy on reserves

The charity aims to maintain unrestricted reserves at a level that equates to around six to nine months of normal unrestricted expenditure. Trustees believe this to be a prudent amount given that the charity operates in a competitive environment and, as the leading specialist provider of support services for people affected by cardiomyopathy, there is a duty to ensure that it can maintain core services for individuals in need.

Towards the end of the year the charity was notified of a large legacy of £154K. This resulted in unrestricted reserves increasing to over 12 months of normal expenditure at the end of the year. Trustees, however, are aware that the charity faces increased unrestricted costs in 2024 as a number of restricted funding grants are due to come to an end during the year and costs will be covered from unrestricted funds. Trustees have also agreed to invest in the charity's research and policy work and its marketing and communication work in 2024 and subsequently expect that unrestricted reserves will return to the six to nine month target by the end of 2024.

Plans for future periods

Aims & key objectives for future periods

Supporting people with cardiomyopathy and their loved ones

We believe the best way to help people affected by cardiomyopathy is to empower them with the information, skills and support they need to feel in control of their lives. Our goal is to be the most comprehensive and trusted provider of support and information for people living with cardiomyopathy and empower all our community so that everyone has the tools they need to live with the condition.

To achieve this, in 2024 we will continue to provide accurate, accessible and up to date information, resources and learning opportunities for all ages and hope to further extend our network of peer support opportunities both face to face and online.

We have always recognised that cardiomyopathy has a significant practical and emotional impact. That is why in 2024 we will be piloting a new professionally led mental health service and increasing the number of people that we can advise on accessing personal independence payments.

Working with health and social care professionals

We want to be the most respected and accessible source of information for health and social care professionals regarding the diagnosis and treatment of cardiomyopathy.

In 2024, we will continue our work to foster a knowledgeable and engaged health and social care community that is better able to serve people affected by cardiomyopathy. In particular, we plan to provide two new online learning modules to our professional education platform and towards the end of the year, return to providing face to face education and training meetings for healthcare professionals, something that we have not done since the COVID-19 pandemic.

Promoting & shaping the most impactful research

Over the last few years we have been doing more to ensure that we can be a leading driver of the highest quality research that delivers real benefits to our community.

We will continue to shape research projects through providing the insights of people with lived experience of cardiomyopathy and will run our bi-annual state of cardiomyopathy national survey.

Trustees also hope to begin the process of providing research funding to projects that focus on our research priorities. We will be working with key stakeholders and, with the support of the Association of Medical Research Charities, putting in place the structures and funding needed to make research grants in line with best practice.

Plans for future periods

Aims & key objectives for future periods

Raising awareness

Raising public awareness is the key to ensuring that people who may have cardiomyopathy or who are at risk of developing the condition seek medical help. When people are aware of the signs and symptoms of cardiomyopathy and the history of heart disease in their family, they are more likely to seek help, get diagnosed and treated sooner, lowering the risk of a sudden cardiac event.

In 2024 we plan to join with the international network of cardiomyopathy charities to lead on an international awareness raising campaign which will highlight the signs and symptoms of cardiomyopathy, the importance of knowing your family's "heart history" and encourage people to seek help.

We will also invest in our marketing and communications work to develop further cardiomyopathy awareness raising materials, case study videos and digital assets. We will be doing more to seek media opportunities and use our own social media platforms to reach as many people as possible and especially individuals and communities that we have not reached before.

Shaping local and national policy throughout the UK

We want to make it simpler and quicker to access appropriate support and treatment and in 2024 we will continue to work with the people who play a role in commissioning and managing the services that people with cardiomyopathy use and who set the policies that have an impact on their lives.

As services and NHS structures in Scotland differ from those in the rest of the UK, in 2024 we aim to do more to ensure that people in that region get the support that they need. We will be working to increase our networks with politicians, health service leaders and other stakeholders in Scotland. We will also continue to strengthen our network of advocacy volunteers throughout the UK to ensure that the voice of people with cardiomyopathy is heard.

Our part in the international community

In 2024 we will continue to engage with the international cardiomyopathy community by playing a significant role as members of Global Heart Hub's Cardiomyopathy Council, the international network of cardiomyopathy charities.

We also plan to continue our work to provide support and advice to the International Cardiomyopathy Network (ICoN), a network of cardiomyopathy healthcare professionals and scientists. We will work with them to develop their programmes for 2024 and beyond and ensure that their work meets the needs of the cardiomyopathy community.

Statement of trustees' responsibilities

The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable to charities in England and Wales, the Charities Act 2011, Charity , (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Disclosure of information to auditor

Each trustee has taken steps that they ought to have taken as a trustee in order to make themselves aware of any relevant audit information and to establish that the charity's auditor is aware of that information. The trustees confirm that there is no relevant information that they know of and of which they know the auditor is unaware.

The annual report was approved by the trustees of the charity on 8 June 2024 and signed on its behalf by:



R Sutton Trustee

Cardiomyopathy UK
the heart muscle charity

Auditor's report



Auditor's Report

Opinion

We have audited the financial statements of Cardiomyopathy UK (the 'charity') for the year ended 31 December 2023, which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is United Kingdom Accounting Standards, comprising Charities SORP - FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and applicable law (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2023 and of its incoming resources and application of resources for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Auditor's Report

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report Trustees' Report.

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Trustees' report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of trustees' responsibilities (set out on page 22), the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's Report

Auditor responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 144 Charities Act 2011 and report in accordance with the Act and relevant regulations made of having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- Obtaining an understanding of the legal and regulatory frameworks that the charity operates in, focusing on those laws and regulations that had a direct effect on the financial statements;
- Enquiry of management to identify any instances of known or suspected instances of fraud;
- Enquiry of management and those charged with governance around actual and potential litigation and claims;
- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates were indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business;
- Reviewing minutes of meetings of those charged with governance; and
- Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards.

In addition, as with any audit, there remained a higher risk of non-detection of fraud, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. Our audit procedures are designed to detect material misstatement. We are not responsible for preventing non-compliance or fraud and cannot be expected to detect noncompliance with all laws and regulations. If a breach of operational regulations is not disclosed to us or evident from relevant correspondence, an audit will not detect that breach.

Auditor's Report

Auditor responsibilities for the audit of the financial statements (cont)

A further description of our responsibilities is available on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities.

This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's Trustees, as a body, in accordance with the Charities Act 2011. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.



Matthew Hodson FCA
For and on behalf of Hodson and Co, Statutory Auditor

Wiston House
1 Wiston Avenue Worthing
West Sussex BN14 7QL

Date: 8 June 2024

Statement of financial activities for the year ended 31 December 2023

	Note	Unrestricted funds £	Restricted funds £	Total 2023 £	Total 2022 £
Income and Endowments from:					
Donations and legacies	3	839,256	175,627	1,014,883	895,732
Charitable activities	4	-	32,700	32,700	135,208
Investment income	5	5,768	-	5,768	193
Total income		845,024	208,327	1,053,351	1,031,133
Expenditure on:					
Raising funds	6	(300,418)	(3,246)	(303,664)	(289,164)
Charitable activities	7	(323,988)	(234,903)	(558,891)	(540,890)
Other expenditure	8	(58,717)	-	(58,717)	(62,159)
Total expenditure		(683,123)	(238,149)	(921,272)	(892,213)
Net income (expenditure)		161,901	(29,822)	132,079	138,920
Net movements in funds		161,901	(29,822)	132,079	138,920
Reconciliation of funds					
Total funds brought forward		516,974	188,908	705,882	566,962
Total funds carried forward	19	678,875	159,086	837,961	705,882

The notes on pages 32 to 48 form an integral part of these financial statements

Statement of financial activities for the year ended 31 December 2023

	Note	Unrestricted funds £	Restricted funds £	Total 2022 £
Income and Endowments from:				
Donations and legacies	3	650,719	245,013	895,732
Charitable activities	4	36,808	98,400	135,208
Investment income	5	193	-	193
Total income		687,720	343,413	1,031,133
Expenditure on:				
Raising funds	6	(287,838)	(1,326)	(289,164)
Charitable activities	7	(219,691)	(321,199)	(540,890)
Other expenditure	8	(57,109)	(5,050)	(62,159)
Total expenditure		(564,638)	(327,575)	(892,213)
Net income		123,082	15,838	138,920
Transfers between funds		(18)	18	-
Net movement in funds		123,064	15,856	138,920
Reconciliation of funds				
Total funds brought forward		393,910	173,052	566,962
Total funds carried forward	19	516,974	188,908	705,882

All of the charity's activities derive from continuing operations during the above two periods. The funds breakdown for 2022 is shown in note 19.

The notes on pages 32 to 48 form an integral part of these financial statements

Balance Sheet as at 31 December 2023

	Note	2023 £	2022 £
Fixed assets			
Tangible assets	14	17,320	4,882
Current assets			
Debtors	15	322,098	269,433
Cash at bank and in hand	16	575,185	489,516
		897,283	758,949
Creditors: Amount falling due within one year	17	(76,642)	(57,949)
Net current assets		820,641	701,000
Net assets		837,961	705,882
Funds of the charity:			
Restricted income funds			
Restricted funds	19	159,086	188,908
Unrestricted income funds			
Unrestricted funds		678,875	516,974
Total funds	19	837,961	705,882

The financial statements on pages 28 to 48 were approved by the trustees, and authorised for issue on 8 June 2024 and signed on their behalf by:



R Sutton Trustee

The notes on pages 32 to 48 form an integral part of these financial statements

Statement of Cash Flows for the Year Ended 31 December 2023

	Note	2023 £	2022 £
Cash flows from operating activities			
Net cash income		132,079	138,920
Adjustments to cash flows from non-cash items			
Depreciation		3,852	5,525
Investment income		(5,767)	(193)
		130,164	144,252
Working capital adjustments			
(Increase)/decrease in debtors	15	(52,664)	4,232
Increase/(decrease) in debtors	17	18,692	(14,056)
Net cash flows from operating activities		96,192	134,428
Cash flows from investing activities			
Interest received		5,767	193
Acquisitions of tangible assets		(16,290)	(1,536)
Net cash flows from investing activities		(10,523)	(1,343)
Net increase in cash and cash equivalents		85,669	133,085
Cash and cash equivalents at 1 January		489,516	356,431
Cash and cash equivalents at 31 December		575,185	489,516

All of the cash flows are derived from continuing operations during the above two periods.

The notes on pages 32 to 48 form an integral part of these financial statements

Notes to the financial statements for the Year Ended 31 December 2023

1. Charity status

Cardiomyopathy UK is a charity limited by guarantee and incorporated in England and Wales. The address of its registered office is:

75A Woodside Road Amersham Buckinghamshire HP6 6AA

These financial statements were authorised for issue by the trustees on 8 June 2024.

2. Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) `Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Basis of preparation

Cardiomyopathy UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

The presentation currency of these financial statements is Sterling (£), being the currency of the primary economic market in which the entity operates. All amounts in these financial statements have been rounded to the nearest pound unless stated otherwise.

Notes to the financial statements for the Year Ended 31 December 2023

Going concern

The finance statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the levels of reserves for the charity to be able to continue as a going concern.

Key sources of estimation uncertainty

Critical accounting judgements and key sources of estimation uncertainty
The charity makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing material adjustment to the carrying amounts of the assets and liabilities within the next financial year are addressed below.

Useful economic lives of tangible assets:
The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are reassessed annually. They are amended when necessary to reflect the current estimates, based on technological advancement, future investments, economic utilisation and physical condition of the assets. The carrying amount is £17,318 (2022 -£4,880).

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Legacy gifts are recognised on a case by case basis following the grant of probate when the administrator/executor for the estate has communicated in writing both the amount and settlement date. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title to the asset having been transferred to the charity.

Notes to the financial statements for the Year Ended 31 December 2023

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Gift aid

Incoming resources from tax reclaims are included in the Statement of Financial Activities at the same time as the gift to which they relate.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Taxation

The charity is exempt from tax on its charitable activities. The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable entity for UK Tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets costing £500 or more are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Computer equipment	variable rates on reducing balance

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.
Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pensions and other post retirement obligations

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Financial instruments

Classification

The charity has applied the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instrument Issues" of FRS 102 to its financial statements.

Recognition and measurement

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

3. Income from donations and legacies

	Unrestricted funds general £	Restricted funds £	Total 2023 £
Donations and legacies;			
Donations	35,157	-	35,157
legacies	195,068	-	195,068
Grants, including capital grants;			
Grants	60,800	175,627	236,427
Fundraising	548,231	-	548,231
	839,256	175,627	1,014,833

	Unrestricted funds general £	Restricted funds £	Total 2022 £
Donations and legacies;			
Donations	143,430	-	143,430
legacies	95,986	-	95,986
Grants, including capital grants;			
Grants	14,000	245,013	259,013
Fundraising	397,303	-	397,303
	650,719	245,013	895,732

Notes to the financial statements for the Year Ended 31 December 2023

Grants included above are as follows:	Note	Unrestricted £	Restricted £	2023 Total £	2022 Total £
Browns Solicitors - Helpline		-	30,000	30,000	30,000
Browns Solicitors - Advocacy		-	-	-	50,400
Alexander Jansons Fund		-	-	-	35
Big Lottery Fund - Community Peer Support		-	-	-	44,918
Max's Foundation		-	-	-	14,776
Masonic Charitable Fund		-	20,000	20,000	20,000
Burdett Trust		-	-	-	2,306
Arrhythmogenic ACT		-	-	-	57,628
CAF Resilience Fund		-	-	-	10,000
CAF Main Fund		-	-	-	14,950
The Moss Family Charitable Trust		-	-	-	1,000
DHPA Project		-	-	-	13,000
National Survey project		-	35,000	35,000	-
Pfizer advocacy		-	26,700	26,700	-
AstraZeneca (MedEd)		-	10,000	10,000	-
BLF		-	53,927	53,927	-
Tenaya		40,800	-	40,800	-
The Norton Rose Fulbright Charitable Foundation		20,000	-	20,000	-
		60,800	175,627	236,427	259,013

4. Income from charitable activities

	Restricted funds £	Total 2023 £
Research	32,700	32,700

	Unrestricted funds general £	Restricted funds £	Total 2022 £
Providing support	-	21,100	21,100
Public and medical education	36,808	15,000	51,808
Research	-	62,300	62,300
	36,808	98,400	135,208

5. Investment income

	Unrestricted funds general £	Total funds £
Interest receivable and similar income; Interest receivable on bank deposits	5,768	5,768
Total for 2023	5,768	5,768
Total for 2022	193	193

6. Expenditure on raising funds

a) Costs of generating donations and legacies

	Direct Costs £	Total 2023 £	Total 2022 £
Costs of generating donations and legacies	303,664	303,664	289,164

Breakdown of costs:	2023 £	2022 £
Staff costs	196,410	187,451
Rates and water	598	365
Insurance	433	200
Postage and stationery	2,173	1,094
Sundries	1,391	4,820
Event costs	47,108	46,708
Marketing	11,364	8,807
Travel and subsistence	887	684
Computer	3,952	4,009
Recruitment	1,027	5,040
Staff training	757	1,386
Rent	10,526	7,647
Professional fees	1,198	842
Donation charges	19,445	14,703
Bank charges	315	249
Subscriptions	4,941	3,823
Depreciation	1,139	1,336
	303,664	289,164

7. Expenditure on charitable activities

	Unrestricted funds general £	Restricted funds £	Total funds £
Providing support	176,381	180,913	357.294
Public and medical education	127,140	10,788	137,928
Campaigning	12,481	-	12,481
Research	7,896	43,202	51,188
Total for 2023	323,988	234,903	558,891
Total for 2022	219,691	321,199	540,890

	Activity undertaken directly £	Grant funding or activity £	Total expenditure £
Providing support	357,294	-	357.294
Public and medical education	137,928	-	137,928
Campaigning	51,188	-	51,188
Research	12,481	-	12,481
Total for 2023	558,891	-	558,891
Total for 2022	481,657	59,233	540,890

8. Other expenditure

	Unrestricted funds general £	Restricted funds £	Total funds £
Staff costs			
Wages and salaries	24,597	-	24,597
Audit fees			
Audit of the financial statements	6,800	-	6,800
Rent	8,583	-	8,583
Office expenses	18,062	-	18,062
Bank charges	105	-	105
Depreciation of office equipment	570	-	570
Total for 2023	58,717	-	58,717
Total for 2022	57,109	5,050	62,159

9. Grant-making

Analysis of grants

The support costs associated with grant-making are £Nil (31 December 2022 - £Nil).

Below are details of material grants made to institutions:

Name of institution	Activity	2023 £	2022 £
AECVP Symposium	Research	-	1,605
University College London	Research	-	57,628
		-	59,233

10. Net incoming/outgoing resources

Net incoming resources for the year include:

	2023 £	2022 £
Audit fees	6,800	6,000
Other non-audit services	1,032	936
Depreciation of fixed assets	3,852	5,525

11. Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

During the year trustees were reimbursed expenses of £2,321 for equipment purchased for the charity and travel expenses of £2,411.
No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.
No trustees have received any other benefits from the charity during the year.

12. Staff costs

Staff costs during the year were:	2023 £	2022 £
Wages and salaries	549,153	488,958
Social security costs	48,162	43,314
Other pension costs	12,365	11,516
	609,680	543,788

The monthly average number of persons (including senior management / leadership team) employed by the charity during the year expressed as full time equivalents was as follows:

	2023 No	2022 No
Employees	19	18

Contributions to the employee pension schemes for the year totalled £12,365 (2022 - £11,516).

The charity operates a defined contribution pension scheme. The pension cost charge for the year repesents contributions payable by the charity.

The number of employees whose emoluments fell within the following bands was:

	2023 No	2022 No
£70,001 - £80,000	1	1

The total employee benefits of the key management personnel of the charity were £72,200 (2022 - £76,081).

Notes to the financial statements for the Year Ended 31 December 2023

13. Taxation

The charity is a registered charity and is therefore exempt from taxation.

14. Tangible fixed assets

	Furniture and equipment £	Total £
Cost		
At January 1 2023	35,119	35,119
Additions	16,290	16,290
At 31 December 2023	51,409	51,409
Depreciation		
At January 1 2023	30,237	30,237
Charge for the year	3,852	3,852
At 31 December 2023	34,089	34,089
Net book value		
At 31 December 2023	17,320	17,320
At 31 December 2022	4,882	4,882

15. Debtors

	2023 £	2022 £
Trade debtors	34,524	39,940
Prepayments and accrued income	287,574	225,487
Other debtors	-	4,006
	322,098	269,433

Debtors includes £Nil (2022: £4,006) receivable after more than one year.

	2023 £	2022 £
Other debtors	-	4,006

16. Cash and cash equivalents

	2023 £	2022 £
Cash on hand	65	32
Cash at bank	108,034	49,877
Short-term deposits	467,086	439,607
	575,185	489,516

17. Creditors: amounts falling due within one year

	2023 £	2022 £
Trade creditors	11,969	521
Other taxation and social security	13,160	11,684
Other creditors	3,321	2,124
Accruals	48,192	43,620
	76,642	57,949

18. Obligations under leases and hire purchase contracts

Operating lease commitments

Total future minimum lease payments under non-cancellable operating leases are as follows:

Land and buildings	2023 £	2022 £
Within one year	26,400	24,200
Between one and five years	79,200	-
After five years	77,000	-
	182,600	24,200

19. Funds

	Balance at 1 January 2023 £	Incoming resources £	Resources expended £	Balance at 31 December 2023 £
Unrestricted funds				
General				
General fund	516,974	845,024	(683,123)	678,875
Restricted funds				
Youth services	1	-	-	1
Helpline	263	30,000	(30,263)	-
BBC Children in Need	1,830	-	(1,830)	-
Advocacy	-	45,000	(22,859)	22,141
Max's Foundation	431	-	(431)	-
Community Peer Support (National Lottery Community Fund)	547	53,927	(43,556)	10,918
Online medical education	-	10,000	(9,982)	18
Advocacy	62,209	(18,300)	(9,184)	34,725
CAF Resilience Fund	11,778	-	(11,778)	-
CAF Support Fund	4,291	-	(3,982)	309
BMS Grant	31,295	-	(10,933)	20,362
BMS Voice	57,332	-	(39,551)	17,781
Masonic Charitable Fund	18,931	20,000	(21,923)	17,008
National Survey	-	35,000	(4,447)	30,553
CureHeart	-	32,700	(27,430)	5,270
Total restricted funds	188,908	208,327	(238,149)	159,086
Total funds	705,882	1,053,351	(921,272)	837,961

Notes to the financial statements for the Year Ended 31 December 2023

Unrestricted funds	Balance at 1 January 2022 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 December 2022 £
General					
General fund	393,910	687,720	(564,638)	(18)	516,974
Restricted funds					
Medical education	10,018	-	(10,018)	-	-
Alexander Janson's Foundation	-	35	(35)	-	-
Youth services	1	-	-	-	1
Helpline	1,179	30,000	(30,916)	-	263
BBC Children in Need	1,968	-	(138)	-	1,830
Max's Foundation	650	14,776	(14,995)	-	431
Community Peer Support (National Lottery Community Fund)	786	44,918	(45,157)	-	547
Online medical education	3,331	15,000	(18,349)	18	-
Advocacy	39,476	71,500	(48,767)	-	62,209
Building the community	11,078	-	(11,078)	-	-
Awareness campaign	8,794	-	(8,794)	-	-
ACT/UCL	-	57,628	(57,628)	-	-
CAF Resilience Fund	9,201	10,000	(7,423)	-	11,728
Burdett Trust	-	2,306	(2,306)	-	-
CAF Support Fund	26,939	14,950	(37,598)	-	4,291
BMS Grant	59,631	-	(28,336)	-	31,295
BMS Voice	-	62,300	(4,968)	-	57,332
Masonic Charitable Fund	-	20,000	(1,069)	-	18,931
Total restricted funds	173,052	343,413	(327,575)	18	188,908
Total funds	566,962	1,031,133	(892,213)	-	705,882

Notes to the financial statements for the Year Ended 31 December 2023

The specific purposes for which the funds are to be applied are as follows:

Providing support helpline - Towards the costs of providing a nurse lead clinical helpline for people affected by cardiomyopathy.

BBC Children in Need - To improve the emotional, physical and psychosocial (empowerment) well-being of young people under 18. Information resources (web and hard copy), paediatric helpline (out of hours), and national event, plus Panel meetings.

Advocacy - To cover the costs associated with the charity's regional advocacy volunteers and national advocacy work to improve access to treatment for people with cardiomyopathy.

Max's Foundation - To support the charity's youth project providing support and information materials for young people with cardiomyopathy and their parents.

Community Peer Support (National Lottery Community Fund) - A five year project partly funded by the National Lottery Community Fund to develop an innovative face to face and phone peer support service for people with life limiting heart muscle disease throughout England.

Online Medical Education - To fund the charity's online medical information and learning resource for healthcare professionals.

Advocacy - Developing the patient voice to affect purposeful change within the relevant statutory agencies.

National Survey - To fund the charity's national state of cardiomyopathy survey ensuring that the charity is able to provide robust evidence to underpin its advocacy work and provide insights as to how to best target its services.

Cure Heart - Income received from the British Heart Foundation funded CureHeart research project looking for genetic cures for cardiomyopathy. Funds go towards the charity's expenditure relating to providing service user insights as part of the research team.

CAF resilience fund - Funding to help the charity improve its ability to raise income, deliver services and develop its policy positions with the support of external consultants. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

CAF support fund - Funding to ensure that the charity can continue to deliver its core services and improve its ability to reach more communities and individuals affected by cardiomyopathy. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

BMS Grant - Funding from the pharmaceutical company, Bristol Myers Squibb to cover the costs of the charity's national conference, website, outreach and awareness work.

BMS patient voice - Funding from the pharmaceutical company, Bristol Myers Squibb to support a program which will use patient experiences to help shape and improve the support and treatment of cardiomyopathy.

Masonic charitable fund - 2-year grant to fund the development of the Youth Support Program.

Notes to the financial statements for the Year Ended 31 December 2023

20. Analysis of net assets between funds

	Unrestricted funds General £	Total funds at 31 December 2023 £
Tangible fixed assets	17,320	17,320
Current assets	897,283	897,283
Current liabilities	(76,642)	(76,642)
Total net assets	837,961	837,961

	Unrestricted funds General £	Total funds at 31 December 2022 £
Tangible fixed assets	4,882	4,882
Current assets	758,949	758,949
Current liabilities	(57,949)	(57,949)
Total net assets	705,882	705,882

21. Related party transactions

There were no related party transactions in the year.

Cardiomyopathy UK
the heart muscle charity

Contact us:

75a Woodside Road, Amersham, Buckinghamshire, HP6 6AA

01494 791 224

Helpline: 01494 791 224

contact@cardiomyopathy.org

www.cardiomyopathy.org

Keep in touch:

facebook.com/cardiomyopathyuk

@cardiomyopathyuk

@cardiomyopathy

youtube.com/cardiomyopathyuk

Cardiomyopathy UK is registered as a charity in England and Wales (no. 1164263) and in Scotland (no. SC053398)

CARDIOMYOPATHY UK

England & Wales - Charity number 1164263

Accounts

Annual Report

The difference we made in 2022



Cardiomyopathy UK
the heart muscle charity

We're Cardiomyopathy UK

We save and improve the lives of people affected by cardiomyopathy. Our vision is a world where everyone affected by cardiomyopathy should live a long and fulfilling life. In pursuit of this vision:



We raise awareness of the condition so that more people know the signs and symptoms and can be diagnosed early.



We campaign to improve access to quality treatment that meets the needs of people with cardiomyopathy.



We promote clinical research to advance the development of new treatments and provide hope for the future.



We support people affected by cardiomyopathy, every step of the way, so that nobody has to face cardiomyopathy alone.

1 in 250 people have cardiomyopathy. That's approximately 266,000 people in the UK currently living with the condition.



Cardiomyopathy UK
the heart muscle charity

Contents

3 Introduction from our Chair of Trustees

6 Our Achievements in 2022

11 Funding our Work

14 Our Ambitions for 2023

17 Trustees' Report

22 Independent Auditor's Report

28 Financial Statements

32 Notes to the Financial Statements



A Message From Our Chair

Cardiomyopathy UK is proud to be the specialist charity for people affected by the heart muscle disease, cardiomyopathy. Our vision is that those affected by cardiomyopathy should live a long and fulfilling life.



As I begin my report, it is with a heavy heart that I acknowledge that on May 16th 2022, one of our longest serving trustees Christopher Horwood (Chris) sadly passed away. Chris joined the Board in 2008 and was highly regarded by his fellow trustees.

As Chris's wife, Esther said: "After 20 years of fighting illness, he simply didn't have the strength to go on". We consider ourselves lucky to have shared Chris with Esther and the family.

The charity has continued to develop and grow its services, helping patients and their families to understand, cope with and work through the challenges they are experiencing. This past year we have been able to re-establish our face-to-face Support Group Meetings, Board Meetings, and our National Conference, with circa 300 attendees.

In March we participated in the first meeting held by NHS England to review, improve, and update the service specification for Inherited Cardiac Conditions Services in the NHS. We continue to be engaged with this work, to ensure that the requirements outlined in our Change Agenda are incorporated into the new Inherited Cardiac Conditions specification.

Our national survey in August received 602 responses. We were able to use some of the detailed analysis to feed into the NICE appraisals of Mavacamten. Our research submission to NICE on Mavacamten, for the treatment of obstructive hypertrophic cardiomyopathy, was received extremely favourably. We also submitted a scoping document on the proposed use of Evusheld to prevent Sars-Covid-2 in immunosuppressed and transplant patients.

The expansion of our research and policy work enables us to raise the profile of the charity and cardiomyopathy within medical and healthcare environments. By developing policies and conducting research, we can have an even greater impact on improving the care and quality of life relating to all aspects of cardiomyopathy and myocarditis.

A Message From Our Chair

The first ever International Cardiomyopathy Awareness Week campaign took place in June. The campaign was led by the Cardiomyopathy Patient Council of the Global Heart Hub. The Global Heart Hub is a group of 10 cardiomyopathy charities from around the world, including Cardiomyopathy UK. The campaign aimed to raise awareness and understanding of what cardiomyopathy is, the signs and symptoms and the importance of knowing your family history. The campaign received a fantastic response.

We were delighted when the CureHeart Project was announced as the winners of the Big Beat Challenge, being awarded £30m. The project aims to find the world's first cure for inherited heart muscle diseases. We are pleased to be working with this exciting and ground-breaking project.

I continue to be inspired by the professionalism, dedication, determination, and hard work of our staff team, ably lead by our Chief Executive, Joel Rose. Together with our committed volunteers who never fail to step up and are involved in a wide range of events and services, from fundraising to committees, support groups and various projects, they have ensured that the cardiomyopathy community has been provided with a wide range of much needed services and support.

Thanks to these combined efforts, I am pleased to be able to report that we ended the year in a strong financial position, with healthy reserves, continued growth and achieving £1 million in net income for only the second time in the history of the charity.

I would like to take this opportunity to thank and commend my fellow trustees, presidents, staff, volunteers, and professionals for their time and the work they have undertaken this past year. Together they have enabled us to continue to support our community and make a difference in people's lives.

As we engage in the process of developing our new Five-Year Strategic Plan January 2024-December 2028, I am optimistic for the future and look forward to the new and exciting opportunities that lie ahead. There is still a great deal of work to be done to improve the diagnosis, care, and treatment that people with cardiomyopathy receive, as our recent survey has shown.

Rita

Rita Sutton,
Chair of the Board of Trustees

Achievements in 2022

Providing support and information

Our support and information services aim to help people affected by cardiomyopathy feel more informed, less scared and better able to cope day to day.

Our support group volunteers did a fantastic job in 2022. Their hard work meant that we could offer a mixture of online and face-to-face groups so that more people could access this fantastic service. One attendee told us:

"Thanks to the group I have made some real friends, who "get it" in a way that not even my family or closest friends do"

As well as our online and face to face support groups, our peer support volunteers continued to help people and our closed Facebook group continued to grow.

Our Cardiomyopathy UK Specialist Nurses continued to be busy on the Helpline supporting people over the phone and online. 96% of our callers said the call was "very helpful" One caller put it simply:

"Thank you so much for listening what would we do without your charity."

180




support group meetings were held across our 38 groups

1,124

people were supported online and on our helpline by our Specialist Nurses





people were supported by our Telephone Peer Support Volunteers



Active members on our closed Facebook group

Achievements in 2022

One of the highlights of the year had to be our National Conference where we were able to meet in person once again after two years of the pandemic. We had a packed programme with session covering all aspects of cardiomyopathy and living with the condition day to day. Feedback from the event was overwhelmingly positive;

"The whole day was extremely informative, relevant warm and friendly"

"I feel more positive and armed with more information"

"I feel more empowered, like I have more control"

"I have more information now, I don't feel so alone"



100% of attendees said that they knew more about cardiomyopathy as a result of attending the conference.

The campaign's video, resources and materials, in 5 different languages reached over



6 million people

Raising Awareness

In 2022 we took part in the first ever International Cardiomyopathy Awareness Week campaign. We worked as part of a network of cardiomyopathy charities from around the world to produce a simple social media campaign to highlight the symptoms of cardiomyopathy and the importance of knowing any history of heart disease in your family.

Achievements in 2022

Promoting Research to improve the care and treatment of people with cardiomyopathy

In 2022 we were able to increase the work we do to shape clinical research as well as do more work to improve our understanding of the impact of cardiomyopathy and how accessing care and treatment has changed since the pandemic.

We were really pleased that we received a fantastic response to our national survey. The results have been incredibly instructive and will arm us with the information that we need when we advocate for better services for people affected by cardiomyopathy. You can read more about the survey and the key results on our website.

A major highlight of 2022 was the announcement that the CureHeart research team, of which we are part, had been successful in the British Heart Foundation's "Big Beat Challenge" winning a £30million pound research grant. As part of the winning team, our job will be to ensure that the project stays focused on the need to deliver results for people with cardiomyopathy and that the cardiomyopathy community is kept up to date with progress.

During the year we were able to support researchers on a wide range of projects from using simple technology to monitor arrhythmias to measuring blood vessels in the tongue for early signs of heart failure. We also continued to work with the Heart Hive team to promote involvement in research and encourage more people to sign up to their research matching website at:

www.thehearthive.org





Achievements in 2022

Advocating for people with cardiomyopathy


2022 saw our advocacy work continue to grow. It was especially pleasing to see how our Change Maker volunteers were able to keep up momentum and make significant and valuable changes to how care and treatment is provided in their area and nationwide. During the year our volunteers, amongst other things, participated in GP's training programmes, pushed for better use of electronic patient records, reviewed advice sheets and patient letters and represented Cardiomyopathy UK at national clinical conferences.

We also worked hard to ensure that we could give a true account of the impact of cardiomyopathy as part of the National Institute for Health and Care Excellence (NICE) review of a new medicine for people with obstructive hypertrophic cardiomyopathy. In 2023, NICE will be deciding whether to make this new medicine available on the NHS and we want to make sure that they have the information that they need to make the right decision.

We all know that cardiomyopathy comes with a range of related conditions and issues. This means it is important that the cardiomyopathy voice is heard in discussions about, for example, heart failure, transplantation, mental wellbeing, genetics and access to benefits. In 2022 we worked in collaboration with other charities and organisations to engage in these discussion and represent the unique needs of our community.

Working with healthcare professionals

It has been our long-term aim to ensure that health care professionals are better able to diagnose cardiomyopathy, provide appropriate support and ensure that at-risk family members are identified. There is still a great deal to do in this area, but our online Medical Education work is starting to make a difference. In 2022 we were able to launch two more accredited online learning courses. We now have over 200 clinicians making use of this important resource and telling us how much their knowledge and practice has improved.



Achievements in 2022

Working as part of the wider cardiomyopathy community

In 2022, we continued to play our part in the wider international cardiomyopathy community as an active part as a member of the Cardiomyopathy Council, a network of 15 cardiomyopathy focused charities from around the world that we founded. In addition to running the first ever international cardiomyopathy awareness campaign the council also worked together to agree best practice in working with clinical researchers and shared ideas on how access to research trials could be improved.

During the year, we also worked closely with the International Cardiomyopathy Network (ICoN), a network of leading cardiomyopathy clinicians and researchers, to help them set out their objectives and secure funding.

International CardiOmyopathy Network | ICON

ICON

NCVO CHAMPIONING VOLUNTARY ACTION

Ensuring good governance

In 2022, our Trustees continued their commitment to ensuring that the charity is well managed and governed appropriately. We worked with the National Council of Voluntary Organisations (NCVO) to review our governance processes and policies and, thanks to the feedback and support of NCVO, trustees are confident that we remain efficient, well managed and best placed to serve the cardiomyopathy community.

The first ever international cardiomyopathy awareness campaign ran across...



9 countries

and reached over...

6 million people



Funding our work
Income & Expenditure

Income



Community and Challenge Events
39%

Donations
10%

Legacies
9%

Trusts and Foundations
25%

Companies
17%

Expenditure

Providing Support
36%


Raising Funds
32%

Research
10%

Public and Professional Education
12%

Governance and Administration
7%

Campaigning
3%



Funding our work

We are delighted to report that 2022 was a successful year for our fundraising. Despite the challenging fundraising environment, income for the year grew to £1,031,133 thanks to the generosity of our supporters and commitment of our volunteer fundraisers. Unrestricted income recovered well in 2022. In 2021, restricted income made up 42% of our total income. In 2022 we were able to shift this balance to a more sustainable position with restricted income only making up 33% of our total income.

Although it took some time in early 2022 for the events industry to regain momentum and return to pre-pandemic levels of activity, we saw the broadest range of activity since the pandemic began. Our fantastic team of London Marathon runners raised over £152,000. It was wonderful to see our runners able to hold public and social events as part of their marathon fundraising once again. We also saw supporters taking part in various local runs, cycles and skydives. International events returned too, including two superstar fundraisers, Dougie and Pete, who were finally able to take on the Marathon des Sables in Morocco, raising £26,000.

Throughout the year, our wonderful community raised funds by organising their own events including golf days, race nights, step challenges, coffee morning to name just a few. It was lovely also to have the return of schools fundraising for us, which hasn't been possible for the past two years.

Although we no longer faced the challenges of pandemic restrictions, the impact of the cost-of-living crisis on fundraising in 2022 was clear. This was most notable in regular giving and donations from individuals where income fell, particularly in the latter half of the year. Our Fundraising Team were conscious of the very real impact of the cost-of-living. We saw instances where supporters struggled to meet sponsorship targets due to economic pressures, stress and even redundancies. In response, our fundraising team provided more frequent and more-hands-on support than ever before. This included our team directly addressing the discomfort that fundraisers were feeling around asking for donations by providing template wording, impact graphics, tips and reassurance.

Funding our work

Fundraising responsibly

We are committed to raising funds in a responsible and sustainable way. Our fundraising is conducted either directly by our fundraising staff team or by volunteer fundraisers under their support and guidance. We do not use the services of third-party professional fundraisers or fundraising companies. We work to ensure that our fundraising activity meets the best practice standards laid out by the Charity Commission and the Fundraising Regulator and in 2022 we received no complaints regarding our fundraising activity. Our work is also conducted in line with all GDPR regulations and we are signed up to the Fundraising Preference Service. The Fundraising Preference Service's purpose is to guard against unreasonable intrusion on privacy, unreasonable persistent approaches for donations or placing undue pressure on a person to give money or other property.

Thank you

Thank you to every single fundraiser, donor and volunteer who has raised funds that enable us to continue saving and changing the lives of people affected by cardiomyopathy, now and in the future.

We would also like to give our heartfelt thanks for every donation made in memory of a loved one, including funeral collections, in memory events, donations and gifts given in Wills. These donations create a lasting legacy by moving us a step closer towards our vision of a world where everyone affected by cardiomyopathy can live a long and full life.

In 2022 we were grateful for new and continued support from: The National Lottery Community Fund, The Masonic Charitable Foundation, Max's Foundation, Browns Solicitors and the CAF Resilience Fund.

Masonic Charitable Foundation

COMMUNITY FUND

CAF Charities Aid Foundation

Ambitions for 2023

Providing Support and Information

In 2023 we will work to ensure that more people, and from a wider range of communities, are able to access our support and information services. We also want to make sure that our services can meet the changing needs of our community and support people with cardiomyopathy, and their loved ones, every step of the way.

In 2023 we aim to reach more people across the UK by working with local hospitals to ensure that all cardiomyopathy patients are made aware of the help that we can provide.

We also recognise that the cost-of-living crisis is having an especially severe impact on many people with cardiomyopathy. In 2023 therefore we will review the services that we provide for people who are struggling to access statutory benefits because the impact of their condition is not being properly understood. We will also continue to grow our support group and peer support networks so that more people have the opportunity to speak to someone who understands what they are going through and test new approaches to addressing mental health needs of our community.

Raising Awareness

In 2023 we hope to build on the success of the first ever international cardiomyopathy awareness campaign held last year. We will once again be working with cardiomyopathy charities from around the world to highlight the importance of genetic testing and family screening in cardiomyopathy.

We will also continue to grow our online presence ensuring that we can make best use of social media platforms to reach new audience with our awareness raising messages. In addition to this, we will continue to seek opportunities to raise the profile of cardiomyopathy and our work in the media.



Ambitions for 2023

Promoting Research to improve the care and treatment of people with cardiomyopathy

In 2023 we aim to continue to grow our research activity and play a significant role in the cardiomyopathy research community so that clinical research meets the needs of people with cardiomyopathy and so that we can increase our own understanding of the condition.

We plan to work with The James Lind Alliance to bring together all the key stakeholders in cardiomyopathy research to identify research priorities and increase our own capacity to support research projects by recruiting and training more research volunteers. We also hope to invest in communications to ensure that research opportunities can be promoted, and findings disseminated to a wider audience.

As well as supporting clinical researchers, in 2023 we plan to undertake our own research into how people with cardiomyopathy access genetic testing and we will be publishing the results of our national survey.

Raising Awareness

We are proud of the advocacy work that we undertook in 2022 and the difference that we were able to make along with our team of volunteer "Change Makers". It is clear however that in 2023 we must continue to grow the Change Maker volunteer network and do more to help volunteers push for improvements in their local health services in line with the agreed national "Change Agenda".

As well as this, in 2023 we will keep working alongside other national and international charities and networks to have a more impactful collective voice and ensure that the needs of people with cardiomyopathy are heard by policymakers across all regions of the UK.

With NICE due to evaluate the first cardiomyopathy specific treatment, and other new drugs on the horizon, we will also continue to provide robust qualitative and quantitative evidence to NICE and other technology appraisers to give a true account of the impact of cardiomyopathy.



Ambitions for 2023

Working with healthcare professionals

Following the successful launch of our online medical education work, in 2023 we will keep growing this important learning resource and publish additional units covering genetics in cardiomyopathy and arrhythmogenic cardiomyopathy.

We will also explore new opportunities to work with other partners to do more to reach healthcare professionals and especially GPs, so that we can tackle the unacceptably high levels of misdiagnosis.

Working as part of the wider cardiomyopathy community

Now that the ICoN group has been able to secure funding for their work, this important new organisation will begin its agreed programme of activity for 2023. We will continue to support their work and ensure that the views of people with cardiomyopathy are central to their discussions.

We will also continue to play our part as a member of the cardiomyopathy council which aims to undertake further awareness raising activities in 2023 along with work to help bring together international research efforts.

Ensuring good governance

2023 will be the final year of our current strategic plan. This means that during the year we will be working to gather the views of our key stakeholders to develop our strategy for the next five years. In 2023 Trustees will continue to regularly review performance against objectives and, where necessary, bring onto the board new trustees so that the trustee team have all the skills, knowledge and experience necessary to lead the charity.



Trustee Report

Structure, Management and Governance

The charity is controlled by its governing document and constitutes a charitable incorporated organisation. The charity is governed by its constitution adopted on 5 November 2015.

The charity continues to review and, where necessary, improve its trustee induction and training resources to ensure that new trustees are equipped to support the work of the charity to their maximum ability. Appropriate policies and procedures have been put in place to ensure good governance including financial management, data protection and employment practice. Trustees maintain a risk register and work with the Chief Executive to ensure that strategies are in place to mitigate against identified risks.

In 2022, Trustees continued to work in accordance with the charity's three-year plan for the years 2021 to 2023. This plan was developed in 2020 with input from staff, clinicians and the wider cardiomyopathy community and is available on the Cardiomyopathy UK website.

Financial Review

Trustees are proud to report that despite the huge challenges faced by all in 2022, the charity was able to further strengthen its financial position. This was achieved by increasing unrestricted income from the community and challenge event fundraising, thanks in a large part to a record London Marathon team, while at the same time managing costs and continuing to build support from trusts and companies.

Trustees note that the key financial challenge for 2023 will be for the charity to maintain levels of restricted income while at the same time growing unrestricted income at a time when many supporters are facing significant increases in their own cost of living. Trustees are hopeful that this can be achieved especially as the charity's network of supporters, fundraising volunteers and challenge eventers remain engaged with the charity.

Trustee Report

Partnerships

The charity works closely with expert clinicians from a number of NHS Trusts to help ensure that its work is clinically appropriate and that it can reach as many people with cardiomyopathy as possible.

During the year the charity continued to work with its President, Prof. Perry Elliott to develop the International Cardiomyopathy Network (ICoN), a registered UK charity. Cardiomyopathy UK's Chief Executive supported ICoN in their efforts to raise funding from corporate partners and provided strategic advice and patient insight as part of a shared commitment to improving the level of cardiomyopathy knowledge among clinicians, developing best practice and fostering research that will make a real difference to the lives of people with the condition. During the year ICoN made a payment of £15,000 to the charity to cover the costs incurred in providing this support.

The charity continued to have a positive relationship with The British Heart Foundation, The Pumping Marvellous Foundation, Gene People, Heart UK and a number of other charities that provide support and information relating to heart diseases. Where possible, the charity works in collaboration with these charities.

During 2022 the charity received funding from five pharmaceutical companies (Sanofi, Pfizer, Alnylam, Tenaya and Bristol Myers Squibb) who have developed or who are developing treatments used by people with cardiomyopathy. The total income from these companies was £131,340; under 15% of the charity's total income. Income from these sources covered the costs associated with the charity's medical education project, advocacy project, research and awareness raising and service delivery work. All funding was provided in accordance with the Association of British Pharmaceutical Industry code of practice and the charity's own policy on working with the pharmaceutical industry which is available at:

www.cardiomyopathy.org/about-us/our-approach

This policy is designed to ensure the charity's independence.

Trustee Report

Reserves Policy

The charity aims to maintain unrestricted reserves at a level that equates to around six to nine months of normal unrestricted expenditure. Trustees believe this to be a prudent amount given that the charity operates in a competitive environment and, as the leading specialist provider of support services for people affected by cardiomyopathy, there is a duty to ensure that it can maintain core services for individuals in need.

Towards the end of the year the charity was notified about two legacies with a total value of £95K. This resulted in unrestricted reserves increasing to 11 months of normal expenditure at the end of the year. Trustees however are aware that the charity faces increased unrestricted costs in 2023 as a number of restricted funding grants are due to come to an end during the year and costs will be covered from unrestricted funds. Trustees expect that unrestricted reserves will return to the six to nine month target by the end of 2023.

Public Benefit

Cardiomyopathy UK confirms that in setting its programme of activity, it has had due regard to the Charity Commission's general guidance on public benefit. The programme of activity also conforms to the charity's charitable objectives and aims. No persons are excluded from the work of the charity on grounds of gender, race or religion.

Reference and Administrative Details

Board of Trustees:

T Amiss
M Bloom (appointed March 2023)
T Bueser
S Cornish MBE (appointed July 2023)
G Favier
C Horwood (Deceased May 2022)
S Kirkham MC
I McPherson OBE
E Jarman
E Power (resigned September 2022)
M Rees (appointed July 2023)
A Smith
R Sutton (Chair)
P Thomas (Treasurer)

Chief Executive Officer:

Mr J Rose

Principal Address:

75A Woodside Road
Amersham
Buckinghamshire, HP6 6AA

Auditors:

Seymour Taylor Limited
57 London Road
High Wycombe
Buckinghamshire, HP11 1BS

Charity Number:

1164263

Bankers:

Charity Aid Foundation Limited
Kings Hill
West Malling
Kent, ME19 4TA

Lloyds
82 High Street
Rickmansworth
Hertfordshire, WD3 1AG

Reference and Administrative Details

The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period.

In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the board of trustees on the 9th of September 2023 and signed on its behalf by Rita Sutton, Chair of Trustees



Rita Sutton

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK

Opinion

We have audited the financial statements of Cardiomyopathy UK (the 'charity') for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2022 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;

and

- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- The information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- Sufficient accounting records have not been kept; or
- The financial statements are not in agreement with the accounting records and returns; or
- We have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- Results of our enquiries of management about their own identification and assessment of the risks of irregularities;
- Any matters we identified having made enquiries of management about their policies and procedures relating to:
- Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
- Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK



Identifying and assessing potential risks related to irregularities - continued

We also obtained an understanding of the legal and regulatory frameworks that the company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act and local tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the charities ability to operate.

Audit response to risks identified

As a result of performing the above, our procedures to respond to risks identified included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- And in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Report Of The Independent Auditors To The Trustees Of Cardiomyopathy UK

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Seymour Taylor Limited

Seymour Taylor Limited, Statutory Auditor
57 London Road
High Wycombe
Buckinghamshire
HP11 1BS

9th September 2023

Statement Of Financial Activities
For The Year Ended 31 December 2022

	Notes	Unrestricted fund £	Restricted funds £	31.12.22 Total funds £	31.12.21 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	650,719	245,013	895,732	815,672
Charitable activities	4				
Providing support		-	21,100	21,100	21,100
Public and medical education		36,808	15,000	51,808	48,800
Research		-	62,300	62,300	59,906
Investment income	3	193	-	193	-
Total		687,720	343,413	1,031,133	945,478
EXPENDITURE ON					
Raising funds	5	287,838	1,326	289,164	276,593
Charitable activities	6				
Providing support		90,009	233,301	323,310	318,800
Public and medical education		85,679	19,379	105,058	93,226
Campaigning		18,853	8,536	27,389	41,834
Research		25,150	59,983	85,133	94,118
Other		57,109	5,050	62,159	76,679
Total		564,638	327,575	892,213	901,250
NET INCOME		123,082	15,838	138,920	44,228
Transfers between funds	16	(18)	18	-	-
Net movement in funds		123,064	15,856	138,920	44,228
RECONCILIATION OF FUNDS					
Total funds brought forward		393,910	173,052	566,962	522,734
TOTAL FUNDS CARRIED FORWARD		516,974	188,908	705,882	566,962

The notes form part of these financial statements

Balance Sheet
31 December 2022

	Notes	Unrestricted fund £	Restricted funds £	31.12.22 Total funds £	31.12.21 Total funds £
FIXED ASSETS					
Tangible assets	12	4,882	-	4,882	8,871
CURRENT ASSETS					
Debtors: amounts falling due within one year	13	265,427	-	265,427	244,659
Debtors: amounts falling due after more than one year	13	4,006	-	4,006	29,006
Cash at bank and in hand		300,608	188,908	489,516	356,431
		570,041	188,908	758,949	630,096
CREDITORS					
Amounts falling due within one year	14	(57,949)	-	(57,949)	(72,005)
NET CURRENT ASSETS		512,092	188,908	701,000	558,091
TOTAL ASSETS LESS CURRENT LIABILITIES		516,974	188,908	705,882	566,962
NET ASSETS		516,974	188,908	705,882	566,962
FUNDS	16				
Unrestricted funds				516,974	393,910
Restricted funds				188,908	173,052
TOTAL FUNDS				705,882	566,962

The financial statements were approved by the Board of Trustees and authorised for issue on 9th September 2023 and were signed on its behalf by:

RSM

Mrs R Sutton - Trustee

The notes form part of these financial statements

Cash Flow Statement
For The Year Ended 31 December 2022

	Notes	31.12.22 £	31.12.21 £
Cash flows from operating activities			
Cash generated from operations	1	134,428	(79,637)
Net cash provided by/(used in) operating activities		134,428	(79,637)
Cash flows from investing activities			
Purchase of tangible fixed assets		(1,536)	(4,617)
Interest received		193	-
Net cash used in investing activities		(1,343)	(4,617)
Change in cash and cash equivalents in the reporting period		133,085	(84,254)
Cash and cash equivalents at the beginning of the reporting period		356,431	440,685
Cash and cash equivalents at the end of the reporting period		489,516	356,431

The notes form part of these financial statements

Notes To The Cash Flow Statement For The Year Ended 31 December 2022

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	31.12.22 £	31.12.21 £
Net income for the reporting period (as per the Statement of Financial Activities)	138,920	44,228
Adjustments for:		
Depreciation charges	5,525	4,603
Interest received	(193)	-
Decrease/(increase) in debtors	4,232	(107,751)
Decrease in creditors	(14,056)	(20,717)
Net cash provided by/(used in) operations	134,428	(79,637)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.22 £	Cash flow £	At 31.12.22 £
Net cash			
Cash at bank and in hand	356,431	133,085	489,516
	356,431	133,085	489,516
Total	356,431	133,085	489,516

The notes form part of these financial statements

Notes To The Financial Statements For The Year Ended 31 December 2022

1. Accounting Policies

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Cardiomyopathy UK is a charity limited by guarantee and incorporated in England and Wales. The charity's principal address is 75A Woodside Road, Amersham, Buckinghamshire, HP6 6AA. The registered charity number is 1164263.

The presentation currency of these financial statements is Sterling (£), being the currency of the primary economic market in which the entity operates. All amounts in these financial statements have been rounded to the nearest pound unless stated otherwise.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

1. Accounting Policies -continued

Allocation and apportionment of costs

Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with use of the resources.

Salaries have been apportioned in accordance with the duties to which they relate.

Premises costs have been apportioned on the basis of percentage of floor space used.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - at variable rates on reducing balance

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Financial instruments

The charity has applied the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instrument Issues" of FRS 102 to its financial statements.

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

1. Accounting Policies - continued

Debtors and creditors due within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities in administrative expenses.

Cash and cash equivalents

Cash and cash equivalents in the Statement of Financial Position comprise cash at bank and in hand and short term deposits with an original maturity date of three months or less. Bank overdrafts are disclosed within creditors on the Statement of Financial Position.

2. Donations and legacies

	2022	2021
	£	£
Donations	143,430	192,761
Grants and legacies	354,999	361,996
Fundraising	397,303	260,915
	895,732	815,672

Grants received included above are as follows:

	Unrestricted	Restricted	2022 Total	2021 Total
	£	£	£	£
Browns Solicitors - Helpline	-	30,000	30,000	64,800
Browns Solicitors - Advocacy	-	50,400	50,400	-
Alexander Jansons Fund	-	35	35	(290)
BBC Children in Need	-	-	-	23,925
Big Lottery Fund - Community Peer Support	-	44,918	44,918	58,821
Heart Hive	-	-	-	(1,891)
Max's Foundation	-	14,776	14,776	-
Masonic Charitable Fund	-	20,000	20,000	-
Burdett Trust	-	2,306	2,306	2,203
Arrhythmogenic ACT	-	57,628	57,628	57,628
CAF Resilience Fund	-	10,000	10,000	10,000
CAF Main Fund	-	14,950	14,950	44,850
The Girdler's Company Charitable Trust	-	-	-	1,450
The Moss Family Charitable Trust	1,000	-	1,000	-
Edith Florence Spencer Memorial Trust	-	-	-	11,000
DHPA Project	13,000	-	13,000	-
Total Grants	14,000	245,013	259,013	272,496
Total Legacies			95,986	89,500
			342,399	361,996

3. Investment income

	31.12.22	31.12.21
	£	£
Deposit account interest	193	-

4. Income from charitable activities

	Unrestricted	Restricted	2022 Total	2021 Total
	£	£	£	£
Pfizer Ltd	-	21,100	21,100	21,100
Online Medical Education (AstraZeneca)	-	-	-	10,000
Medical education grant (Sanofi Genzyme)	-	5,000	5,000	5,000
PSG Grant (Novartis)	-	-	-	23,800
e-learning courses (Alnylam UK Limited)	-	10,000	10,000	10,000
Growth & Development Project (Bristol-Myers Squibb Pharmaceuticals Limited)	-	62,300	62,300	59,906
Tenaya grant	36,808	-	36,808	-
Total Grants	36,808	94,400	135,208	129,806

5. Raising funds

Raising donations and legacies

	31.12.22 £	31.12.21 £
Staff costs	187,451	153,704
Rates and water	365	1,013
Insurance	200	422
Postage and stationery	1,094	2,157
Sundries	4,820	5,187
Event costs	46,708	64,351
Marketing	8,807	15,953
Travel and subsistence	684	32
Computer	4,009	6,223
Recruitment	5,040	550
Staff training	1,386	26
Rent	7,647	11,301
Professional fees	842	917
Donation charges	14,703	9,860
Bank charges	249	347
Subscriptions	3,823	3,674
Depreciation	1,336	876
	289,164	276,593

6. Charitable activities cost

	Direct Costs £	Grant funding of activities (see note 7) £	Totals £
Providing support	323,310	-	323,310
Public and medical education	105,058	-	105,058
Campaigning	27,389	-	27,389
Research	25,900	59,233	85,133
	481,657	59,233	540,890

7. Grants payable

	31.12.22	31.12.21
	£	£
Research	59,233	81,882

The following Grants were paid to Institutions during the year;

	2022	2021
	£	£
Alexander Janson's Myocarditis	-	1,269
AECVP Symposium	1,605	-
Global Heart Hub	-	22,985
University College London	57,628	57,628
Total	59,233	81,882

8. Support costs

	Management	Governance costs	Totals
	£	£	£
Other resources expended	56,159	6,000	62,159

Analysis of support and governance costs

The charity initially identifies the costs of its support function. It then identifies those costs which relate to the governance function. Having identified its governance costs and support costs these are apportioned between the key charitable activities undertaken in the year. Please refer to the table below for the basis of apportionment and the key analysis of support.

	General Support	Governance function	Basis of apportionment
	£	£	
Wages	26,128	-	The duties to which they relate
Property related expenses	5,883	-	Floor space
General office and administration	22,558	-	Specific support costs
Legal and professional fees	-	-	Specific support costs
Bank charges	217	-	General charges
Depreciation	1,373		Floor space
Audit fees	-	6,000	Governance
Total	56,159	6,000	

9. Auditors' remuneration

The auditor's remuneration amounts to an audit fee of £6,000 (2021 - £6,500) and payroll services paid to the auditor of £936 (2021 - £864) are included in legal and professional fees.

10. Trustees' remuneration and benefits

There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2022 nor for the year ended 31 December 2021.

11. Staff costs

	2022	2021
	£	£
Wages and salaries	488,958	464,818
Social security costs	43.314	39,087
Other pension costs	11,516	12,353
	543,786	516,258

Total redundancy / termination payments during the year amounted to £nil (2021 - £nil)

Transactions with key management personnel

	2022	2021
	£	£
Total compensation of key management personnel	76,081	71,993

The average monthly number of employees during the year was as follows:

	2022	2021
	18	18

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022	2021
£70,001 - £80,000	1	1

12. Tangible fixed assets

	Computer equipment £
COST	
At 1 January 2022	33,583
Additions	1,536
At 31 December 2022	35,119
DEPRECIATION	
At 1 January 2022	24,712
Charge for year	5,525
At 31 December 2022	30,237
NET BOOK VALUE	
At 31 December 2022	4,882
At 31 December 2021	8,871

13. Debtors: Amounts falling due within one year

	31.12.22 £	31.12.21 £
Trade debtors	39,940	69,906
Prepayments and accrued income	225,487	174,753
	265,427	244,659

14. Creditors: Amounts falling due within one year

	31.12.22 £	31.12.21 £
Trade creditors	521	11,009
Social security and other taxes	11,684	11,353
Other creditors	2,124	2,528
Accruals and deferred income	43,620	47,115
	57,949	72,005

15. Leasing agreements

Minimum lease payments under non-cancellable operating leases fall due as follows:

	31.12.22 £	31.12.21 £
Within one year	24,200	26,400
Between one and five years	-	24,200
	24,200	50,600

16. Movement in funds

	At 1.1.22 £	Net movement in funds £	Transfers between funds £	At 31.12.22 £
Unrestricted funds				
General fund	393,910	123,082	(18)	516,974
Restricted funds				
Medical education	10,018	(10,018)	-	-
Youth services	1	-	-	1
Helpline	1,179	(916)	-	263
BBC Children in Need	1,968	(138)	-	1,830
Max's Foundation	650	(219)	-	431
Community Peer Support (National Lottery Community Fund)	786	(239)	-	547
Online Medical Education	3,331	(3,349)	18	-
Advocacy	39,476	22,733	-	62,209
Building the Community	11,078	(11,078)	-	-
Awareness Campaign	8,794	(8,794)	-	-
CAF Resilience Fund	9,201	2,577	-	11,778
CAF Support Fund	26,939	(22,648)	-	4,291
BMS Grant	59,631	(28,336)	-	31,295
BMS Voice	-	57,332	-	57,332
Masonic Charitable Fund	-	18,931	-	18,931
	173,052	15,838	18	188,908
TOTAL FUNDS	566,962	138,920	-	705,882

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	687,720	(564,638)	123,082
Restricted funds			
Medical education	-	(10,018)	(10,018)
Alexander Janson's Foundation	35	(35)	-
Helpline	30,000	(30,916)	(916)
BBC Children in Need	-	(138)	(138)
Max's Foundation	14,776	(14,995)	(219)
Community Peer Support (National Lottery Community Fund)	44,918	(45,157)	(239)
Online Medical Education	15,000	(18,349)	(3,349)
Advocacy	71,500	(48,767)	22,733
Building the Community	-	(11,078)	(11,078)
Awareness Campaign	-	(8,794)	(8,794)
ACT/UCL	57,628	(57,628)	-
CAF Resilience Fund	10,000	(7,423)	2,577
Burdett Trust	2,306	(2,306)	-
CAF Support Fund	14,950	(37,598)	(22,648)
BMS Grant	-	(28,336)	(28,336)
BMS Voice	62,300	(4,968)	57,332
Masonic Charitable Fund	20,000	(1,069)	18,931
	343,413	(327,575)	15,838
TOTAL FUNDS	1,031,133	(892,213)	138,920

16. Movement in funds - continued

Comparatives for movement in funds

	At 1.1.21 £	Net movement in funds £	Transfers between funds £	At 31.12.21 £
Unrestricted funds				
General fund	331,200	60,819	1,891	393,910
Restricted funds				
Medical education	10,018	-	-	10,018
Providing support helpline	-	1,180	-	1,180
Youth services	3,974	(3,974)	-	-
West Midlands support fund	924	-	(924)	-
Alexander Janson's Foundation	1,260	(1,260)	-	-
BBC Children in Need	4,314	(2,345)	-	1,969
Heart Hive	1,891	-	(1,891)	-
Max's Foundation	13,929	(13,278)	-	651
Community Peer Support (National Lottery Community Fund)	-	(139)	924	785
Building Capabilities (National Lottery Community Fund)	17,844	(17,844)	-	-
Online Medical Education	19,574	(16,242)	-	3,332
Advocacy	27,803	11,672	-	39,475
PPCM Campaign	4,941	(4,941)	-	-
BLF Helpline	20,572	(20,572)	-	-
Building the Community	64,490	(53,412)	-	11,078
Awareness Campaign	-	8,794	-	8,794
CAF Resilience Fund	-	9,201	-	9,201
CAF Support Fund	-	26,938	-	26,938
BMS Grant	-	59,631	-	59,631
	191,534	(16,591)	(1,891)	173,052
TOTAL FUNDS	522,734	44,228	-	566,962

16. Movement in funds - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	553,435	(492,616)	60,819
Restricted funds			
Providing support helpline	30,000	(28,820)	1,180
Youth services	-	(3,974)	(3,974)
Alexander Janson's Foundation	10	(1,270)	(1,260)
BBC Children in Need	23,925	(26,270)	(2,345)
Max's Foundation	-	(13,278)	(13,278)
Community Peer Support (National Lottery Community Fund)	58,821	(58,960)	(139)
Building Capabilities (National Lottery Community Fund)	-	(17,844)	(17,844)
Online Medical Education	25,000	(41,242)	(16,242)
Advocacy	55,900	(44,228)	11,672
PPCM Campaign	-	(4,941)	(4,941)
BLF Helpline	-	(20,572)	(20,572)
Building the Community	-	(53,412)	(53,412)
Awareness Campaign	23,800	(15,006)	8,794
ACT/UCL	57,628	(57,628)	-
CAF Resilience Fund	10,000	(799)	9,201
Burdett Trust	2,203	(2,203)	-
CAF Support Fund	44,850	(17,912)	26,938
BMS Grant	59,906	(275)	59,631
	392,043	(408,634)	(16,591)
TOTAL FUNDS	945,478	(901,250)	44,228

16. Movement in funds - continued

Medical education - Towards the costs of providing educational events and opportunities for healthcare professionals. This includes the Olsen-Gourley Lecture fund and the M Hicks Educational fund transferred from Cardiomyopathy Association.

Youth services - Towards the costs of developing and providing support services for children, youth and young adults.

Providing support helpline - Towards the costs of providing a nurse lead clinical helpline for people affected by cardiomyopathy.

West Midland support group - To provide support for those with cardiomyopathy in the West Midlands.

Alexander Janson's Foundation - To fund research into the causes, prevention and cures for myocarditis.

BBC Children in Need - To improve the emotional, physical and psychosocial (empowerment) well-being of young people under 18. Information resources (web and hard copy), paediatric helpline (out of hours), and national event, plus Panel meetings.

Heart Hive - Online platform that aims to match researchers at Imperial College with individuals interested in taking part in research trials. The objective is to seek ways of improving treatment for cardiomyopathy and myocarditis.

Community Peer Support (National Lottery Community Fund) - A five year project partly funded by the National Lottery Community Fund to develop an innovative face to face and phone peer support service for people with life limiting heart muscle disease throughout England.

Building Capabilities (National Lottery Community Fund) - National audit pan England of those NHS trusts and service providers providing clinical care and treatment to people affected by cardiomyopathy and myocarditis.

Online medical education - Towards the development of an online learning program which will improve diagnoses of cardiomyopathy and access to treatment by upskilling clinical knowledge of patient facing clinicians.

16. Movement in funds - continued

Advocacy - Developing the patient voice to affect purposeful change within the relevant statutory agencies.

PPCM campaign - To raise public awareness of peripartum cardiomyopathy in particular statutory health providers.

BLF helpline - To provide a dedicated front-line service to anyone affected by cardiomyopathy or related conditions.

Building the community - To raise awareness of Cardiomyopathy to English speaking countries internationally.

Awareness campaign - To fund a national awareness campaign aimed at raising awareness of the signs and symptoms of cardiomyopathy among hard to reach communities. This funding has been received from Novartis Pharmaceuticals UK.

CAF resilience fund - Funding to help the charity improve its ability to raise income, deliver services and develop its policy positions with the support of external consultants. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

CAF support fund - Funding to ensure that the charity can continue to deliver its core services and improve its ability to reach more communities and individuals affected by cardiomyopathy. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

BMS Grant - Funding from the pharmaceutical company, Bristol Myers Squibb to cover the costs of the charity's national conference, website, outreach and awareness work.

ACT/UCL Grant - Funding from the arrhythmogenic cardiomyopathy Trust (Charity No.1176790) to fund a research project based at University College London focused on risk stratification in arrhythmogenic cardiomyopathy.

BMS patient voice - Funding from the pharmaceutical company, Bristol Myers Squibb to support a program which will use patient experiences to help shape and improve the support and treatment of cardiomyopathy.

Masonic charitable fund - 2-year grant to fund the development of the Youth Support Program.

17. Employee benefit obligations

The company operates a defined contribution pension scheme. The pension costs charged to the income statement represent contributions payable by the company to the fund in the year and amounted to £11,767 (2021 - £12,353).

18. Related party disclosures

There were no related party transactions for the year ended 31 December 2022.

Cardiomyopathy UK
the heart muscle charity

Contact us:

75a Woodside Road, Amersham, Buckinghamshire, HP6 6AA

01494 791 224

Helpline: 0800 0181024

contact@cardiomyopathy.org

www.cardiomyopathy.org

Keep in touch:

facebook.com/cardiomyopathyuk

@cardiomyopathyuk

@cardiomyopathy

youtube.com/cardiomyopathyuk

Cardiomyopathy UK is a registered charity in England and Wales no 1164263

CARDIOMYOPATHY UK

England & Wales - Charity number 1164263

Accounts

Cardiomyopathy UK
the heart muscle charity


Annual Report

The difference we made in 2021



Contents

3	Introduction
4	Statement From Cardiomyopathy UK Chair
6 - 11	Our Achievements & Performance in 2021
13 - 15	Funding Our Work
17 - 19	Our Ambitions For 2022
21 - 23	Trustees Report
25 - 28	Independant Auditor's Report
29 - 32	Financial Statements
33 - 46	Notes To The Financial Statements



We're Cardiomyopathy UK.

We save and improve the lives of people affected by cardiomyopathy. Our vision is a world where everyone affected by cardiomyopathy should live a long and fulfilling life. In pursuit of this vision:



We raise awareness of the condition so that more people know the signs and symptoms and can be diagnosed early.



We campaign to improve access to quality treatment that meets the needs of people with cardiomyopathy.




We promote clinical research to advance the development of new treatments and provide hope for the future.



We support people affected by cardiomyopathy, every step of the way, so that nobody has to face cardiomyopathy alone.

1 in 250 people have cardiomyopathy. That's approximately 266,000 people in the UK currently living with the condition.



Cardiomyopathy UK
the heart muscle charity

A Message From Our Chair

As I look back over the last year, I'd like to first thank Cardiomyopathy UK's team of dedicated staff, volunteers, and healthcare partners. Together we have ensured that individuals and families affected by cardiomyopathy receive the advice and support needed for them to cope and move forward in times of vulnerability, uncertainty, and concern; especially regarding COVID-19 and the potential impact on our clinically vulnerable people.



With remote meetings replacing face-to-face consultations and clinics, the demand for our services greatly increased. With the magic of Zoom we were able to ensure all meetings not only continued but were increased.

The theme for our conference in October was "Resilience". We are right to be proud as we reflect on our achievements during the past year. The annual report demonstrates not only our ability to manage change and challenges but also highlights how we have moved forward in the face of adversity.

The expansion of our research and policy work, including the recruitment of our first Head of Research and Policy, is key to raising the profile of the charity and cardiomyopathy within medical and healthcare environments. By developing policies and conducting research, we can have an even greater impact on improving the care and quality-of-life relating to all aspects of cardiomyopathies and myocarditis.


Particularly pleasing is ending the year in good financial shape. Most of the charity's income comes from our community. We are blessed to have the continued support of our committed fundraisers who participate in a variety of events and challenges throughout the year, usually in support of a loved one affected by cardiomyopathy or myocarditis. Our grateful thanks go out to every one of them for their support.

A special highlight during the year was our ex-chair and Vice President; Alison Fielding, being awarded a British Empire Medal in the Queen's Birthday Honours, for her services to cardiomyopathy. Alison is a true advocate for the charity. Through managing her own ill-health experiences, Alison ably represents the patient's voice.

As we move forward, we plan to build on this year's success and will continue to provide the tools, strategies, and support that will help those with cardiomyopathy or myocarditis and their families to understand and cope with their condition.

Rita

Rita Sutton,
Chair of the Board of Trustees



When I heard there wasn't a support group in the Bristol area, but there were people looking to join, I put myself forwards to set up a group. This group has been a great source of support and knowledge for me, and I have been enriched by working with a group of such inspiring people.

Tony Hampson, Support Group Leader

Achievements in 2021

Providing Support and Information

Our Helpline

In 2021, as the pandemic continued to impact people's lives, our helpline provided support to those concerned about how COVID-19 could affect them and where people with cardiomyopathy fitted into the government's classifications of vulnerabilities.

As the year progressed, the number of COVID-19 related questions began to decrease, and these questions moved away from clinical concerns, focussing more on the emotional and practical impact of living with cardiomyopathy during the pandemic. We're proud that we were able to help our community through these concerns on the helpline, and that helpline satisfaction levels remained high with 98% of callers feeling they had gained a better understanding of their condition after speaking to one of our support nurses.

In 2021 we also saw an increase in the number of people coming to us for support after experiencing difficulties accessing Personal Independence Payment (PIP) benefits. During the year, we supported 188 people to successfully appeal their negative PIP assessment outcomes by helping assessors to understand the condition and its impact. We are now considering how this support could be extended to help more people.




calls were made to the helpline.



98%

of people who called our helpline felt they had gained a better understanding of their condition after speaking to one of our nurses.

89%



of callers felt like they were ready to take the next step after speaking to a nurse.

Achievements in 2021

Providing Support and Information

Peer Support

Our peer support work continued to flourish in 2021 with the support group network and peer support volunteers providing vital support online and over the phone. Overall, support group attendance continued to grow, and we achieved our targets for the peer support project funded by the National Lottery Community Fund.

Unfortunately, the ongoing pandemic meant that it was not possible to provide in-clinic peer support this year. We still aim to provide this important service as soon as it is possible in an NHS setting.



100%

of people who used our peer support services would recommend them to others.

310




individuals were supported by our telephone peer support service.



167

support group meetings were held.

2041



total support group attendees, a 46% increase compared to 2020.

Achievements in 2021

Providing Support and Information

Information

2021 also saw the launch of our new website, which has been designed to make it easier for visitors to access the information they need and discover the range of support services available to them. The importance of digital and accessible health information and support has been growing for some time, and never more so than in the past two years when face-to-face services have been cut. It was fitting therefore, that we launched our new website in 2021. Our hope is that the new site enables people affected by cardiomyopathy to easily access a range of reliable, clear and accurate information when they need it. We were delighted to receive positive feedback on the new website from our community, with users finding it easier to navigate and access information and services.

Our Annual Conference

In October, we held our national conference online once again, ensuring the event was safe and accessible amidst pandemic restrictions. We provided a diverse and inspiring programme of talks aimed at helping our community to improve their understanding of cardiomyopathy and feel better able to cope with their condition day-to-day. Feedback from the conference was overwhelmingly positive and, as with the previous year, the online format meant that many people who were previously unable to attend face-to-face events were able to join us online.





Achievements in 2021

Improving Diagnosis and Access to Treatment

Change Makers

At the close of 2020 we launched our Change Maker project which brings together volunteers trained to advocate for better cardiomyopathy services in their local NHS organisations. During 2021, this project continued to grow with 20 active volunteers making real and impactful changes locally that will benefit the wider cardiomyopathy community. Our Change Makers have continued to raise the needs of people with cardiomyopathy in their area in accordance with our Change Agenda, a 16-point plan which outlines what people with cardiomyopathy want at all stages of their healthcare pathway.

MedEd

We were delighted to launch our online medical education platform, MedEd. We created MedEd to increase the knowledge of cardiomyopathy and related disorders amongst healthcare professionals, consequently improving their ability to diagnose and treat the condition. The platform was launched with two live courses focused on the most common forms of cardiomyopathy: dilated cardiomyopathy and hypertrophic cardiomyopathy.

The courses have been created in collaboration with globally renowned experts in cardiomyopathy and offer 15 hours of CPD-certified learning.

Within the courses, healthcare professionals can access over 1,000 clinical images and diagrams, patient experience videos and expert videos to expand their clinical knowledge.

Following the launch, we have begun promoting MedEd to the clinical community at conferences and through our relationships with cardiology centres and networks across the UK. Since launching in October, we're delighted that 93 clinicians have registered with MedEd.

1000+ clinical images, diagrams and videos.





93 clinicians have registered with MedEd.

15 hours of CPD-certified learning.



Achievements in 2021

Improving Diagnosis and Access to Treatment


Research

Cardiomyopathy UK is uniquely placed to play an important role in supporting and shaping research projects for the benefit of our community by providing patient insight to researchers. In 2021, we participated as co-researchers in the CRUCIAL project looking at the connection between heart failure and cognitive function. We also provided insight to a number of clinical researchers to help them develop research projects that matter for the cardiomyopathy community. These projects included studies investigating the difference between male and female hearts, when medication can be stopped in dilated cardiomyopathy and genetic cures for cardiomyopathy. We also conducted our own research to understand how people with cardiomyopathy felt about remote appointments compared to face-to-face care. We shared the findings of this work with clinicians and NHS service managers so that they were better able to design their cardiomyopathy services during the pandemic.

Collaborating With Partners

In 2021, we continued our work as an active member of The Alliance for Heart Failure and The Heart and Circulatory Disease Network. These coalitions of clinicians and heart disease charities work together to raise awareness of the importance of the diagnosis of heart conditions in primary care and in particular advocate for improved access to and greater use of diagnostic testing. In December 2021, the Cardiomyopathy Council was officially launched. This group, chaired by our Chief Executive, Joel Rose, is part of the international Global Heart Hub, a charity that brings together the leaders of nine cardiomyopathy charities around the world.





Achievements in 2021

Improving Diagnosis and Access to Treatment

Raising Awareness

When cardiomyopathy goes undiagnosed, it can cost lives. We know that raising awareness can change that. We'd like to thank everyone who shared their cardiomyopathy story in 2021, helping us to share real-life experiences, raise awareness of signs and symptoms and help people affected by cardiomyopathy to feel less isolated.

In February 2021 we launched a nationwide campaign called '#BeatingForTwo' to raise awareness of peripartum cardiomyopathy, a form of cardiomyopathy that can occur towards the end of pregnancy and the following months. Our research showed that the signs and symptoms of peripartum cardiomyopathy are very often dismissed as being normal during pregnancy or as a new mother. For this reason, our campaign focused on what was "normal" and "not normal" during pregnancy and the months afterwards.

The campaign was developed with support from women who kindly shared their experience of peripartum cardiomyopathy and a clinical team. The campaign was also supported by the Chief and Deputy Chief Midwife for England and Wales.



5.5 million were reached with the #BeatingForTwo campaign.




98% of people from our patient survey were unaware that serious heart conditions could occur during pregnancy.

66% of people from our patient survey would not seek medical help if they were to experience symptoms.





32 pieces of regional and national media coverage of the #BeatingForTwo campaign.




“It was interesting to hear other people’s stories as I thought I was one of the only few young people with the condition, but I saw there were a lot. Being able to hear other people’s stories has helped me a lot. In the hospital I was always in cardiac wards with elderly people which made me feel very out of place.”

Lucy, Speaking From The Heart

Funding Our Work

Income and Expenditure

Income:



Community and Challenge Events
33%

Companies and Trusts
43%

Donations
14%

Legacies
10%

Expenditure:

Providing Support
35%


Raising Funds
31%

Research
10%

Public and Professional Education
10%

Governance and Administration
9%

Campaigning
5%



Total Expenditure:
901k

Funding Our Work

Fundraising in 2021

Like many, we entered 2021 with hope that the social restrictions of the pandemic were largely behind us. We had hoped that large fundraising events would be possible by the spring, but unfortunately, events continued to be cancelled or postponed until the late summer and autumn.

Despite these challenges, we continued to be inspired by the creativity and determination of our community as they found imaginative ways to raise funds during pandemic restrictions. One supporter baked every day for a month as part of 30-Day Challenge event, another held a livestream DJ set and another did a mobile car wash in their local area. We saw larger community fundraising events gradually return from the late summer months with golf days and cricket events taking place.

The return of the London Marathon, our largest single fundraising event of the year, in October was a highlight. We were delighted to see our amazing #TeamCardio finally have their day on the iconic 26-mile course and were honoured to meet runners and their families at our post-race event. Having not been able to meet and thank any of our wonderful supporters in-person for the past 18 months, the day felt even more special. A huge thank you goes to our 46 runners who raised over £116,00 - a significant contribution to our successful end to the year of fundraising in 2021.

In addition, over 100 people fundraised for us on Facebook and Instagram, raising over £16,000 in celebration of birthdays, weddings and anniversaries. We also received just over £48,000 in donations made in memory of loved ones raised through funeral collections, tribute funds and memorial events.

Although the first half of 2021 continued to be a challenging fundraising environment, thanks to continued support from our funders and the return of community and challenge events in the latter half of the year, we were delighted to finish our financial year in December in a positive position with an income total of £945,478.





Funding Our Work

Fundraising Responsibly

We are committed to raising funds in a responsible and sustainable way. Our fundraising is conducted either directly by our fundraising staff team or by volunteer fundraisers under their support and guidance. We do not use the services of third-party professional fundraisers or fundraising companies. We work to ensure that our fundraising activity meets the best practice standards laid out by the Charity Commission and the Fundraising Regulator and in 2021 we received no complaints regarding our fundraising activity. The charity also meets all GDPR regulations and has signed up to the Fundraising Preference Service. The Fundraising Preference Service's purpose is to guard against unreasonable intrusion on privacy, unreasonable persistent approaches for donations or placing undue pressure on a person to give money or other property.

Thank you

We would like to take this opportunity to thank our community for their support during another challenging year. Together, we met these challenges head-on to ensure that we continued to deliver for our community.
Thanks to the dedication and commitment of our volunteers, fundraisers, donors and funders we were able to remain a source of support and information that our community could count on during these most uncertain times.


In 2021 we were grateful for new and continued support from:

The National Lottery Community Fund, BBC Children In Need, The Garfield Weston Foundation, The Edward Gostling Foundation (formerly The ACT Foundation), Max's Foundation, The Edith Florence Spencer Memorial Trust, Browns Solicitors and the CAF Resilience Fund.

BBC Children in Need

COMMUNITY FUND

CAF Charities Aid Foundation



My world was flipped upside down when I was told I was in heart failure – my heart was failing me. Over time, I began getting back into walking and eventually got my steps up. I wanted to make something positive come out of my experience, so I decided to set myself a challenge to walk 10,000 steps a day. To some people, this is not a challenge, but when you come from not being able to walk up the stairs to be able to walk 5km in one go, it's a big deal. It's been amazing to give back to Cardiomyopathy UK.

Jodie, Fundraising Superstar

Ambitions for 2022

Providing Support and Information

In 2020 we saw an increase in the number of people using our services. Although this trend has continued in 2021, we recognise that the number of people that we help still represents a small proportion of the total number of people who could benefit from our services. We want to do more to increase the accessibility of our services so that a wider range of individuals feel that they can benefit from our support and feel welcome in our community. In 2022 we will be establishing an outreach committee tasked with taking a broad view of all the ways that we support people affected by cardiomyopathy and making practical suggestions for how we can improve accessibility.

There is no doubt that the pandemic has had a transformational impact on the NHS, our charity and the people we support. As the pandemic starts to abate, the time is right for the charity to look at its portfolio of support and information services and assess if they are still meeting the needs of people affected by cardiomyopathy, what adaptions, if any, are needed, and whether there are new or unmet needs that we may be able to meet. In 2022 we will be reviewing our services and gathering feedback from stakeholders to ensure that we continue to meet needs in the new "post-pandemic" world. At the same time, we will continue to grow our youth activity and expand our peer support services.

Like many, we had expected and hoped that COVID restrictions would ease fairly early on in 2021, but sadly this was not the case. However, we are hopeful that we will see a return to in-person support groups and that peer support volunteers will be able to return to hospitals in 2022. We are also excited about the possibility of once again running an in-person national conference.

In 2022 We Plan To...



Do more outreach to increase accessibility to our services.



Review our services to ensure we meet the needs of our community.



See a return to in-person support groups and peer support services.

Ambitions for 2022

Improving Diagnosis & Access to Quality Treatment

At the end of 2021, trustees decided that the time was right to invest in our research and policy activity through the recruitment of a new Head of Research and Policy. This new member of the Senior Management Team will be responsible for developing our research infrastructure so that we are better able to provide patient insight to clinical research projects and undertake our own social research to direct and underpin policy activity.

In 2022 we plan to further grow our Change Maker project by welcoming new volunteer Change Makers to the team and working to ensure that existing volunteers have the support, information and training that they need to successfully advocate for meaningful change in their local NHS organisations.

We are excited by the news that the first ever treatments designed for people with cardiomyopathy are likely to begin the drug approval process in 2022. One of these is the drug, mavacamten, which will begin its review in late 2022.
As an important stakeholder, we are ready to play our part in providing meaningful evidence and feedback from people with lived experience of cardiomyopathy to the National Institute of Health and Care Excellence (NICE), the body that determines the availability of treatments on the NHS.

In 2022, we will also aim to build on the initial success of MedEd, with three new modules covering genetics, arrhythmogenic cardiomyopathy (ARVC) and a "Hidden in Heart failure" unit to help clinicians understand the importance of providing a full diagnosis.

In 2022, we will continue to play our part in national initiatives such as the Alliance for Heart Failure, and the Heart and Circulatory Disease Network; working collaboratively with other relevant organisations to improve care and treatment for people with cardiomyopathy. In 2022, we will continue to lead the Cardiomyopathy Council and seek further opportunities to collaborate with members of the worldwide cardiomyopathy community.

In 2022 We Plan To...



Ambitions for 2022

Raising Awareness

A person with cardiomyopathy who has not been treated is at greater risk of experiencing a cardiac arrest. That's why one of our strategic goals is to get more people to seek medical help. To do this we need to raise public awareness of cardiomyopathy and its signs and symptoms. However, to truly have an impact, we need to raise awareness across the full spectrum of our population. To only reach a narrow segment of the population is simply not enough.

In 2022, extending our reach beyond the most common groups and audiences will be one of our key areas of focus. Through a digital awareness campaign, we will reach out to communities to whom our services may have been or appeared previously inaccessible.

We have identified that people with cardiomyopathy from BAME communities and people with lower health literacy are underrepresented and under-supported in our work. Therefore, these are two groups which we will do more to support and engage in 2022.

In 2022 We Plan To...



Raise awareness of cardiomyopathy, the signs and symptoms.



Launch a digital awareness campaign to extend our reach.



Do more to support communities that are underrepresented.



My brother, Alex, a.k.a. Scouse, had the greatest group of friends a man could ask for and they have done everything possible to honour his name and make sure that he didn't pass away in vain. When I heard that they were running for Cardiomyopathy UK I really wanted to get on board to raise money and to show Alex that I miss him dearly.

Gareth, Team Scouse
Our London Marathon Super Team

Trustees Report

Structure, Management and Governance

The charity is controlled by its governing document and constitutes a charitable incorporated organisation. The charity is governed by its constitution adopted on 5 November 2015.

The charity continues to review and, where necessary, improve its trustee induction and training resources to ensure that new trustees are equipped to support the work of the charity to their maximum ability.

Appropriate policies and procedures have been put in place to ensure good governance including financial management, data protection and employment practice. Trustees maintain a risk register and work with the Chief Executive to ensure that strategies are in place to mitigate against identified risks.

In 2021, Trustees continued to work in accordance with the charity's three-year plan for the years 2021 to 2023. This plan was developed in 2020 with input from staff, clinicians and the wider cardiomyopathy community and is available on the Cardiomyopathy UK website.

Alison Fielding, the Chair for the previous 5 years stepped down at the start of the year and the Trustees were pleased to welcome Rita Sutton as their chair. During the year the charity took occupation of its new premises in Amersham.

Financial Review

Trustees are proud to report that despite the huge challenges faced by all in 2021, the charity was able to strengthen its financial position and rebound from the fall in income experienced in 2020 due to COVID-19 restrictions. This was achieved by the charity being able to increase unrestricted income from the community and challenge event fundraising, thanks in a large part to the London Marathon team, while at the same time continuing to build its restricted funding income.

Trustees note that the key financial challenge for 2022 will be for the charity to maintain levels of restricted income while at the same time returning unrestricted income to "pre-pandemic" levels. Trustees are hopeful that this can be achieved especially as the charity's network of supporters, fundraising volunteers and challenge eventers remain engaged with the charity and ready to continue their fundraising activities as soon as it is safe to do so.

Trustees Report

Related Parties

The charity works closely with expert clinicians from a number of NHS Trusts to help ensure that its work is clinically appropriate and that it is able to reach as many people with cardiomyopathy as possible.

During the year the charity continued to work with its President, Prof. Perry Elliott to develop the International Cardiomyopathy Network (ICoN), a registered UK Charity. The charity's Chief Executive provided strategic advice and patient insight to ICoN as part of a shared commitment to improving the level of cardiomyopathy knowledge among clinicians, developing best practice and fostering research that will make a real difference to the lives of people with the condition. The charity has a positive relationship with The British Heart Foundation, The Pumping Marvellous Foundation and a number of other charities that provide support and information relating to heart diseases. Where possible, the charity works in collaboration with these charities.

During 2021 the charity received funding from six pharmaceutical companies (Sanofi, Pfizer, Alnylam, Novartis, AstraZeneca and Bristol Myers Squibb) who have developed or who are developing treatments used by people with cardiomyopathy. The total income from these companies was £129,806; under 14% of the charity's total income. Income from these sources covered the costs associated with the charity's medical education project, advocacy project, awareness raising and service delivery work. All funding was provided in accordance with the Association of British Pharmaceutical Industry code of practice and the charity's own policy on working with the pharmaceutical industry which is available at www.cardiomyopathy.org/about-us/our-approach. This policy is designed to ensure the charity's independence.

Reserve Policy

The charity aims to maintain unrestricted reserves at a level that equates to around six to nine months of normal unrestricted expenditure. Trustees believe this to be a prudent amount given that the charity operates in a competitive environment and, as the leading specialist provider of support services for people affected by cardiomyopathy, there is a duty to ensure that it can maintain core services for individuals in need.

Public Benefit

Cardiomyopathy UK confirms that in setting its programme of support, it has had due regard to the Charity Commission's general guidance on public benefit. The programme of support also conforms to the charity's charitable objectives and aims. No persons are excluded from the work of the charity on grounds of gender, race or religion.

Trustees Report
Reference and Administrative Details

Board of Trustees:
- A Fielding (Resigned Chair February 2021)
- T Amiss
- G Favier
- C Horwood
- S Kirkham
- I McPherson OBE
- E Jarman (Appointed February 2021)
- E Power
- A Smith
- R Sutton (Appointed Chair February 2021)
- T Bueser
- A Tickell (Resigned June 2021)
- P Thomas (Treasurer)

Chief Executive Officer:
Mr J Rose

Principal Address:
75A Woodside Road
Amersham
Buckinghamshire
HP6 6AA

Auditors:
Seymour Taylor Limited Statutory Auditors
57 London Road
High Wycombe
Buckinghamshire
HP11 1BS

Charity Number:
1164263

Bankers:
CafCash Limited
Kings Hill
West Malling
Kent
ME19 4TA

Lloyds
82 High Street
Rickmansworth
Hertfordshire
WD3 1AG

Trustees Report

Statement of Trustees' Responsibility

The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the board of trustees on:

and signed on its behalf by:



Rita Sutton, Chair of Trustees

Independant Auditor's Report

Opinion

We have audited the financial statements of Cardiomyopathy UK (the 'charity') for the year ended 31 December 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2021 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis For Opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions Related To Going Concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other Information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- The information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Our responsibilities for the audit of financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
Identifying and assessing potential risks related to irregularities
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- results of our enquiries of management about their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the charity's documentation of their policies and procedures relating to: - identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of noncompliance; - detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud; - the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

We also obtained an understanding of the legal and regulatory frameworks that the charity operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Charities Act and local tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the charity's ability to operate.

Audit Response to Risks Identified

As a result of performing the above, our procedures to respond to risks identified included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- reading minutes of meetings of those charged with governance; and
- in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Seymour Taylor Limited

Seymour Taylor Limited,
Statutory Auditor
57 London Road
High Wycombe
Buckinghamshire
HP11 1BS

Date: 23 June 2022 .....

CARDIOMYOPATHY UK

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	Unrestricted funds £	Restricted funds £	31.12.21 Total funds £	31.12.20 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	553,435	262,237	815,672	749,555
Charitable activities	4				
Providing support		-	21,100	21,100	21,100
Public and medical education		-	48,800	48,800	-
Research		-	59,906	59,906	-
Investment income	3	-	-	-	1,174
Total		553,435	392,043	945,478	771,829
EXPENDITURE ON					
Raising funds	5	276,593	-	276,593	271,179
Charitable activities	6				
Providing support		75,351	243,449	318,800	319,348
Public and medical education		46,439	46,787	93,226	72,674
Campaigning		21,887	19,947	41,834	48,049
Research		12,236	81,882	94,118	17,184
Other		60,110	16,569	76,679	64,927
Total		492,616	408,634	901,250	793,361
NET INCOME/(EXPENDITURE)		60,819	(16,591)	44,228	(21,532)
Transfers between funds	16	1,891	(1,891)	-	-
Net movement in funds		62,710	(18,482)	44,228	(21,532)
RECONCILIATION OF FUNDS					
Total funds brought forward		331,200	191,534	522,734	544,266
TOTAL FUNDS CARRIED FORWARD		393,910	173,052	566,962	522,734

The notes form part of these financial statements

CARDIOMYOPATHY UK

BALANCE SHEET 31 DECEMBER 2021

	Notes	Unrestricted fund £	Restricted funds £	31.12.21 Total funds £	31.12.20 Total funds £
FIXED ASSETS					
Tangible assets	12	8,871	-	8,871	8,857
CURRENT ASSETS					
Debtors: amounts falling due within one year	13	244,659	-	244,659	161,908
Debtors: amounts falling due after more than one year	13	29,006	-	29,006	4,006
Cash at bank and in hand		183,379	173,052	356,431	440,685
		457,044	173,052	630,096	606,599
CREDITORS					
Amounts falling due within one year	14	(72,005)	-	(72,005)	(92,722)
NET CURRENT ASSETS		385,039	173,052	558,091	513,877
TOTAL ASSETS LESS CURRENT LIABILITIES		393,910	173,052	566,962	522,734
NET ASSETS		393,910	173,052	566,962	522,734
FUNDS	16				
Unrestricted funds				393,910	331,200
Restricted funds				173,052	191,534
TOTAL FUNDS				566,962	522,734

The financial statements were approved by the Board of Trustees and authorised for issue on 23rd June 2022 . and were signed on its behalf by:

Rita Sutton, Chair of Trustees

The notes form part of these financial statements

CARDIOMYOPATHY UK

CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	31.12.21 £	31.12.20 £
Cash flows from operating activities			
Cash generated from operations	1	(79,637)	6,224
Net cash (used in)/provided by operating activities		(79,637)	6,224
Cash flows from investing activities			
Purchase of tangible fixed assets		(4,617)	(5,063)
Interest received		-	1,174
Net cash used in investing activities		(4,617)	(3,889)
Change in cash and cash equivalents in the reporting period		(84,254)	2,335
Cash and cash equivalents at the beginning of the reporting period		440,685	438,350
Cash and cash equivalents at the end of the reporting period		356,431	440,685

The notes form part of these financial statements

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES

	31.12.21 £	31.12.20 £
Net income/(expenditure) for the reporting period (as per the Statement of Financial Activities)	44,228	(21,532)
Adjustments for:		
Depreciation charges	4,603	2,751
Interest received	-	(1,174)
Increase in debtors	(107,751)	(19,266)
(Decrease)/increase in creditors	(20,717)	45,445
Net cash (used in)/provided by operations	(79,637)	6,224

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.21 £	Cash flow £	At 31.12.21 £
Net cash			
Cash at bank and in hand	440,685	(84,254)	356,431
	440,685	(84,254)	356,431
Total	440,685	(84,254)	356,431

The notes form part of these financial statements

Notes To The Financial Statements For The Year Ended 31st December 2021

1. Accounting Policies

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Cardiomyopathy UK is a charity limited by guarantee and incorporated in England and Wales. The charity's principal address is 75A Woodside Road, Amersham, Buckinghamshire, HP6 6AA. The registered charity number is 1164263.

The presentation currency of these financial statements is Sterling (£), being the currency of the primary economic market in which the entity operates. All amounts in these financial statements have been rounded to the nearest pound unless stated otherwise.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

In light of the rapid global spread of the Coronavirus "COVID-19" since early 2020, the trustees have reviewed and stress tested projections and budgets for the next twelve months. Following this review, the trustees consider there to be little impact on the Charity's ability to act as a going concern.

The trustees have reviewed the fundraising possibilities and the capital resources available and consider that the charity has adequate resources in place to continue operations for the next twelve months.

1. Accounting Policies (continued)

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Government Grants

The charity receives government grants in respect of Coronavirus Job Retention Scheme. Income from government grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably. If entitlement is not met then these amounts are deferred.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Allocation and apportionment of costs

Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with use of the resources.

Salaries have been apportioned in accordance with the duties to which they relate.

Premises costs have been apportioned on the basis of percentage of floor space used.

Tangible Fixed Assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - at variable rates on reducing balance

Taxation

The charity is exempt from tax on its charitable activities.

1. Accounting Policies (continued)

Fund Accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Financial Instruments

The charity has applied the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instrument Issues" of FRS 102 to its financial statements.

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Debtors and creditors due within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities in administrative expenses.

Cash and cash equivalents

Cash and cash equivalents in the Statement of Financial Position comprise cash at bank and in hand and short term deposits with an original maturity date of three months or less. Bank overdrafts are disclosed within creditors on the Statement of Financial Position.

2. DONATIONS AND LEGACIES

	31.12.21	31.12.20
	£	£
Donations	192,761	178,166
Grants and legacies	361,996	246,868
Fundraising	260,915	324,521
	815,672	749,555

Grants received included above are as follows:

	Unrestricted	Restricted	2021 Total	2020 Total
	£	£	£	£
Browns Solicitors	-	64,800	64,800	60,800
Alexander Jansons Fund	-	(290)	(290)	-
BBC Children in Need	-	23,925	23,925	10,825
Big Lottery Fund - CommunityPeerSupport	-	58,821	58,821	108,868
Heart Hive	-	(1,891)	(1,891)	-
The Edward Gostling Foundation	-	-	-	15,000
Max's Foundation	-	-	-	14,776
Cunningham Family Trust	-	-	-	10,000
Myokardia/Vistra IE UK	-	-	-	10,000
The Moss Family Charitable Trust	-	-	-	1,000
European Consultancy	-	-	-	6,356
Burdett Trust Due	-	2,203	2,203	-
Arrhythmogenic ACT	-	57,628	57,628	-
CAF Resilience Fund	-	10,000	10,000	-
CAF Main Grant	-	44,850	44,850	-
The Girdler's Company CharitableTrust	1,450	-	1,450	-
Edith Florence Spencer MemorialTrust	11,000	-	11,000	-
Total Grants	12,450	260,046	272,496	237,625
Total Legacies			89,500	4,000
Coronavirus Job Retention Scheme			-	5,243
			361,996	246,868

3. INVESTMENT INCOME

	31.12.21	31.12.20
	£	£
Deposit account interest	-	1,174

4. INCOME FROM CHARITABLE ACTIV TIES

Grants received included above are as follows:

	Unrestricted	Restricted	2021 Total	2020 Total
	£	£	£	£
Pfizer Ltd	-	21,100	21,100	21,100
Online Medical Education(AstraZen)	-	10,000	10,000	-
Medical education grant (SanofiGenzyme)	-	5,000	5,000	-
PSG Grant (Novartis)	-	23,800	23,800	-
e-learning courses (Alnylam UKLimited)	-	10,000	10,000	-
Growth & Development Project (Bristol-Myers SquibbPharmaceuticals Limited)	-	59,906	59,906	
Total Grants	-	129,806	129,806	21,100

5. RAISING FUNDS

Raising donations and legacies

	31.12.21	31.12.20
	£	£
Staff costs	153,704	175,069
Rates and water	1,013	605
Insurance	422	926
Postage and stationery	2,157	4,839
Sundries	5,187	146
Event costs	64,351	31,950
Marketing	15,953	23,122
Travel and subsistence	32	56
Computer	6,223	3,456
Recruitment	550	7,692
Staff training	26	-
Rent	11,301	9,486
Professional fees	917	2,777
Donation charges	9,860	6,512
Bank charges	347	3,481
Subscriptions	3,674	238
Depreciation	876	824
	276,593	271,179

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Grant funding of activities (see note 7)	Totals
	£	£	£
Providing support	318,800	-	318,800
Public and medical education	93,226	-	93,226
Campaigning	41,834	-	41,834
Research	12,236	81,882	94,118
	466,096	81,882	547,978

7. GRANTS PAYABLE

	31.12.21	31.12.20
	£	£
Research	81,882	1,646

The following Grants were paid to Institutions during the year;

	2021	2020
	£	£
Alexander Janson's Myocarditis	1,269	1,646
Global Heart Hub	22,985	-
University College London	57,628	-
Total	81,882	1,646

8. SUPPORT COSTS

	Management	Governance costs	Totals
	£	£	£
Other resources expended	70,179	6,500	76,679

Analysis of support and governance costs

The charity initially identifies the costs of its support function. It then identifies those costs which relate to the governance function. Having identified its governance costs and support costs these are apportioned between the key charitable activities undertaken in the year. Please refer to the table below for the basis of apportionment and the key analysis of support.

	General Support	Governance function	Basis of apportionment
	£	£	
Wages	24,736	-	The duties to which they relate
Property related expenses	10,950	-	Floor space
General office and administration	33,408	-	Specific support costs
Legal and professional fees	-	-	Specific support costs
Bank charges	219	-	General charges
Depreciation	866	-	Floor space
Audit fees	-	6,500	Governance
Total	70,179	6,500	

9. Auditor's Remuneration

The auditor's remuneration amounts to an audit fee of £6,500 (2020 - £5,050) and payroll services paid to the auditor of £864 (2020 - £1,716) are included in legal and professional fees.

10. Trustee's Remuneration and Benefits

There were no trustees' remuneration or other benefits for the year ended 31 December 2021 nor for the year ended 31 December 2020.

Trustee's Expenses

During the year ended 31 December 2021, trustees received reimbursed expenses of £nil (2020:
£547) for travel and other charitable related costs. At the year end date £nil (2020: £nil) was due to trustees in relation to expenses.

11. Staff Costs

	2021	2020
	£	£
Wages and salaries	464,818	482,236
Social security costs	39,087	39,020
Other pension costs	12,353	13,463
	516,258	534,719

Total redundancy / termination payments during the year amounted to £nil (2020 - £17,881)

Transactions with key management personnel

	2021	2020
	£	£
Total compensation of key management personnel	64,297	64,297

The average monthly number of employees during the year was as follows:

	2021	2020
	18	18

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2021	2020
£60,001 - £70,000	1	1

12. Tangible Fixed Assets

	Computer equipment £
COST	
At 1 January 2021	28,966
Additions	4,617
At 31 December 2021	33,583
DEPRECIATION	
At 1 January 2021	20,109
Charge for year	4,603
At 31 December 2021	24,712
NET BOOK VALUE	
At 31 December 2021	8,871
At 31 December 2020	8,857

13. Debtors: Amounts Falling Due Within One Year

	31.12.21 £	31.12.20 £
Trade debtors	69,906	15,982
Prepayments and accrued income	174,753	145,926
	244,659	161,908

14. Creditors: Amounts Falling Due Within One Year

	31.12.21 £	31.12.20 £
Trade creditors	11,009	8,503
Social security and other taxes	11,353	12,312
Other creditors	2,528	4,018
Accruals and deferred income	47,115	67,889
	72,005	92,722

15. Leasing Agreements

Minimum lease payments under non-cancellable operating leases fall due as follows:

	31.12.21 £	31.12.20 £
Within one year	26,400	33,393
Between one and five years	105,600	105,600
In more than five years	103,400	129,800
	235,400	268,793

16. Movement in Funds

	At 1.1.21 £	Net movement in funds £	Transfers between funds £	At 31.12.21 £
Unrestricted funds				
General fund	331,200	60,819	1,891	393,910
Restricted funds				
Medical education	10,018	-	-	10,018
Providing support helpline	-	1,180	-	1,180
Youth services	3,974	(3,974)	-	-
West Midlands support fund	924	-	(924)	-
Alexander Janson's Foundation	1,260	(1,260)	-	-
BBC Children in Need	4,314	(2,345)	-	1,969
Heart Hive	1,891	-	(1,891)	-
Max's Foundation	13,929	(13,278)	-	651
Community Peer Support (National Lottery Community Fund)	-	(139)	924	785
Building Capabilities (National Lottery Community Fund)	17,844	(17,844)	-	-
Online Medical Education	19,574	(16,242)	-	3,332
Advocacy	27,803	11,672	-	39,475
PPCM Campaign	4,941	(4,941)	-	-
BLF Helpline	20,572	(20,572)	-	-
Building the Community	64,490	(53,412)	-	11,078
Awareness Campaign	-	8,794	-	8,794
CAF Resilience Fund	-	9,201	-	9,201
CAF Support Fund	-	26,938	-	26,938
BMS Grant	-	59,631	-	59,631
	191,534	(16,591)	(1,891)	173,052
TOTAL FUNDS	522,734	44,228	-	566,962

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	553,435	(492,616)	60,819
Restricted funds			
Providing support helpline	30,000	(28,820)	1,180
Youth services	-	(3,974)	(3,974)
Alexander Janson's Foundation	10	(1,270)	(1,260)
BBC Children in Need	23,925	(26,270)	(2,345)
Max's Foundation	-	(13,278)	(13,278)
Community Peer Support (National Lottery Community Fund)	58,821	(58,960)	(139)
Building Capabilities (National Lottery Community Fund)	-	(17,844)	(17,844)
Online Medical Education	25,000	(41,242)	(16,242)
Advocacy	55,900	(44,228)	11,672
PPCM Campaign	-	(4,941)	(4,941)
BLF Helpline	-	(20,572)	(20,572)
Building the Community	-	(53,412)	(53,412)
Awareness Campaign	23,800	(15,006)	8,794
ACT/UCL	57,628	(57,628)	-
CAF Resilience Fund	10,000	(799)	9,201
Burdett Trust	2,203	(2,203)	-
CAF Support Fund	44,850	(17,912)	26,938
BMS Grant	59,906	(275)	59,631
	392,043	(408,634)	(16,591)
TOTAL FUNDS	945,478	(901,250)	44,228

16. Movement in Funds (continued)

Comparatives for movement in funds

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	457,553	(126,353)	331,200
Restricted funds			
Medical education	22,600	(12,582)	10,018
Providing support helpline	164	(164)	-
Youth services	6,664	(2,690)	3,974
West Midlands support fund	924	-	924
Alexander Janson's Foundation	116	1,144	1,260
BBC Children in Need	2,937	1,377	4,314
Heart Hive	1,891	-	1,891
Max's Foundation	11,755	2,174	13,929
Community Peer Support (National Lottery Community Fund)	4,662	(4,662)	-
Building Capabilities (National Lottery Community Fund)	25,000	(7,156)	17,844
Online Medical Education	10,000	9,574	19,574
Advocacy	-	27,803	27,803
PPCM Campaign	-	4,941	4,941
BLF Helpline	-	20,572	20,572
Building the Community	-	64,490	64,490
	86,713	104,821	191,534
TOTAL FUNDS	544,266	(21,532)	522,734

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	420,657	(547,010)	(126,353)
Restricted funds			
Medical education	179	(12,761)	(12,582)
Providing support helpline	30,000	(30,164)	(164)
Youth services	15,000	(17,690)	(2,690)
Alexander Janson's Foundation	2,924	(1,780)	1,144
BBC Children in Need	10,825	(9,448)	1,377
Max's Foundation	14,776	(12,602)	2,174
Community Peer Support (National Lottery Community Fund)	63,218	(67,880)	(4,662)
Building Capabilities (National Lottery Community Fund)	-	(7,156)	(7,156)
Online Medical Education	30,000	(20,426)	9,574
Advocacy	51,900	(24,097)	27,803
PPCM Campaign	18,700	(13,759)	4,941
BLF Helpline	45,650	(25,078)	20,572
Building the Community	68,000	(3,510)	64,490
	351,172	(246,351)	104,821
TOTAL FUNDS	771,829	(793,361)	(21,532)

16. Movement in Funds (continued)

Total Funds

Medical education - Towards the costs of providing educational events and opportunities for healthcare professionals. This includes the Olsen-Gourley Lecture fund and the M Hicks Educational fund transferred from Cardiomyopathy Association.

Youth services - Towards the costs of developing and providing support services for children, youth and young adults. This includes the Wates Foundation fund, the Childrens Book Restricted Fund, Chairman's Appeal 2013 fund and the Children and Young People Office fund transferred from Cardiomyopathy Association.

Providing support helpline - Towards the costs of providing a nurse lead clinical helpline for people affected by cardiomyopathy. This includes the Chairman's Appeal 2013 fund, Support Nurse Helpline fund, Raft Race Appeal fund and the Cardio Connect fund transferred from Cardiomyopathy Association.

BLF Heart to Heart Project - To fund the support and provision of a network of support groups throughout England. This includes the Sussex Support Group fund, Hampshire Support Group fund and the Winchester Support Group fund transferred from Cardiomyopathy Association.

West Midland support group - to provide support for those with cardiomyopathy in the West Midlands.

Alexander Janson's Foundation - to fund research into the causes, prevention and cures for Myocarditis.

BBC Children in Need - To improve the emotional, physical and psychosocial (empowerment) well-being of young people under 18. Information resources (web and hard copy), paediatric helpline (out of hours), and national event, plus Panel meetings.

Tesco's Community Groundwork Fund - Towards the holding of a musical event raising the awareness of Cardiomyopathy in Leeds.

Heart Hive - Online platform that aims to match researchers at Imperial College with individuals interested in taking part in research trials. The objective is to seek ways of improving treatment for cardiomyopathy and myocarditis.

Max's Foundation - Three year grant to fund the position of Youth Support Manager.

Community Peer Support (National Lottery Community Fund) - A five year project partly funded by the National Lottery Community Fund to develop an innovative face to face and phone peer support service for people with life limiting heart muscle disease throughout England.

Building Capabilities (National Lottery

Community Fund) - National audit pan England of those NHS trusts and service providers providing clinical care and treatment to people affected by cardiomyopathy and myocarditis.

Online Medical Education - Towards the development of an online learning program which will improve diagnoses of cardiomyopathy and access to treatment by upskilling clinical knowledge of patient facing clinicians.

Advocacy - Developing the patient voice to affect purposeful change within the relevant statutory agencies.

PPCM Campaign - To raise public awareness of peripartum Cardiomyopathy in particular statutory health providers.

BLF Helpline - To provide a dedicated frontline service to anyone affected by Cardiomyopathy or related conditions.

Building the Community - To raise awareness of Cardiomyopathy to English speaking countries internationally.

Awareness campaign - To fund a national awareness campaign aimed at raising awareness of the signs and symptoms of cardiomyopathy among hard to reach communities. This funding has been received from Novartis Pharmaceuticals UK.

CAF Resilience Fund - Funding to help the charity improve its ability to raise income, deliver services and develop its policy positions with the support of external consultants. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

CAF Support Fund - Funding to ensure that the charity can continue to deliver its core services and improve its ability to reach more communities and individuals affected by cardiomyopathy. This funding has been received from the Charities Aid Foundation's coronavirus emergency fund.

BMS Grant - Funding from the pharmaceutical company, Bristol Myers Squibb to cover the costs of the charity's national conference, website, outreach and awareness work.

ACT/UCL Grant - Funding from the Arrhythmogenic Cardiomyopathy Trust (Charity No.1176790) to fund a research project based at University College London focused on risk stratification in Arrhythmogenic Cardiomyopathy.

17. Related Party Disclosures

There were no related party transactions for the year ended 31 December 2021.

CARDIOMYOPATHY UK

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2021

	31.12.21 £	31.12.20 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	192,761	178,166
Grants and legacies	361,996	246,868
Fundraising	260,915	324,521
	815,672	749,555
Investment income		
Deposit account interest	-	1,174
Charitable activities		
Grants	129,806	21,100
Total incoming resources	945,478	771,829
EXPENDITURE		
Raising donations and legacies		
Wages	138,826	156,741
Social security	11,662	13,030
Pensions	3,216	5,298
Rates and water	1,013	605
Insurance	422	926
Postage and stationery	2,157	4,839
Sundries	5,187	146
Event costs	64,351	31,950
Marketing	15,953	23,122
Travel and subsistence	32	56
Computer	6,223	3,456
Recruitment	550	7,692
Staff training	26	-
Rent	11,301	9,486
Professional fees	917	2,777
Donation charges	9,860	6,512
Bank charges	347	3,481
Subscriptions	3,674	238
Depreciation of tangible fixed assets	876	824
	276,593	271,179
Charitable activities		
Wages	303,533	302,165
Social security	25,698	24,146
Pensions	8,587	7,534
Insurance	5,200	3,970
Carried forward	343,018	337,815

CARDIOMYOPATHY UK

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2021

	31.12.21 £	31.12.20 £
Charitable activities		
Brought forward	343,018	337,815
Light and heat	1,623	662
Telephone	5,000	3,254
Postage and stationery	4,021	5,494
Advertising	58,767	49,375
Sundries	178	320
Medical conferences and events	10,065	2,253
Public conferences and events	11,580	14,036
Computer	7,364	9,167
Travel and subsistence	1,949	1,402
Recruitment	275	11,075
Staff training	911	1,491
Support costs	1,015	1,519
Consultancy	1,254	210
Rent	16,215	15,975
Depreciation of tangible fixed assets	2,861	1,561
Grants to institutions	81,882	1,646
	547,978	457,255
Support costs		
Management		
Wages	22,459	23,330
Social security	1,727	1,844
Pensions	550	631
Rates and water	421	708
Insurance	-	307
Light and heat	573	44
Telephone	1,500	2,218
Postage and stationery	4,981	3,819
Sundries	1,505	3,768
Computer	21,858	8,232
Rent	6,518	3,225
Repairs and maintenance	3,438	5,581
Travel and subsistence	-	493
Subscriptions	868	1,061
Legal and professional fees	2,696	4,148
Bank charges	219	102
Depreciation of tangible and heritageassets	866	366
	70,179	59,877
Governance costs		
Auditors' remuneration	6,500	5,050
Total resources expended	901,250	793,361
Net income/(expenditure)	44,228	(21,532)

This page does not form part of the statutory financial statements

CARDIOMYOPATHY UK

England & Wales - Charity number 1164263

Accounts

REGISTERED CHARITY NUMBER: 1164263

REPORT OF THE TRUSTEES AND

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

FOR

CARDIOMYOPATHY UK

Seymour Taylor Audit Limited, Statutory Auditor
57 London Road
High Wycombe
Buckinghamshire
HP11 1BS

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2020

The trustees present their report with the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Cardiomyopathy UK is the national charity for people affected by the heart muscle disease cardiomyopathy. The charity exists to ensure that people with cardiomyopathy can live longer and fuller lives. This is achieved through:

1) Providing support and information services for people affected by cardiomyopathy to increase their understanding of the condition, provide skills and motivation to cope day to day and limit the damage to psychological well-being.

2) Working with healthcare professionals and clinical experts to enhance their ability to make appropriate diagnoses and improve treatment outcomes.

3) Raising awareness of cardiomyopathy amongst the general public to reduce the number of sudden and avoidable cardiac deaths through early diagnosis.

4) Campaigning to encourage policy makers and health service commissioners to improve access to quality treatment.

5) Increasing understanding of cardiomyopathy and its impact so that the charity can support the search for new treatments and ensure that its own work is effective.

ACHIEVEMENT AND PERFORMANCE

2020 has been a year like no other, presenting unique challenges for all charities and the people that they support. The charity has had to contend with a huge increase in demand for its support whilst at the same time coping with a considerable decrease in unrestricted income.

Given the extent of these challenges, Trustees are particularly pleased to report that during the year the charity was able to adapt quickly and effectively so that it could continue to support people affected by cardiomyopathy, make significant progress in-line with its strategic plan and remain financially viable. Staff and volunteers really stepped up to all challenges thrown at them and Trustees would like to acknowledge their achievements and thank them for their commitment. Trustees would like to highlight the following achievements:

Providing support and information

In March 2020, as the pandemic began to impact on peoples' lives the Charity's helpline saw demand increase by over 300%. Helpline users were concerned about how COVID-19 would affect them and where people with cardiomyopathy fitted into the government's developing classifications of vulnerabilities. During this time the most common questions that the Charity's nurses were asked was whether a caller should be shielding or self-isolating. In the following few months, call volume remained around 50% more than in previous years as callers began to need support in coping with practical issues such as how to manage working whilst being vulnerable or having to shield. Trustees are proud that the charity was able to increase capacity on the helpline, thanks to additional volunteer support, and that helpline satisfaction levels remained very high with 93% of callers finding their call very helpful.

At the same time as managing the increase in demand on the helpline, it was clear that there was a real need to provide accurate and timely cardiomyopathy specific information about the pandemic. The Charity was able to work closely with its network of clinical experts to provide regular information on its website as well as a number of FaceBook Live question and answer sessions with Professor Perry Elliott and other experts that received a total of over 17,000 views.

The Charity was also able to provide high quality information and access to clinical experts at its National Conference. Pandemic restrictions meant that it was necessary to move the conference to an online only format, something that the charity had not done previously. Trustees can report that feedback from the conference was overwhelmingly positive and noted that the online format meant that many people who were previously unable to attend were able to join. Total attendance was up 160% and the charity welcomed attendees from 20 different countries.

It was clear from the outset of the pandemic that the Charity's service users were not only going to need more information and advice but that there was also a need to increase the Charity's ability to provide emotional and peer support. This was challenging as the Charity has traditionally provided this form of support in face-to-face settings via its support group network and in-Hospital volunteers, this was no longer possible due to pandemic restrictions.

Trustees are happy to report that the Charity was able to transform its support group network and work with its volunteer support group leaders to be able to provide online meetings. In addition to this, new groups were established including one social group to provide a much-valued opportunity to take a break from pandemic concerns. One of the new groups focuses on advanced heart failure, something that Trustees had committed to provide during the year. Remarkably, overall support group attendances was up 25% on previous years and the Charity was able to meet its targets for peer support work funded by the National Lottery Community Fund. Although it was not possible to replicate in-Hospital peer support during this time due to pandemic restrictions, the Charity is confident that this form of support will return in 2021.

Trustees noted that due to the pandemic and the shift towards more online service provision not only did the total number of service users increase, but that those using services were from a more diverse background. This has re-inforced Trustees commitment to consider how the Charity can do more to ensure that its support and information services remain accessible to as many people from as many backgrounds as possible as the community comes out of the pandemic.

Improving diagnosis and access to quality treatment

In their report for the financial year 2019, Trustees announced that the charity will be aiming to do more to improve access to treatment throughout the UK by launching an advocacy project. Trustees are pleased to report that during 2020, the charity was able to secure funding for this work and launched its "Change Makers" project. As part of the project, 18 volunteers "change makers" were recruited and undertook training to prepare them to act as local advocates working to effect change in their local communities. Change Makers also worked with the Charity and other stakeholders to update the Charity's "National Plan for Cardiomyopathy" document to ensure that it remained relevant.

Last year, Trustees reported that the Charity was due to launch an online medical education platform to increase the level of knowledge of cardiomyopathy and related disorders among healthcare professional and improve their ability to diagnose and treat the condition. Unfortunately, this project has been delayed as the pandemic has made it challenging to record the necessary video materials and secure the time of health care professionals needed to ensure that information on the platform is fit for purpose. Trustees are confident that the online platform will be ready to launch in 2021.

In their report for 2019, Trustees also commented on how the charity aimed to continue to engage with the research community and was working with the Arrhythmogenic Cardiomyopathy Trust to fund new research into arrhythmogenic cardiomyopathy. Trustees can report that after a competitive selection process, it was decided to fund an innovative research project based at University College London that aims to develop a unique resource to bolster existing and future arrhythmogenic cardiomyopathy research projects.

During the year, the Charity also began to work with clinicians and other cardiomyopathy focused charities from outside of the UK to help improve its own networks and create more opportunities to share information, research and resources. This work will continue in the coming year.

Campaigning and raising awareness

During the year the Charity worked to develop a nationwide campaign to raise awareness of peripartum cardiomyopathy, a form of cardiomyopathy that can occur towards the end of pregnancy and the following few months. The Charity's own research showed that the signs and symptoms of peripartum cardiomyopathy are very often dismissed as being normal in pregnancy or becoming a new mother. For this reason, the campaign focused on what was "normal" and "not normal" during pregnancy and the months afterwards. The campaign was developed with a group of women who had experience of peripartum cardiomyopathy as well as a clinical team and was supported by the Chief and Deputy Chief Midwife for England and Wales.

Trustees had hoped to launch this campaign in September 2020 but it was decided to postpone this activity until 2021. It was felt that launching the campaign while the COVID-19 pandemic was worsening would not be effective and that there would be a better chance of securing coverage and making the necessary impact if it was postponed.

Although the pandemic caused the Charity to delay its national awareness campaign, there was a large increase in the number of people reached via social media. Overall reach increased by 10% as the Charity improved its social media presence and sought new ways to engage with supporters and the wider community.

Fundraising activities

The Charity does not use commercial, third party fundraising agencies to raise funds on its behalf. The small fundraising team is aided by a network of volunteer fundraisers whose activities are monitored to ensure that their fundraising efforts comply with all relevant legislation and are in-line with recognised best practice including guidance on protecting vulnerable people. The charity has not received any complaints relating to its fundraising practice this financial year.

FINANCIAL REVIEW

Income

Trustees are proud to report that despite the huge financial challenges that the Charity has faced in 2020, the drop in overall income was kept to £80K and the deficit for the year was only £20K. This was achieved by the Charity being able to balance the significant loss of unrestricted income from community and challenge event fundraising with an increase in restricted funding, a proportion of which could be used to cover core costs. This increase in restricted income along with additional cost control measures means that the Charity's unrestricted reserve at the end of the financial year remain within the Trustee's reserve policy.

Trustees note that the key financial Challenge for 2021 will be for the Charity to maintain levels of restricted income while at the same time, gradually returning unrestricted income to "pre-pandemic" levels. Trustees are hopeful that this can be achieved especially as the Charity's network of supporters, fundraising volunteers and challenge eventers remain engaged with the Charity and ready to continue their fundraising activities as soon as it is safe to do so.

Reserves policy

The charity aims to maintain unrestricted reserves at a level that equates to around six to nine months of normal unrestricted expenditure. Trustees believe this to be a prudent amount given that we operate in a competitive environment and, as the leading specialist provider of support services for people affected by cardiomyopathy, there is a duty to ensure that we can maintain our core services for individuals in need.

FUTURE PLANS

Providing Support and Information

Although the Charity has seen the number of people who use its services increase this is still a small proportion of the total number of people who could benefit from its work. As stated above, the pandemic has meant that people from a wider range of backgrounds are beginning to use its services, but Trustees are still aware that more needs to be done to increase accessibility. In 2021, Trustees want to see more people coming to the charity for support and a better representation of all communities involved in its work. Trustees believe that one of the ways that this can be achieve will be to continue to adapt the Charity's services so that they are more accessible online and do more to connect online service users with each other and the wider cardiomyopathy community.

Next year the Charity will be launching a new website that aims to make it easier for visitors to access the information that they need and engage with the Charity. After the success of the Charity's online National Conference in 2020, the Charity's 2021 National Conference will also be accessible online but, pandemic restrictions permitting, will also incorporate some face-to-face content so that participants may choose to take advantage of opportunities to network and participate in peer support activity.

It is expected that once COVID restrictions begin to ease in the second half of 2021 there will be a return to in person support groups and peer support volunteers will be able to return to hospital settings. While the peer support volunteers and support group leaders are keen to get back to their normal style of meeting, there are some real benefits to meeting on-line. In particular, online support group meetings have proven to be attractive to new members and individuals who would otherwise find it difficult to attend a face-to-face meeting. The Charity was also able to launch a series of subject matter support groups to complement those based on location. Many of these are led by the Charity's helpline nurses and allow people to learn about their specific condition in a supportive group environment. For this reason, the Charity will continue some online support group provision as it expands its peer support network in line with the three-year plan agreed with the National Lottery Community Fund.

Improving diagnosis and access to quality treatment

Next year, the Charity's Change Makers Project is set to start to make a real impact on local communities. Volunteers are expected to have completed their training by the end of March and be ready to start to work with local clinicians and other stakeholders to improve access to treatment for people with cardiomyopathy in their area. This is an exciting next step for the Change Makers project and Trustees look forward to being able to report some tangible results next year.

In 2021 the Charity will continue to work with clinicians and other cardiomyopathy focused charities from outside the UK, playing its part in creating and supporting a worldwide cardiomyopathy community of supporters and healthcare professionals. The Charity will work with these networks to develop educational and awareness programmes as Trustees believe that being part of a worldwide community benefits everyone as all partners can share knowledge and information more widely.

Campaigning and raising awareness

In 2021 the Charity plans to run two national awareness campaigns. As well launching the delayed peripartum cardiomyopathy campaign at the start of the year, the Charity is also planning to develop a campaign that is designed to reach audiences that we feel we have not yet reached. Trustees are especially keen that the BAME community and people with lower levels of health literacy are aware of the signs and symptoms of cardiomyopathy and the support that the charity can offer. This campaign will be an integral part of the Charity's broader strategy to increase access to its services as mentioned above.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The charity is controlled by its governing document and constitutes a charitable incorporated organisation. The charity is governed by its constitution adopted on 5 November 2015.

The charity continues to review and, where necessary, improve its trustee induction and training resources to ensure that new trustees are equipped to support the work of the charity to their maximum ability.

Appropriate policies and procedures have been put on place to ensure good governance including financial management, data protection and employment practice. Trustees maintain a risk register and work with the Chief Executive to ensure that strategies are in place to mitigate against identified risks.

In 2020, Trustees worked to develop the Charity's three year plan for the years 2021 to 2023. This plan was developed with input from staff, clinicians and the wider cardiomyopathy community and is available on the Cardiomyopathy UK website.

Alison Fielding, the Chair for the previous 5 years, announced that she would not seek re-appointment as Chair. The Board was pleased to welcome Rita Sutton, a previous trustee and winner of the Carolyn Biro Award for her contribution to the charity, back to the board as Vice Chair and Chair Elect. An induction and hand over period took place in the autumn and winter of 2020. In February 2021, Rita took over as Chair and Alison Fielding accepted an invitation to become a Vice President of Cardiomyopathy UK in line with the Charity's focus on having people affected by cardiomyopathy at the centre of its strategy and governance.

During the year the Charity was informed by its landlord that the lease on its premises in Chesham would not be renewed when it expired in February 2021. Suitable alternative office space was identified in the local area and lease negotiations were completed with the pro-bono legal support of Mayer Brown International LLP. The Charity took occupation of its new premises in February 2021 and Trustees would like to thank Mayer Brown International LLP for their kind support in this process.

Related parties

The charity works closely with expert clinicians from a number of NHS Trusts to help ensure that its work is clinically appropriate and that it is able to reach as many people with cardiomyopathy as possible.

During the year the charity worked with its President, Prof. Perry Elliott to develop the International Cardiomyopathy Network (ICoN) a registered UK Charity. The Charity's Chief Executive provided strategic advice and patient insight to ICoN as part of a shared commitment to improving the level of cardiomyopathy knowledge among clinicians, developing best practice and fostering research that will make a real difference to the lives of people with the condition.

The charity has a positive relationship with The British Heart Foundation, The Pumping Marvellous Foundation and a number of other charities that provide support and information relating to heart diseases. Where possible, the charity works in collaboration with these charities. During the year, the Charity's Chief Executive continued to play an active part in the Heart Failure Alliance, a collaboration between medical colleges, pharmaceutical and health technology companies, charities and other stakeholders working to improve accesses to quality treatment for heart failure.

As stated above, during 2020 the charity received funding from six pharmaceutical companies (Sanofi, Pfizer, Alnylam, Novartis, AstraZeneca and MyoKardia) the total income from these companies was £138,000 around 18% of the charity's total income. Income from these sources covered the costs associated with the Charity's medical education project, advocacy project, awareness campaign and international work. A full copy of the charity's policy on working with these companies is available on its website.

Public Benefit

Cardiomyopathy UK confirms that in setting its programme of support, it has had due regard to the Charity Commission's general guidance on public benefit. The programme of support also conforms to the charity's charitable objectives and aims. No persons are excluded from the work of the charity on grounds of gender, race or religion.

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2020

REFERENCE AND ADMINISTRATIVE DETAILS

Trustees	Mrs A Fielding	Resigned Chair February 2021
	Mrs T Amiss	
	Mrs T Bueser	Appointed January 2020
	Mr G Favier	
	Mr C Horwood	
	Mr S Kirkham	
	Dr I McPherson OBE	
	Mrs J O'Connell	
	Mr E Power	Appointed January 2020
	Mrs A Smyth	Appointed January 2020
	Mrs R Sutton	Appointed June 2020 Appointed Chair February 2021
	Professor A Tickell	
	Mr P Thomas	Treasurer
Chief Executive Officer	Mr J Rose	
Principal Address	75A Woodside Road Amersham Buckinghamshire HP6 6AA	
Bankers	CafCash Limited Kings Hill West Malling Kent ME19 4TA	
	Lloyds 82 High Street Rickmansworth Hertfordshire WD3 1AG	
Auditors	Seymour Taylor Audit Limited Registered Auditors 57 London Road High Wycombe Buckinghamshire HP11 1BS	
Charity number	1164263	

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).


STATEMENT OF TRUSTEES' RESPONSIBILITIES - continued

The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the board of trustees on 10 May 2021 and signed on its behalf by:



Mrs R Sutton - Trustee

Opinion

We have audited the financial statements of Cardiomyopathy UK (the 'charity') for the year ended 31 December 2020 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2020 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception
We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:
- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees
As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Identifying and assessing potential risks related to irregularities
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- results of our enquiries of management about their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the charity's documentation of their policies and procedures relating to: - identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of noncompliance; - detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud; - the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

We also obtained an understanding of the legal and regulatory frameworks that the charity operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Charities Act and local tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the charity's ability to operate.

Audit response to risks identified
As a result of performing the above, our procedures to respond to risks identified included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- reading minutes of meetings of those charged with governance; and
- in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Seymour Taylor Audit Limited

Seymour Taylor Audit Limited, Statutory Auditor
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
57 London Road
High Wycombe
Buckinghamshire
HP11 1BS

10 May 2021

CARDIOMYOPATHY UK

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	Unrestricted fund £	Restricted funds £	2020 Total funds £	2019 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	419,483	351,172	770,655	849,225
Investment income	3	1,174	-	1,174	502
Total		420,657	351,172	771,829	849,727
EXPENDITURE ON					
Raising funds	4	271,045	134	271,179	309,167
Charitable activities	5				
Providing support		113,857	205,491	319,348	232,978
Public and medical education		52,461	20,213	72,674	150,818
Campaigning		34,290	13,759	48,049	48,455
Research		15,538	1,646	17,184	297,439
Other		59,819	5,108	64,927	75,378
Total		547,010	246,351	793,361	1,114,235
NET INCOME/(EXPENDITURE)		(126,353)	104,821	(21,532)	(264,508)
RECONCILIATION OF FUNDS					
Total funds brought forward		457,553	86,713	544,266	808,774
TOTAL FUNDS CARRIED FORWARD		331,200	191,534	522,734	544,266

The notes form part of these financial statements

BALANCE SHEET
31 DECEMBER 2020

	Notes	Unrestricted fund £	Restricted funds £	2020 Total funds £	2019 Total funds £
FIXED ASSETS					
Tangible assets	11	8,857	-	8,857	6,545
CURRENT ASSETS					
Debtors: amounts falling due within one year	12	161,908	-	161,908	120,153
Debtors: amounts falling due after more than one year	12	4,006	-	4,006	26,495
Cash at bank and in hand		249,151	191,534	440,685	438,350
		415,065	191,534	606,599	584,998
CREDITORS					
Amounts falling due within one year	13	(92,722)	-	(92,722)	(47,277)
NET CURRENT ASSETS		322,343	191,534	513,877	537,721
TOTAL ASSETS LESS CURRENT LIABILITIES		331,200	191,534	522,734	544,266
NET ASSETS		331,200	191,534	522,734	544,266
FUNDS	15				
Unrestricted funds				331,200	457,553
Restricted funds				191,534	86,713
TOTAL FUNDS				522,734	544,266

The financial statements were approved by the Board of Trustees and authorised for issue on 10 May 2021 and were signed on its behalf by:

R Sut

Mrs R Sutton - Trustee

The notes form part of these financial statements

CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	2020 £	2019 £
Cash flows from operating activities			
Cash generated from operations	1	6,224	(167,410)
Net cash provided by/(used in) operating activities		6,224	(167,410)
Cash flows from investing activities			
Purchase of tangible fixed assets		(5,063)	(3,781)
Interest received		1,174	502
Net cash used in investing activities		(3,889)	(3,279)
Change in cash and cash equivalents in the reporting period		2,335	(170,689)
Cash and cash equivalents at the beginning of the reporting period		438,350	609,039
Cash and cash equivalents at the end of the reporting period		440,685	438,350

The notes form part of these financial statements

NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2020

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2020 £	2019 £
Net expenditure for the reporting period (as per the Statement of Financial Activities)	(21,532)	(264,508)
Adjustments for:		
Depreciation charges	2,751	1,884
Interest received	(1,174)	(502)
(Increase)/decrease in debtors	(19,266)	105,832
Increase/(decrease) in creditors	45,445	(10,116)
Net cash provided by/(used in) operations	6,224	(167,410)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.20 £	Cash flow £	At 31.12.20 £
Net cash			
Cash at bank and in hand	438,350	2,335	440,685
	438,350	2,335	440,685
Total	438,350	2,335	440,685

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Cardiomyopathy UK is a charity limited by guarantee and incorporated in England and Wales. The charity's principal address is 75A Woodside Road, Amersham, Buckinghamshire, HP6 6AA. The registered charity number is 1164263.

The presentation currency of these financial statements is Sterling (£), being the currency of the primary economic market in which the entity operates. All amounts in these financial statements have been rounded to the nearest pound unless stated otherwise.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

In light of the rapid global spread of the Coronavirus "COVID-19" in early 2020, the trustees have reviewed and stress tested projections and budgets for the next twelve months. Following this review, the trustees consider there to be little impact on the Charity's ability to act as a going concern.

The trustees have reviewed the fundraising possibilities and the capital resources available and consider that the charity has adequate resources in place to continue operations for the next twelve months.

Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Government grants
The charity receives government grants in respect of Coronavirus Job Retention Scheme. Income from government grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably. If entitlement is not met then these amounts are deferred.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Allocation and apportionment of costs
Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with use of the resources.

Salaries have been apportioned in accordance with the duties to which they relate.

1. ACCOUNTING POLICIES - continued

Allocation and apportionment of costs

Premises costs have been apportioned on the basis of percentage of floor space used.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - at variable rates on reducing balance

Taxation
The charity is exempt from tax on its charitable activities.

Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits
The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Financial instruments
The charity has applied the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instrument Issues" of FRS 102 to its financial statements.

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Debtors and creditors due within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities in administrative expenses.

Cash and cash equivalents
Cash and cash equivalents in the Statement of Financial Position comprise cash at bank and in hand and short term deposits with an original maturity date of three months or less. Bank overdrafts are disclosed within creditors on the Statement of Financial Position.

2. DONATIONS AND LEGACIES

	2020	2019
	£	£
Donations	106,895	75,957
Grants and legacies	267,968	236,009
Memberships and donations	71,271	80,864
Fundraising	324,521	456,395
	770,655	849,225

Grants received included above are as follows:

	Unrestricted	Restricted	2020 Total	2019 Total
	£	£	£	£
Big Lottery Fund	-	-	-	40,330
The Lilley Benevolent Trust	-	-	-	1,000
Browns Solicitors	-	60,800	60,800	30,000
Alexander Jansons Fund	-	-	-	10,000
BBC Children in Need	-	10,825	10,825	2,745
Big Lottery Fund - Community PeerSupport	-	108,868	108,868	30,557
Heart Hive	-	-	-	21,175
Tesco	-	-	-	1,000
The Edward Gostling Foundation	-	15,000	15,000	15,000
Max's Foundation	-	14,776	14,776	15,276
Cunningham Family Trust	10,000	-	10,000	5,000
BP Foundation US	-	-	-	63
John Mason Raven (dec'd) Trust	-	-	-	50,000
Pfizer Ltd	-	21,100	21,100	-
Myokardia/Vistra IE UK	-	10,000	10,000	-
The Moss Family Charitable Trust	1,000	-	1,000	-
European Consultancy	6,356	-	6,356	-
Total Grants	17,356	241,369	258,725	222,146

Total Legacies	4,000	13,863
Coronavirus Job Retention Scheme	5,243	-
	267,968	236,009

3. INVESTMENT INCOME

	2020	2019
	£	£
Deposit account interest	1,174	502

4. RAISING FUNDS

Raising donations and legacies

	2020	2019
	£	£
Staff costs	175,069	175,030
Rates and water	605	304
Insurance	926	-
Postage and stationery	4,839	3,525
Sundries	146	243
Event costs	31,950	55,304
Marketing	23,122	28,661
Travel and subsistence	56	1,801
Computer	3,456	4,642
Recruitment	7,692	5,309
Staff training	-	107
Rent	9,486	9,489
Professional fees	2,777	8,745
Donation charges	6,512	11,703
Bank charges	3,481	3,250
Subscriptions	238	198
Depreciation	824	856
	271,179	309,167

5. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Grant funding of activities (see note 6)	Totals
	£	£	£
Providing support	319,348	-	319,348
Public and medical education	72,674	-	72,674
Campaigning	48,049	-	48,049
Research	15,538	1,646	17,184
	455,609	1,646	457,255

6. GRANTS PAYABLE

	2020	2019
	£	£
Research	1,646	264,200

The following Grants were paid to Institutions during the year;

	2020	2019
	£	£
Royal Brompton Hospital	-	92,500
Imperial College Hospital	-	39,284
Alexander Janson's Myocarditis	1,646	132,416
Total	1,646	264,200

7. SUPPORT COSTS

	Management	Governance costs	Totals
	£	£	£
Other resources expended	59,877	5,050	64,927

Analysis of support and governance costs

The charity initially identifies the costs of its support function. It then identifies those costs which relate to the governance function. Having identified its governance costs and support costs these are apportioned between the key charitable activities undertaken in the year. Please refer to the table below for the basis of apportionment and the key analysis of support.

	General Support	Governance function	Basis of apportionment
	£	£	
Wages	25,806	-	The duties to which they relate
Property related expenses	10,756	-	Floor space
General office and administration	22,847	-	Specific support costs
Legal and professional fees	-	-	Specific support costs
Bank charges	102	-	General charges
Depreciation	366	-	Floor space
Audit fees	-	5,050	Governance
Total	59,877	5,050	

8. AUDITORS' REMUNERATION

The auditor's remuneration amounts to an audit fee of £5,050 (2019 - £5,720) and payroll services paid to the auditor of £1,716 (2019 - £1,051) are included in legal and professional fees.

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2020 nor for the year ended 31 December 2019.

Trustees' expenses

During the year ended 31 December 2020, 2 trustees received reimbursed expenses of £547 (2019: £2,094) for travel and other charitable related costs. At the year end date £nil (2019: £1,345) was due to trustees in relation to expenses.

10. STAFF COSTS

	2020	2019
	£	£
Wages and salaries	482,236	443,061
Social security costs	39,020	40,145
Other pension costs	13,463	11,614
	534,719	494,820

Total redundancy / termination payments during the year amounted to £17,881 (2019 - £nil)

Transactions with key management personnel

	2020	2019
	£	£
Total compensation of key management personnel	64,297	63,036

The average monthly number of employees during the year was as follows:

	2020	2019
	18	20

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2020	2019
£60,001 - £70,000	1	1

11. TANGIBLE FIXED ASSETS

	Computer equipment £
COST	
At 1 January 2020	23,903
Additions	5,063
At 31 December 2020	28,966
DEPRECIATION	
At 1 January 2020	17,358
Charge for year	2,751
At 31 December 2020	20,109
NET BOOK VALUE	
At 31 December 2020	8,857
At 31 December 2019	6,545

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020 £	2019 £
Trade debtors	15,982	-
Prepayments and accrued income	145,926	120,153
	161,908	120,153

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020 £	2019 £
Trade creditors	8,503	4,132
Social security and other taxes	12,312	8,982
Other creditors	4,018	2,795
Accruals and deferred income	67,889	31,368
	92,722	47,277

14. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:

	2020	2019
	£	£
Within one year	33,393	23,468
Between one and five years	105,600	3,911
In more than five years	129,800	-
	268,793	27,379

15. MOVEMENT IN FUNDS

	At 1.1.20	Net movement in funds	At 31.12.20
	£	£	£
Unrestricted funds			
General fund	457,553	(126,353)	331,200
Restricted funds			
Medical education	22,600	(12,582)	10,018
Providing support helpline	164	(164)	-
Youth services	6,664	(2,690)	3,974
West Midlands support fund	924	-	924
Alexander Janson's Foundation	116	1,144	1,260
BBC Children in Need	2,937	1,377	4,314
Heart Hive	1,891	-	1,891
Max's Foundation	11,755	2,174	13,929
Community Peer Support (National Lottery Community Fund)	4,662	(4,662)	-
Building Capabilities (National Lottery Community Fund)	25,000	(7,156)	17,844
Online Medical Education	10,000	9,574	19,574
Advocacy	-	27,803	27,803
PPCM Campaign	-	4,941	4,941
BLF Helpline	-	20,572	20,572
Building the Community	-	64,490	64,490
	86,713	104,821	191,534
TOTAL FUNDS	544,266	(21,532)	522,734

15. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	420,657	(547,010)	(126,353)
Restricted funds			
Medical education	179	(12,761)	(12,582)
Providing support helpline	30,000	(30,164)	(164)
Youth services	15,000	(17,690)	(2,690)
Alexander Janson's Foundation	2,924	(1,780)	1,144
BBC Children in Need	10,825	(9,448)	1,377
Max's Foundation	14,776	(12,602)	2,174
Community Peer Support (National Lottery Community Fund)	63,218	(67,880)	(4,662)
Building Capabilities (National Lottery Community Fund)	-	(7,156)	(7,156)
Online Medical Education	30,000	(20,426)	9,574
Advocacy	51,900	(24,097)	27,803
PPCM Campaign	18,700	(13,759)	4,941
BLF Helpline	45,650	(25,078)	20,572
Building the Community	68,000	(3,510)	64,490
	351,172	(246,351)	104,821
TOTAL FUNDS	771,829	(793,361)	(21,532)

15. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
Unrestricted funds			
General fund	550,909	(93,356)	457,553
Restricted funds			
Medical education	23,049	(449)	22,600
Providing support helpline	-	164	164
Youth services	10,156	(3,492)	6,664
BLF Heart to Heart Project	2,366	(2,366)	-
West Midlands support fund	924	-	924
Alexander Janson's Foundation	210,390	(210,274)	116
BBC Children in Need	10,980	(8,043)	2,937
Heart Hive	-	1,891	1,891
Max's Foundation	-	11,755	11,755
Community Peer Support (National Lottery Community Fund)	-	4,662	4,662
Building Capabilities (National Lottery Community Fund)	-	25,000	25,000
Online Medical Education	-	10,000	10,000
	257,865	(171,152)	86,713
TOTAL FUNDS	808,774	(264,508)	544,266

15. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	622,171	(715,527)	(93,356)
Restricted funds			
Medical education	-	(449)	(449)
Providing support helpline	30,000	(29,836)	164
Youth services	15,000	(18,492)	(3,492)
BLF Heart to Heart Project	40,330	(42,696)	(2,366)
Alexander Janson's Foundation	41,473	(251,747)	(210,274)
BBC Children in Need	2,745	(10,788)	(8,043)
Tesco's Community Groundwork Fund	1,000	(1,000)	-
Heart Hive	41,175	(39,284)	1,891
Max's Foundation	15,276	(3,521)	11,755
Community Peer Support (National Lottery Community Fund)	5,557	(895)	4,662
Building Capabilities (National Lottery Community Fund)	25,000	-	25,000
Online Medical Education	10,000	-	10,000
	227,556	(398,708)	(171,152)
TOTAL FUNDS	849,727	(1,114,235)	(264,508)

Medical education - Towards the costs of providing educational events and opportunities for healthcare professionals. This includes the Olsen-Gourley Lecture fund and the M Hicks Educational fund transferred from Cardiomyopathy Association.

Youth services - Towards the costs of developing and providing support services for children, youth and young adults. This includes the Wates Foundation fund, the Childrens Book Restricted Fund, Chairman's Appeal 2013 fund and the Children and Young People Office fund transferred from Cardiomyopathy Association.

Providing support helpline - Towards the costs of providing a nurse lead clinical helpline for people affected by cardiomyopathy. This includes the Chairman's Appeal 2013 fund, Support Nurse Helpline fund, Raft Race Appeal fund and the Cardio Connect fund transferred from Cardiomyopathy Association.

BLF Heart to Heart Project - To fund the support and provision of a network of support groups throughout England. This includes the Sussex Support Group fund, Hampshire Support Group fund and the Winchester Support Group fund transferred from Cardiomyopathy Association.

West Midland support group - to provide support for those with cardiomyopathy in the West Midlands.

Alexander Janson's Foundation - to fund research into the causes, prevention and cures for Myocarditis

15. MOVEMENT IN FUNDS - continued

BBC Children in Need - To improve the emotional, physical and psychosocial (empowerment) well-being of young people under 18. Information resources (web and hard copy), paediatric helpline (out of hours), and national event, plus Panel meetings.

Tesco's Community Groundwork Fund - Towards the holding of a musical event raising the awareness of Cardiomyopathy in Leeds.

Heart Hive - Online platform that aims to match researchers at Imperial College with individuals interested in taking part in research trials. The objective is to seek ways of improving treatment for cardiomyopathy and myocarditis.

Max's Foundation - Three year grant to fund the position of Youth Support Manager.

Community Peer Support (National Lottery Community Fund) - A five year project partly funded by the National Lottery Community Fund to develop an innovative face to face and phone peer support service for people with life limiting heart muscle disease throughout England.

Building Capabilities (National Lottery Community Fund) - National audit pan England of those NHS trusts and service providers providing clinical care and treatment to people affected by cardiomyopathy and myocarditis.

Online Medical Education - Towards the development of an online learning program which will improve diagnoses of cardiomyopathy and access to treatment by upskilling clinical knowledge of patient facing clinicians.

Advocacy - Developing the patient voice to affect purposeful change within the relevant statutory agencies.

PPCM Campaign - To raise public awareness of peripartum Cardiomyopathy in particular statutory health providers.

BLF Helpline - To provide a dedicated frontline service to anyone affected by Cardiomyopathy or related conditions.

Building the Community - To raise awareness of Cardiomyopathy to English speaking countries internationally.

16. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2020.